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Neonates, particularly those born preterm (PTB) and low birthweight (LBW), are especially 
susceptible to bacterial infections that cause an estimated 225,000 deaths annually. Iron is a 
vital substrate for the most common organisms causing septicaemia. Full-term babies elicit an 
immediate post-natal hypoferremia assumed to have evolved as an innate defence. This 
thesis aimed to test whether preterm and low birthweight newborns are capable of a similar 
response.  
 
A longitudinal observational study was conducted in 430 hospital-delivered Gambian babies. 
Demographic, anthropometric and haematological data were collected from 152 babies who 
were either PTB (between ≥32-<37 weeks gestational age) and/or LBW (<2500g) (PTB/LBW) 
and 278 full-term, normal-weight babies (FTB/NBW). Blood was sampled from the umbilical 
cord and matched venous blood samples from all neonates between 6-24 hours after delivery. 
An additional matched venous blood sample was taken from all full-term, normal birth weight 
newborns between 24-192 hours of life. In both FTB/NBW and PTB/LBW neonates, serum 
iron decreased 3-fold compared to umbilical blood concentrations within 12h of delivery 
(23·3±0·35 vs 7·5±0·22 ng/ml, P<0.001, n=425). Hepcidin levels doubled (27·0±0·96 vs 
52·9±1·63 ng/ml, P<0·001, n=425). In FTB/NBW neonates, a steady increase in serum iron 
and TSAT follows (to 16.5±3.9µmol/L and 36.7±9.2% respectively by 136-192hrs post-
delivery), even in the presence of relatively high serum hepcidin levels (45.2±19.1ng/ml) 
suggestive of hepcidin resistance possibly caused by iron saturation of macrophages.  
 
Our findings confirm that a very rapid hypoferremia occurs in the early hours of post-natal life 
with evidence that it is mediated by an increase in hepcidin. The strength and consistency of 
this effect in all neonates indicates that it may have evolved as an innate immune response 
designed to protect newborns from bacterial septicaemia. 
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GLOSSARY OF KEY TERMS 
 
Hypoferremia: A deficiency of iron in the blood. 
 
Nutritional immunity: To prevent infection from pathogenic organisms 
by restricting access to essential metals. 
 
Neonatal sepsis: A type of infection in neonates that specifically 
refers to the presence of bacteria in the blood 
stream (due to meningitis, pneumonia, 
pyelonephritis or gastroenteritis) in the setting 
of fever. Early-onset (appearing 0-3 days of life) 
and late-onset (appearing >4 days of life) are 
further levels of categorisation.  
 
Bacteriostatic: Substance or process that reversibly inhibits 
growth or reproduction of bacteria. Different 
from bactericidal (capable of killing bacteria 
outright). 
 
Hepcidin: A 25-amino acid peptide (HAMP gene) 
exclusively synthesized by the liver that is the 
main regulator of systemic iron metabolism. Its 
primary role is to inhibit iron efflux into the blood 
by binding to the transmembrane protein, 
ferroportin. 
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Transferrin saturation: The percentage of transferrin molecules that 
are bound to two iron ions in the ferric form 
(Fe3+). This is a ratio of serum iron 
concentration and the total iron-binding capacity 
(TIBC) expressed as a percentage.  
 
TIBC (total iron-binding capacity): An indirect measure of the amount of total 
serum transferrin (apotransferrin, 
monotransferrin, diferric transferrin) 
concentration in the circulation.  
 
Post-natal: The period immediately after the birth of a child.  
 
Preterm birth: Babies born alive before 37 weeks of 
pregnancy are completed. Sub-categories 
included extremely preterm (<28 weeks), very 
preterm (28-32 weeks) and moderate to late 
preterm (32-37 weeks).  
 










Chapter 1 – Background to Thesis 
 
 
Summary of Chapter 
 
In this chapter, I briefly introduce the background information and rationale to this thesis. 
This involves discussing the previous work completed by the HYPO-G Study at MRCG Unit 
The Gambia by lead investigator Dr Sarah Prentice, which laid the foundations for this 
further research. I then define the aims, objectives and structure of my research degree. 
Additionally, I describe the role I played in all aspects of the study, with further information 
on the research degree timeline. Funding and the subsequent publications produced are 
also detailed. This chapter then reviews the high-level background literature to this thesis, 
including research into neonatal mortality linked to infection, the transition to extrauterine life 





























1.1 Introduction and Rationale 
 
1.1.1 Why study neonatal iron metabolism? 
 
Neonatal sepsis is the third highest cause of death globally, accounting for 225,000 deaths 
each year.1 Neonatal infections cause an estimated 23% of all neonatal deaths, with 
neonatal sepsis alone accounting for 15%. The increasing global threat of antimicrobial 
resistance will no doubt exacerbate these figures in the future.2 
 
Humans undergo the most complex physiological adaption in their life during the transition 
from a semi-allogeneic, protected foetal setting to a microbe-rich extrauterine environment.3,4 
The initial mass bacterial colonisation of mucosa in the digestive, respiratory, urogenital 
tracts, as well as the skin5,6 occurs during the very early neonatal period and can positively 
affect gut maturation,7 metabolic homeostasis and immune function8–10 in early life and 
beyond. Early-onset neonatal sepsis (EONS) occurs in <72 hours of life, with most causative 
pathogens being transmitted vertically from mother to infant before or during delivery.11  
 
Iron is a cofactor in numerous metabolic pathways that are critical for the human host as well 
as most pathogens, making it an important mineral in the host-pathogen battle for 
resources.12 Therefore, systemic iron distribution is usually strictly regulated.13 The 
assimilation of iron from its human host via a plethora of molecular mechanisms (e.g. iron 
transporters and siderophores14), results in increased growth15 and virulence16 of many 
human pathogens. For example, individuals with chronically high iron states (e.g. 
hemochromatosis), not only have increased free radical redox damage,17 but an enhanced 




The hormone hepcidin is the primary regulator of iron homeostasis.20 Host inflammatory 
mediators, IL-6,21 IL-2222 and IFN-α,23 have been observed to increase the transcription of 
hepcidin through several Toll-like receptor (TLR) ligands24 and STAT3 signalling.25,26 
Hepcidin binds to the transmembrane protein ferroportin in macrophages, hepatocytes and 
enterocytes, resulting in its internalization and degradation.27–29 Consequently, enteric 
absorption from dietary iron is reduced, and iron is sequestered in macrophages, which 
causes a reduction in the extracellular iron concentration. Research carried out in animal 
models has shown that when the innate immune system is activated, it elicits a hypoferremic 
response which then limits the risk and severity of bacterial infections.30–32 
 
Previous research by our group has suggested that the hepcidin concentration in full-term 
neonates increases over the first hours of life, which is linked to a significant reduction in 
serum iron and transferrin saturation over a similar time period.33 Nevertheless, an accurate 
and reliable representation of iron homeostasis in all neonates (in particular preterm and/or 
low birthweight) is still lacking. The process of reviewing this mechanism between multiple 
studies was previously made harder by the lack of inter-assay standardisation of hepcidin 
ELISA assays until the recent research conducted by Van der Vorm et al.34  
 
1.1.2 What has previous work by our group provided towards the field? 
 
Before the start of this research degree, previous research conducted at MRC Unit The 
Gambia showed the presence of hepcidin-mediated neonatal hypoferremia in vaginally-
delivered healthy full-term neonates in rural Kiang Keneba.33 This proof-of-concept 
observational study observed the following key learning points: 
 
• Normal healthy term neonates display a rapid suppression of serum iron and TSAT 
within the first 6-12 hours post-partum.  
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• This response is thought to last for 2-3 days, followed by a slow increase up to 92 
hours.  
• There is a strong negative correlation between hepcidin and serum iron during this 
period, suggesting that hepcidin regulates this response through the redistribution of 
iron into circulating macrophages. 
• These findings were correlated to levels of IL-6, suggesting that inflammatory 
stimulation of hepcidin is in part, the driving mechanism of systemic hypoferremia.  
• Growth rates of the ex vivo micro cultured neonatal sepsis causing bacteria 
Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae and 
Streptococcus agalactiae were significantly lower in neonate venous serum (6-24 hr 
time period) as compared to cord serum. 
• Each organism’s growth rates was significantly associated with TSAT level in the 
serum.  
 
To conclude, the evidence to date suggests that neonatal hypoferremia takes place 
immediately post-partum in healthy term neonates, but there is limited research into the 
effects of gestational age and birthweight on this method of protection.33 Our research group 
pilot data suggests this change in iron distribution could provide a bacteriostatic method of 
protection to neonates in the first hours of life, when immune defences are immature.33 The 
rationale to conduct my research was to confirm this earlier discovery of acute neonatal 
hypoferremia in full-term neonates in another population, and to test whether preterm (PTB) 
and/or low birthweight (LBW) infants are equally effective in sequestering iron away from the 
bloodstream. If this was not the case, we aimed to describe the proportion of such babies 







1.2 PhD Aims and Objectives 
 
 
Figure 1.1 PhD study logo (NeoInnate Study). 
 
Overall Aim:  To characterise the effects that gestational age and birthweight have 
on iron distribution immediately after birth and during the first week of 
life in healthy Gambian neonates.  
 
Specific Objectives:  
 
• Conduct a comprehensive review of hepcidin, serum iron and TSAT concentration in 
neonates in umbilical cord and venous blood (up to 1 month of age).  
 
• Characterise iron metabolism in full-term, preterm and low birthweight neonates at 
birth and during the first 24 hours of life. Do premature and/or low birthweight 
neonates have a defect in their ability to sequester iron at 6-24 hours after birth in 
comparison to full-term newborns with normal birthweight? 
 
• Describe how concentrations of hepcidin, serum iron and TSAT change in full-term 





The PhD conceptional framework is displayed in Figure 1.2. This PhD is split into 
preparation (A) and observation (B) phases. B is itself divided into two sections, with Part B1 
focussing on a comparison of iron homeostasis in first hours of life between full-term, normal 
birthweight (FTB+NBW) neonates and preterm (PTB) and/or low birthweight (LBW) 
neonates. Part B2 focuses on iron and infection parameters in FTB+NBW neonates after the 
first week of life only. 
 
 
Figure 1.2 PhD conceptional framework. 
 
1.3 PhD Outline 
 
This thesis is formatted in a research paper style in accordance with the London School of 
Hygiene & Tropical Medicine write-up regulations. The manuscripts and published articles 
are included without any adaption for this thesis. As a result, repetition is common between 
chapters in regard to materials and methods. This has been reduced with the production of a 
protocol paper (Chapter 4). If supplementary material is part of the manuscripts or 
publications, it has been added at the end of the chapter. Each chapter begins with a 




This thesis contains seven chapters, one of which is a published protocol paper (Chapter 4), 
one is a published original research publication (Chapter 5) and two submitted manuscripts 
(Chapter 3 and 6). An outline of all the chapters is as follows: 
 
Chapter 1: An introduction to the thesis content and structure, with detailed information on 
the PhD aims, objectives, rationale, candidate involvement, publications and timeframe.  
 
Chapter 2: An introduction to the study setting at Kanifing General Hospital and the 
surrounding communities.  
 
Chapter 3: A prepared (submitted) manuscript containing a literature review of the 
concentrations of hepcidin, serum iron and TSAT in newborn blood in the first weeks of life.  
 
Chapter 4: A published research article containing the methodology of all study methods 
involved in the production of the two original articles (Chapters 5 & 6). It should be noted 
that it was not possible to complete secondary objective (III) in this publication (e.g. ex vivo 
bacterial growth in neonatal serum) due to the lack of adequate blood sample volumes from 
the initial blood draws.   
 
Chapter 5: A published research article comparing the concentrations of hepcidin, serum 
iron and TSAT in full-term, normal birthweight newborns against preterm and/or low 
birthweight neonates in the first hours of life.  
 
Chapter 6: A prepared (submitted) manuscript describing concentrations of hepcidin, serum 




Chapter 7: A final discussion chapter to highlight the overall study findings, limitations of this 
thesis and reflection on what future research should be conducted in the field of neonatal 
iron homeostasis and beyond.  
 
1.4 Candidate’s Involvement  
 
The original idea of assessing iron and inflammation makers in newborns at birth and shortly 
afterwards in order to assess if hypoferremia was present came from Dr Sarah Prentice, Dr 
Carla Cerami (Higher Scientific Officer for MRC Unit The Gambia) and Professor Andrew 
Prentice (Nutrition Theme Leader for MRC Unit The Gambia). Dr Carla Cerami obtained the 
funding from the Bill and Melinda Gates Foundation. I assisted in completing the narrative 
and budget components of the grant (OPP1152353). I worked closely with Dr Carla Cerami 
(primary supervisor) to develop and implement this observational study and received 
technical support from Professor Andrew Prentice (secondary supervisor).  
 
As seen in Chapter 3, I was responsible for searching the literature, analysing data and 
formulating the first draft of the narrative review. Dr Carla Cerami and Professor Andrew 
Prentice (co-authors) supervised me and provided technical support and feedback during 
the production of the review.  
 
The methodology of the NeoInnate Study (Chapter 4) was prepared predominantly from 
pilot research conducted by Dr Sarah Prentice and Professor Andrew Prentice. Dr Carla 
Cerami and I adapted previous study procedures and protocols to fit with a change in the 
study setting. Dr Ousman Jarjou and the nursing team provided clinical insight into the 
development of study-specific protocols (SPPs). Mr Bakary Sonko oversaw the development 
of data handling and management, ensuring all aspects followed MRCG data management 
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policies. Dr Nuradin Ibahim Mohammed provided statistical oversight to ensure the study 
was adequately powered for our formal analysis.  
 
My role during the NeoInnate Study was a PhD student, along with co-investigator and 
project manager. I assisted in the writing of the funding application and regular reports to the 
Bill and Melinda Gates Foundation (BMGF). I assisted in the production of a study budget, 
monitored spending and procurement/logistics daily. I developed all clinical, data and 
laboratory study-specific protocols (SSPs). I orchestrated the renovation of a new study-
specific laboratory at Kanifing General Hospital (with the help of construction workers, 
labours and senior hospital staff). I assisted in the production of a successful ethics 
application to MRCG at LSHTM Scientific Coordinating Committee, MRCG at 
LSHTM/Gambian Government Joint Ethics Committee and London School of Hygiene and 
Tropical Medicine Ethics Committee, alongside assisting with the formal registration of the 
study at ClinicalTrials.gov. I actively supported the communication between Kanifing General 
Hospital and the NeoInnate study team, holding regular meetings with senior hospital 
administration. I worked with a team of MRCG at LSHTM staff to arrange a study-specific 
open day at Kanifing General Hospital, working with hospital administration, local media, 
international and local non-governmental organisations (NGOs), religious leaders, national 
and local government and the local population of Kanifing. Furthermore, I aided the 
assembly of a study team consisting of a research clinician, eight clinical nurses, ten 
laboratory technicians and two international students by shortlisting candidates, helping 
conduct interviews and working closely with the Human Resources Department (MRCG at 
LSHTM). I coordinated the fulfilment of daily project administration and laboratory 
management (staff appraisal, organising subject community visits, producing staff rotas, and 
running laboratory controls). I conducted regular shift work at the NeoInnate laboratory, 
completing primary laboratory analysis and supporting the study nurse team. I developed 
and verified all electronic data records on the study-specific REDCap (Research Electronic 
Data Capture) database, executing data curation and management leading to formal 
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statistical analysis in collaboration with study team members (Dr Carla Cerami and Prof 
Andrew Prentice) and the study statistician (Dr Nuradin Ibrahim Mohammed). Additionally, I 
conducted all secondary biochemical processes, sample handling and analysis (ELISA and 
biochemistry analysis). I provided regular training days to Kanifing General Hospital and 
NeoInnate Study staff on study procedures, theory and protocols. This work led me to the 
scientific writing of the manuscripts seen in Chapters 5 and 6.  
 
While here, I summarised my contribution to the contents of this thesis, it is essential to note 
that this study was designed, conducted and analysed in a collaborative approach. I have 
provided the names and roles of everyone involved in these areas in Annex 1.11. 
 




• Cross JH, Jarjou O, Mohammed NI, et al. Neonatal iron distribution and infection 
susceptibility in full term, preterm and low birthweight babies in urban Gambia: study 
protocol for an observational study. Gates Open Res 2019;3:1469. (Chapter 4) 
 
• Cross JH, Jarjou O, Mohammed NI, et al. Early postnatal hypoferremia in low 




• Cross JH, Prentice AM, Cerami C. Hepcidin, serum iron and transferrin saturation in 
full term and premature infants during the first month of life: A review of existing 




• Cross JH, Jarjou O, Mohammed NI, et al. Iron homeostasis in full term, normal 
birthweight Gambian neonates over the first week of life. American Journal of Clinical 




• Iron and Infection: Neonatal Iron Transition (NeoInnate Study – Prospective). Cross 
JH, Jarjou O, Touray BJB, Prentice AM, Cerami C. Presented at MRC Unit The 
Gambia 70th Anniversary Symposium: 27-29th November 2017. 
 
• Iron and Infection: Neonatal Iron Transition (NeoInnate Study – Prospective). Cross 
JH, Jarjou O, Touray BJB, Prentice AM, Cerami C. Presented at MRC Scientific 
Advisory Board Meeting 2016, MRC Keneba, The Gambia. 
 
• Iron and Infection: Neonatal Iron Transition (NeoInnate Study – Prospective). Cross 
JH, Jarjou O, Touray BJB, Prentice AM, Cerami C. Presented at IUIS-FAIS-
ImmunoGambia 2016, MRCG at LSHTM, The Gambia. 
 
• Iron and Infection: Neonatal Iron Transition. Cross JH, Prentice AM, Cerami C. 









• MRC Unit The Gambia – Nutrition Retreat Presentation. 21st February 2018. Iron and 
Infection: Neonatal Iron Transition (NeoInnate Study). 
 
• London School of Hygiene and Tropical Medicine – M. Phil. / Ph.D. Upgrading 
Seminar. 30th September 2017. Iron and Infection: Neonatal Iron Transition 
(NeoInnate Study). 
 
• MRC Unit The Gambia / MRC International Nutrition Group (Unit Wide). 22nd 
September 2017. Iron and Infection: Neonatal Iron Transition (NeoInnate Study – 
Prospective). 
 
• MRC Scientific Advisory Board Meeting (10 Minute Elevator Talks). 30th March 2016. 
Iron and Infection: Neonatal Iron Transition (NeoInnate Study – Prospective). 
 
• MRC Unit The Gambia – Nutrition Retreat Presentation. 3rd March 2016. Iron and 
Infection: Neonatal Iron Transition (NeoInnate Study – Prospective). 
 
There was one other paper that I was involved in as part of my laboratory work at MRC Unit 
The Gambia at LSHTM during my PhD registration. This was in the same field (iron 
homeostasis) as my thesis, but was unrelated to my PhD research:  
 
• Bah A, Muhammad AK, Wegmüller R, Verhoef H, Goheen MM, Sanyang S, Danso 
E, Sise EA, Pasricha SRS, Armitage AE, Drakesmith H, Cross JH, Moore SE, 
Cerami C, Prentice AM. Hepcidin-guided screen-and-treat interventions against iron 
deficiency anaemia in pregnancy: a randomised controlled trial in Gambian women. 
Lancet Glob Heal 2019;7:e1564–74 
 
 30 
1.6 PhD Timeframe 
 
The PhD registration period ran from 28th September 2015 until 31st December 2019. A 




The research was undertaken with a research grant provided by the Bill & Melinda Gates 
Foundation (OPP1152353), under principal investigator Dr Carla Cerami (primary 
supervisor). The funding agency had no role in the design and conduct of the study and did 
not have any in the collection, management, analyses or interpretation of the data nor in the 
preparation, review, or approval of the manuscripts. This research grant was used to pay for 
all my costs, including my travel and PhD stipend. The Nutrition Theme of the MRC Unit The 
Gambia at LSHTM are supported by core funding MC-A760-5QX00 to the MRC Unit The 
Gambia/MRC International Nutrition Group by the UK MRC and the UK Department for the 
International Development (DFID) under the MRC/DFID Concordat agreement. 
 
1.8 Ethics  
 
This study has been approved by The Gambia Government/MRC Joint Ethics Committee 
(no. SCC1525) (Annex 1.13-1.14) and Ethics Committee of London School of Hygiene and 
Tropical Medicine (LSHTM) (ref no. 14316) (Annex 1.15). This study was registered with 






1.9.1 Ending Preventable Neonatal Mortality  
 
Since the formation of the World Health Organisation (WHO) Millennium Development Goal 
4, significant progress in under-5 child survival has been made over the last two decades.35 
Neonatal deaths have decreased from 5 million (1990) to 2.5 million (2019).35 Despite this, 
nearly two million of these newborns die in their first week of life,36 with 24-45% of all 
neonatal deaths occurring in the first 24 hours of life.37 With the substantial reduction in 
under-5 mortality rates occurring mostly in the older cohort, a more significant proportion of 
under-5 deaths now occur in the neonatal period. This has been estimated as an increase 
from 40% in 1990 to 47% globally in 2019.35  
 
With the creation of the Sustainable Development Goal 3.2 in 2015, health professionals, 
academics and policymakers are aiming to end preventable deaths of all children under the 
age of five by 2030.38 Part of this is a target for all countries to reduce their neonatal 
mortality rate to <12 per 1000 live births. Emphasis has also been placed on the ongoing 
major global health challenge of high rates of stillbirth. It is estimated that a similar number 




Figure 1.3 Global distribution of newborn death by cause. Source: Levels & Trends in Child 
Mortality, WHO and Maternal and Child Epidemiology Estimation Group (MCEE) interim 
estimates produced in September 2019.35  
 
Preterm birth, intrapartum-related complications and infections (including sepsis and 
pneumonia) are the most common causes of neonatal death.35 Many of these deaths are 
due to gaps in the continuum of pre- and post-natal care.40 This includes pre-pregnancy, 
antenatal, intrapartum, delivery, postpartum, and postnatal periods for both the mother and 
her newborn.  
 
1.9.2 Neonatal Mortality in Low- and Middle-Income Countries (LMICs) 
 
Analysis of global neonatal mortality rates has highlighted substantial disparities at a country 
and regional level. Almost 99% of all neonatal deaths occur in low- and middle-income 
countries.37 In particular, the geographical region of Sub-Saharan Africa is struggling to stem 
the tide, with the highest neonatal mortality rate globally of 28 per 1000 births (2018).41 This 
suggests that African newborns are nearly nine times more likely to die in the first month of 
life than a child born in a high-income country.41 An extreme example of how much work 
remains to be done over the next decade is that some regional neonatal death rates in 
LMICs reach close to 46 deaths per 1000 births.38 
 
Simple interventions related to antenatal care, education, nutrition, and maternal health can 
all help reduce the prevalence of preterm and low birthweight newborns. One of the most 
effective is the low-cost mass drug distribution of oral iron and folic acid supplementation to 
pregnant women during pregnancy.42 This has been shown to reduce the risk of maternal 
iron deficiency and anaemia at term in the mother, leading to a reduced risk of delivering a 
preterm and/or low birthweight neonate. 
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Antenatal care is critical for reducing adverse outcomes in mother and baby. The WHO 
currently recommend that mothers receive a minimum of eight antenatal care contact visits 
during their pregnancy.43 However, only 65% of pregnant mothers in the world achieve four 
visits before delivery.44 This is significantly worse in LMICs.45 Moreover, this analysis does 
not take into account the skill level of the healthcare provider or the quality of the antenatal 
care received. The lack of pregnancy-related healthcare education and the high burden of 
adverse pregnancy and newborn outcomes in LMICs, results in mothers not seeking medical 
care when necessary. This can apply to both the onset of labour and newborn illness. The 
lack of regular attendance to antenatal care contact visits can also result in issues relating to 
micronutrient supplementation, hypertension, immunisations, sexual health screening, and 
acquiring insecticide-treated mosquito nets. Barriers to these interventions may include 
physical, financial and cultural aspects.46 
 
WHO guidelines support the delivery of a baby by a skilled birth attendant (SBA) at a health 
facility.47 Unlike previously, high proportions of deliveries in HICs and LMICs now take place 
in healthcare facilities.48,49 The reason for this recommendation was to offer the opportunity 
to deliver in a safe and clean environment, while providing skilled, good quality essential 
newborn and maternal care. This policy was designed to allow for the identification of high-
risk neonates and promotes their management quickly and effectively. However in LMICs, 
this has often resulted in more pregnant mothers delivering in unhygienic hospitals with 
inadequate health infrastructure or technology.50–52 The upsurge in healthcare facility 
deliveries has also increased the risk of newborns and mothers acquiring hospital-
associated infections, which commonly possess antimicrobial-resistance mechanisms.53 
This is made worse by the fact that many maternity and neonatal wards lack a continuous 
water supply, basic resuscitation equipment, resources for hand hygiene and waste 
disposal.53,54 Similarly, the ratio of skilled healthcare professionals to the number of beds is 
often far lower than recommended by the WHO.54 This situation is deteriorating in public 
hospitals in LMICs faster than anywhere else in the world due to staff attrition to different 
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countries or to newly established private healthcare facilities.55 This results in services being 
overstretched, leading to a reduced quality of care. Mothers as a result may then feel less 
inclined to remain in the delivery facility for the recommended 24 hours after birth. Ironically, 
this is the period in which most maternal and neonatal complications present.56 Studies also 
suggest that many newborns born in LMICs struggle to receive thermal protection 
immediately after delivery (e.g. kangaroo mother care (KMC)57), hygienic umbilical cord 
care58 or early and exclusive breastfeeding.59 All of these interventions are associated with a 
reduced risk of infection-related deaths in the newborn.60–62  
 
However, high-quality data are required to better understand the fundamental issues 
affecting newborns and their ability to survive and thrive. Analysis of global mortality rates 
and their causes has shown that both are influenced by inadequate coverage and poor 
quality of data.63 This can result in the misdirection of funds, resulting in inappropriate or 
weak interventions. Birth registration is a fundamental human right and is vital to economic, 
social and health planning, yet birth registration is at a prevalence of just 46% in sub-
Saharan Africa64. The lack of registered births, deaths, and accurate birthweight and delivery 
records may result in a misunderstanding of the true scale of the issue relating to neonatal 
mortality. Now there is greater advocacy to collect accurate, timely and disaggregated 
newborn data from LMICs, which can be used to support evidence-based decision-making, 
programming and planning.36,37,65 
 
1.9.3 Neonatal Mortality in The Gambia 
 
The Gambia has achieved the Millennium Development Goals of improving the under-5 
mortality rate, immunisation coverage, the proportion of the population using an improved 
drinking water source, primary schools enrolment and reduction in malaria disease burden 
by the 2015 deadline.66 Much less progress has been made in the reduction of neonatal 
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mortality rates. National neonatal death levels, as a proportion of under-5 deaths, have 
increased from 31% in 1990 to 45% in 2017.67 Like many other LMICs, preterm birth, 
intrapartum complications and sepsis are responsible for nearly three quarters of all 
newborn deaths (Figure 1.4). On this record, it is unlikely The Gambia can meet its 
Sustainable Development Goal 3.2 for neonatal mortality by 2030 unless vast and effective 
interventions are put into practice. 
 
 
Figure 1.4 Distribution of newborn deaths by cause in The Gambia. Source: Estimates 
generated by the WHO and Maternal and Child Epidemiology Estimation Group (MCEE) 
2018 (http://data.unicef.org).68  
 
Issues that face neonatal healthcare in The Gambia are similar to those in other LMICs. 
High levels of poverty, along with a shortage of adequately trained staff and a significant 
urban bias (66%) in the distribution of the workforce are amongst the issues.69 In general, 
Gambian healthcare system suffers from a limited amount of medical supplies and a lack of 
durable infrastructure and technology.70 The proportions of birth registration, skilled birth 
attendants present at delivery, postnatal care for newborns and exclusive breastfeeding 




Maternal and Neonatal Health-Related Statistics Value 
Total Births Per Year (000): 81 (2016) 
Total Under-5 Population (000): 360 (2016) 
Birth Registration (%): 72% (2013) 
Total Maternal Deaths Per Year: 590 (2015) 
Neonatal Mortality Rate (per 1000 live births) 22 (2013) 
Total Stillbirth Rate (per 1000 total births): 24 (2015) 
Neonatal Deaths Per Year (as % of all <5 deaths): 45% (2015) 
Total Under-5 Deaths Pear Year (000): 5 (2016) 
Skilled Birth Attendant (%): 57% (2013) 
Postnatal Care for Neonates (%): 6% (2013) 
Exclusive Breastfeeding (%): 47% (2013) 
Antenatal Care, 4+ Visits (%): 78% (2013) 
Low Birthweight Prevalence (%): 10% (2010) 
Iron/Folic Acid Supplementation During Pregnancy (%): 45% (2013) 
Physician Density (per 1000 population) 0.11 (2015) 
Nurse and Midwife Density (per 1000 population) 1.62 (2015) 
Table 1.1 Health-related statistics for The Gambia. Source: Countdown to 2030, Maternal, 
Newborn and Child Survival, Healthy Newborn Network.67 
 
1.9.4 Maternal and Newborn Care at Kanifing General Hospital 
 
Annually, Kanifing General Hospital (KGH) provides antenatal care to 500–700 pregnant 
mothers (unpublished hospital data, 2017), with many presenting very late in their 
pregnancy. This is thought to be due to pregnant mothers failing to see the advantages 
gained by early uptake of antenatal care. It is viewed as a curative rather than preventative 
measure.71 Local healthcare centres report that few mothers meet the new requirement for 
eight antenatal visits, with close to half receiving the old requirement of four antenatal 
visits.72 This significantly differs from the data produced by a Gambian demographic health 
survey (DHS).70  
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Antenatal care at Kanifing General Hospital is provided by a group of dedicated, skilled and 
experienced nurses and midwives. However, as in other hospitals in LMICs, barriers to their 
care remain. Blood pressure monitoring, urine sampling, blood sampling, tetanus protection, 
iron supplementation, fetal monitoring and health education are seven routine components 
of antenatal care that are available at Kanifing General Hospital. Nonetheless, it is rare for 
all to be available at one antenatal visit. Critical for detecting pre-eclampsia, the lack of back 
up or charged (i.e. lack of electrical supply) electrical blood pressure monitors results in 
blood pressure measures being missed. Similarly, due to the lack of full blood count 
laboratory supplies and broken haemoglobinometers, many weeks’ worth of haemoglobin 
measurements can be lost. This increases the risk of maternal anaemia not being 
diagnosed, and subsequently could led to increases rates of stillbirths, low birth weight and 
preterm babies.73 During the initiation of this study, it also became apparent that only one 
Pinard horn for fetal monitoring was available throughout the whole hospital. 
 
The total number of births at Kanifing General Hospital equals close to 3500–4500 per year 
(based on hospital data from 2014-2015, unpublished). This is 5-6-fold higher than the 
number receiving antenatal care at the hospital. The percentage of these that are live, low 
birth weight neonates (<2.5kg) is approximately 10% (based on hospital data from 2014-
2015, unpublished). Further details relating to delivery care at Kanifing General Hospital can 
be seen in Section 2.1.3.  
 
1.9.5 Contribution of Neonatal Infections 
 
Neonatal sepsis is the third highest cause of death globally, accounting for 225,000 deaths 
each year.1 This results in neonatal infections (e.g. bacterial sepsis, meningitis, pneumonia, 
and tetanus) causing an estimated 23% of all neonatal deaths. Neonatal sepsis alone 
accounts for 15% of these deaths,36 with the majority occurring in Sub-Saharan Africa.74 
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Intrauterine and neonatal infections do not just cause death, but also can result in 
substantial long-term multisystem morbidity, affecting not just the individual but the local 
community as well as national productivity.75,76 
 
Early-onset neonatal sepsis (EONS) is defined as bacteraemia or bacterial meningitis 
occurring within <72 hours of life, with most causative pathogens being transmitted vertically 
from mother to infant before or during delivery.77 Maternal chorioamnionitis, prematurity, fetal 
distress (i.e. fetal tachycardia or passage of meconium), prolonged rupture of membranes 
and maternal colonisation with group B streptococcus (GBS) are all deemed influential risk 
factors.77 Quite different to this is late-onset neonatal sepsis, which occurs after this point 
(>72 hours), with transmission often occurring horizontally from the surrounding delivery 
environment.78 As a result, many of the causative microorganisms are nosocomially derived.  
 
In a recent highly informative review conducted by Okomo et al.,79 it is suggested that 
aetiology data of neonatal infections in sub-Saharan Africa is of poor quality with 
publications rarely using the STROBE-NI reporting guidelines. Studies that solely observe 
the epidemiology of neonatal infections in Gambian newborns are lacking. This is despite a 
high burden of infectious disease in this population and region. In 1999, Mulholland et al. 
suggested that the most important causes of serious, very young infant infections were 
Streptococcus pneumoniae, Staphylococcus aureus, and Salmonella spp.80 New data 
analysis by Okomo et al. now suggests that Staphylococcus aureus, Klebsiella spp. and 
Escherichia coli are the most common causes of bacteraemia and sepsis in African 
newborns.79 This change in aetiology over the last twenty years is thought to be due 
advances in delivery and newborn care along with the introduction of several new vaccines 
(e.g. Pneumococcal conjugate vaccines and Haemophilus influenza type b).81 Though not 
given directly to the newborn, Okomo et al. speculates that both vaccines have reduced the 
transmission of pathogenic isolates in the community. Subsequently, herd immunity could be 
 
 39 
affecting the colonisation rates and densities of these and other species of pathogenic and 
commensal bacteria in the newborn. 
 
Part of the reason why S. aureus is found to be a predominant cause of neonatal sepsis in 
developing countries is believed to be due to its ability to colonise the skin of newborns, 
mothers and caregivers.82,83 However, care must be taken with interpreting its apparent high 
prevalence, as inadequate site sterilisation when blood cultures are taken may also lead to 
increased rates of false detection.84 Confirmed S. aureus sepsis is strongly associated with 
higher mortality rates as compared to other bacterial pathogens. This is partly due to 
metastatic complications in disease progression85 and its strong association with sepsis in 
low birthweight newborns.86  
 
Enterobacteriaceae such E. coli and Klebsiella spp. are widespread in the maternal genital 
tract, and hence neonates acquire these isolates commonly via their gastrointestinal or 
respiratory tracts during delivery.87 Okomo et al. observed Klebsiella spp. to be the second 
leading cause of neonatal infections in their study.81 A potential reason for this may be its 
strong association to nosocomial settings,88 the capacity to produce biofilms89 and its ability 
to display multidrug-resistant phenotypes by producing extended-spectrum β-lactamases 
(ESBLs) or carbapenemases.90 With regards to E. coli, strains that commonly cause 
neonatal sepsis often express plasmids, which are essential in processes such as iron 
acquisition and virulence.91 Interestingly, E. coli and Klebsiella strains are associated with 
risk factors such as prematurity and very low birthweight.90  
 
1.9.6 Diagnosis and Treatment of Neonatal Sepsis 
 
Diagnosis of neonatal sepsis remains difficult, partly as there is no accepted definition. 
Identification with high accuracy and specificity is a challenge not only in developing 
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countries but even in well-equipped tertiary healthcare facilities in HIC settings.92 Blood 
cultures are the gold standard for the diagnosis of neonatal sepsis. Because of economic, 
logistical and infrastructure-related restrictions, developing countries face multiple 
challenges when implementing blood culture-based diagnostic testing. Microbiological 
identification of a pathogen isolated from blood cultures has high specificity, but sensitivity is 
low. This is supported by the Aetiology of Neonatal Infections in South Asia (ANISA) study,93 
conducted in Bangladesh, India, and Pakistan. This was designed to investigate the 
incidence of possible severe bacterial infection (pSBI) episodes in the first two months of life 
and estimate the proportions of bacterial and viral causes. This large study implemented the 
use of the latest metagenomic approaches, and still only detected 28% of all causative 
organisms of pSBI. Reasons for low sensitivity of microbiological identification include the 
collection of small neonatal blood volumes, the presence of low or intermittent isolate 
concentrations and maternal intrapartum antibiotic exposure.94 In order to combat this issue, 
the WHO launched the Integrated Management of Childhood Illness (IMCI) algorithm as part 
of the WHO Young Infants Clinical Signs Studies (YICSS).95 This has led to the production 
of a seven clinical signs diagnosis to use when laboratory services are not available. This 
clinical algorithm is associated with 85% sensitivity and 75% specificity for severe bacterial 
infection in the first week of life.96 Other investigations that are thought to assist in the 
diagnosis if appropriate include full blood count, chest radiograph, CRP measurement, CSF 
or skin swabs.97  
 
The WHO Integrated Management of Childhood Illness (IMCI) policy suggests that 
prophylactic intramuscular (IM) or intravenous (IV) ampicillin and gentamicin should be given 
to neonates with documented risk factors for neonatal sepsis.98 WHO recommends that this 
should continue for two days following which the neonate should be reassessed. In LMIC 
settings, however, the use of parenteral therapies in newborns may be limited by the 
availability of inpatient neonatal care, transportation to healthcare facilities, economic and 
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social factors.99 New interventions to prevent severe neonatal infections are required and 
are of great interest to the maternal and newborn research community.  
 
1.9.7 The Threat of Antimicrobial-Resistant Infections 
 
It has been estimated that the number of people who will die as a result of antibiotic-resistant 
infections will rise from 700,000 to 10 million each year by 2050.100 Antibiotic resistance is a 
major global health threat, with nearly half of the pathogens that cause severe neonatal 
bacterial infections worldwide reported to be resistant to the first-line (ampicillin or penicillin, 
and gentamicin) and second-line (third-generation cephalosporins) WHO-recommended 
treatments.101 Laxminarayan et al. produced estimates suggest 30% of all neonatal deaths 
can be attributable to multidrug-resistant pathogens.102 A disproportionate number of these 
deaths occur in developing countries, and the rates are increasing. In particular, a small 
group of studies conducted in Sub-Saharan Africa show a high prevalence of resistance to 
recommended empirical therapies to neonatal sepsis.103,104  
 
In developing countries, gram-negative bacteria have frequently been reported as the cause 
of neonatal sepsis.79 This is a worrying trend, with many gram-negative bacteria intrinsically 
resistant to many antibiotics, along with the ability to transfer genetic material of new 
resistance mechanisms between species.105 Klebsiella spp. and E. coli can both can carry 
extended-spectrum beta-lactamase (ESBL) producing plasmids, enabling them to become 
resistant to a wide variety of penicillin and cephalosporin antibiotics.106 In this scenario, 
carbapenems are the last remaining treatment option,106 however, the availability of second-
line antibiotics in developing counties is known to be poor.107 K. pneumoniae is also the 
leading cause of infections caused by carbapenem-resistant bacteria worldwide.108 The 
acquisition of an enzyme called New Delhi metallo-beta-lactamase (NDM-1) is a significant 
reason for this.109 Bacteria with this genetic element can cause disease with increased 
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morbidity and mortality,110 especially in preterm newborns.111 Previous authors have 
commented that strains harbouring these antimicrobial-resistant components are a massive 
threat to neonatal units, particularly in LMIC hospitals as neonates are subjected to poor 
infection control and high antimicrobial exposure.112  
 
With regards to S. aureus antimicrobial resistance, methicillin-resistant Staphylococcus 
aureus (MRSA) infections have now spread worldwide,113 with some of the fastest rates of 
the increase occurring in community settings.114 The WHO now reports that in some 
locations of Africa, 80% of S. aureus infection are caused by MRSA.115 Nevertheless, 
optimism remains, with MRSA still remaining sensitive to glycopeptides such as vancomycin 
and teicoplanin, and other antibiotics like linezolid, tigecycline, and daptomycin.114 However, 
many of these drug options are expensive, regularly unavailable in LMICs and have potent 
side-effects on newborns.98 
 
1.9.8 Interventions to Combat Neonatal Infections  
 
Staphylococcus aureus, Klebsiella spp., and Escherichia coli are all pathogens associated 
with poor hygiene in hospital environments, suggesting that new interventions are required 
in sub-Saharan hospitals to increase infection control from surfaces, hands and water.  
One such intervention is the use of a bundle of hygiene-based interventions for a hospital 
maternity ward. A study that implemented such a bundle provided enhanced infection 
prevention and control training, clean delivery kits (e.g. a blade, cord thread, antiseptics), 
text message reminders, alcohol hand rub, timed environmental cleaning and the 
introduction of bathing babies >1.5 kg with 2% chlorhexidine gluconate.116 This study 
subsequently observed reductions in sepsis and death rates in hospitalised neonates in a 
high-risk setting in a developing country. These kinds of interventions offer simplicity and 
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reasonable levels of sustainability, with the production of standardised protocols helping to 
improve aseptic practices in the delivery rooms and neonatal units.  
 
A further intervention toward the prevention of neonatal sepsis in LMICs is the use of oral 
azithromycin given to the mother during labour.117 Azithromycin is a macrolide antibiotic that 
has a broad antimicrobial activity. Azithromycin has also been found to reduce the proportion 
of low birthweight births by a quarter, when given intrapartum to the mother for the last few 
months of pregnancy.118 Equally, it has been able to reduce overall under-5 mortality when 
given in the form of a mass drug administration trial.119 More recent studies have shown that 
azithromycin during labour can significantly reduce bacterial carriage (e.g. mainly S. aureus, 
GBS and S. pneumoniae) both in the mother and her newborn.117 This suggests that it halts 
the vertical transmission of neonatal sepsis-causing organisms from mother to child and 
hence may lower their risk of neonatal sepsis, pneumonia and meningitis. It is now believed 
that this simple one dose intervention could dramatically improve neonatal mortality in 
LMICs. However, questions remain about the effect MDA of antibiotics will have on the 
levels of antimicrobial resistance in the mother, newborn and the broader community.120  
Symbiotics are a combination of probiotics and prebiotics; the latter is added to promote 
growth and sustain the colonisation of the probiotic bacterial strain. Studies looking at the 
effects of symbiotics, prebiotics and probiotics have grown more popular over recent years. 
This is primarily due to the naive immune system of the neonate and the undeveloped 
gastrointestinal microbiome making it easier to establish probiotic strains.121 One of the main 
successes of this area of study is the use of probiotics to reduce the incidence and severity 
of necrotising enterocolitis in premature infants.122,123 Now, research suggests that 
symbiotics can be used to reduce neonatal sepsis mortality rates in LMICs.124,125 One of the 
most prominent studies using symbiotics, is the one conducted by Panigrahi et al.126 This 
was a randomised, double-blind, placebo-controlled oral symbiotic trial of Lactobacillus 
plantarum plus fructo-oligosaccharide in India. This study identified that a single symbiotic 
preparation was protective against neonatal sepsis and death in the first week of life. This is 
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an exciting finding, that may relate to the findings of our study, as Lactobacillus plantarum is 
an organism that does not require iron for growth, and instead uses manganese in many of 
its metalloenzymes.127 The establishment of Lactobacillus plantarum colonisation at birth 
could be out competing pathogenic species (i.e. that require iron) for space and niches, due 
to the hypoferremic conditions. Panigrahi et al. believe that these findings suggest that this 
cost-effective method could be used in developing countries to reduce the rates of neonatal 
sepsis.126  
 
1.9.9 Transition to Extrauterine Life  
 
The higher rates of mortality relating to severe bacterial infections in newborns are 
suggested to be partially due to the immense physiological and immunological strain on the 
neonate in the first few days of life. The transition from fetal to extrauterine life leads to all 
organ systems being involved in major instantaneous adaptions to respiratory exchange, 
cardiovascular flow, endocrine function, haematological maturation, substrate metabolism 
and thermogenesis.128  
 
Though the sterile womb paradigm versus in utero colonisation hypothesis continues to 
divide,129,130 childbirth is still characterised by a neonate descending from a semi-allogeneic, 
protected environment to one that is far more abundant in a diverse array of microbes. This 
is the initial focal point of mass bacterial colonisation of the skin and gastrointestinal tract of 
the neonate, resulting in changes to nutritional and immunological functions in early life and 
beyond.5,6 
 
Regarding iron homeostasis, as seen in our study, increases in newborn haematocrit and 
haemoglobin occur within the first hours post-delivery. This is likely due to post-delivery 
dehydration, as well as vasomotor instability and venous pooling.131 Similarly, serum ferritin 
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levels increase due to the physiological haemolysis of fetal red blood cells, which contain 
ferritin in high concentrations.132 This process leads to fetal haemoglobin recycling into the 
adult form to aid respiratory exchange in the extrauterine environment.133 A frequent side-
effect of this red cell turnover is hyperbilirubinemia (i.e. physiological or idiopathic jaundice), 
which is a common clinical issue in most (60-80%) neonates in the first weeks of life.134 
 
1.9.10 Immune Responses of the Neonate  
 
Neonates are also partly hindered by possessing a functionally immature and developing 
immune system. The broad-range killing capacity of the innate immune system consists of 
granulocytes, antigen-presenting cells, NK cells and γδ-T cells.135 Neutrophils are the 
predominant cell type of the innate immune system, with their role being to engulf and 
degrade pathogens during infection. Nevertheless, neonatal neutrophils at birth can be 
measured as low as 1.5 × 109 cells/L blood, compared to 4.4 × 109 cells/L in adults.136 
Neonatal neutrophils also possess qualitative deficiencies in respect to low levels of 
expression of TLR4 (critical for IL-6 expression), cell surface L-selectin, Mac-1 (critical for 
transmigration) and neutrophil extracellular traps (NETs).137,138 These deficiencies are even 
more pronounced in preterm neonates. Similarly, DC cells, γδ-T cells and monocytes are 
also all in low concentrations in the neonate and exhibit low expression levels of MHC-II, 
CD80, CD86, CD40 and ICAM-115. This is thought to inhibit their ability to activate antigen-
specific B and T cell populations.136  
 
The immune system of premature neonates is further underdeveloped when compared to 
full-term newborns (Figure 1.5). Antimicrobial proteins and peptides (APPs) are released to 
destroy pathogens by iron-binding, enzymatic destruction, zinc deprivation and membrane 
pore formation. Such proteins and peptides are secreted into the vernix caseosa found 
coating the skin, respiratory and gastrointestinal tracts of newborn babies.139 However, the 
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production of APPs and vernix caseosa is positively correlated with gestational age,140 
potentially leading to early preterms being at higher risk of infection. Preterms also start life 
with a lower endowment of antigen-specific IgG than full-term neonates, resulting in reduced 
opsonisation and phagocytosis. This is due to IgG being transferred across the placenta 
from the maternal circulation in large amounts after 32 weeks of gestation.140 In full-term 
neonates, the complement pathways (classical, alternative and lectin) are generally similar 
to adult levels, this aids the destruction of bacterial cells. However, these pathways are also 
all immature in preterm neonates.141 
 
 
Figure 1.5 An overview of innate immune deficiencies of preterm and low birthweight 
babies. Adapted from Melville et al.140 
 
Immunological deficiencies in neonates (exaggerated in low birthweight and preterm babies) 
no doubt reflect in the typical clinical presentation of neonatal sepsis. This presentation is 
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often rapid in progression, with many nonspecific clinical signs.97 This is further confirmed by 
unusual haematological laboratory results coming from newborn blood samples.142 Our 
study experienced such results, with even healthy newborns found to have increased white 
blood cell counts from cord and venous samples; though we suspect that this might be an 
artefact of nucleated red blood cells being identified as granulocytes.  
 
1.9.11 Iron in Infection and Immunity  
 
Iron is a cofactor in numerous metabolic pathways that are critical for the human host. 
Transition metals (e.g. Fe, Cu and Mg) are commonly built-in to metalloenzymes, storage 
proteins and transcription factors.143 This results in children and pregnant woman requiring 
adequate iron stores for growth and development. The lack of such stores leads to iron 
deficiency and anaemia, which subsequently negatively affects the immune response to 
infection.144 However, the catalytic action of these metals also potentiates their toxicity when 
in high concentrations (i.e. equalling tissue damage and inflammation), so the levels of these 
metals must be well regulated.145 The mechanisms that regulate the toxicity of free transition 
metals in the body, additionally function as a countermeasure against local pathogens 
(Figure 1.6).143 This is seen clinically with individuals suffering from high iron states (e.g. 
haemochromatosis), not only resulting in free radical redox damage but also an enhanced 
risk of infection from iron-dependent species of bacteria.18,19 This host-pathogen battle for 
resources is due to iron also being a vital commodity for growth, replication and virulence of 
most pathogenic microorganisms. Subsequently, pathogens have evolved counteractions to 





Figure 1.6 The host-pathogen battle of iron.  
 
Neonatal sepsis-causing bacterial pathogens can produce a plethora of molecular 
mechanisms such as siderophores and iron-specific channels (Table 1.2). These iron 
acquisition genes are frequently concentrated on high pathogenicity islands.147 
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Table 1.2 Iron sources of neonatal sepsis causing bacteria. Source: Adapted from Andrews 
et al.196  
 
In 2000-2001, three independent research groups discovered the hormone hepcidin.197–199 
Hepcidin is now understood to be the master regulator of human iron homeostasis, and 
consequently iron-restriction.200 Host inflammatory mediators, IL-621, IL-2222 and Type 1 
interferon23 increase transcription of hepcidin in the liver through several toll-like receptor 
(TLR) ligands24 and STAT3 signalling.24,25 This results in the internalization of the 
transmembrane protein ferroportin in macrophages and enterocytes. This leads to the 
breakdown of ferroportin in the lysosome. Consequently, enteric absorption of dietary iron is 
reduced, and sequestration of iron in macrophages causes a decrease in systemic iron 
concentration in the circulation.201 In neonates, due to the relatively small amounts of iron 
absorbed enterically, iron restriction mainly takes place in circulating macrophages. Hepcidin 
synthesis is also known to be controlled by high iron stores, hypoxia, and erythropoiesis 
(Figure 1.7).200  
 
 




The human host also produces many host chaperone molecules such as transferrin, 
lactoferrin, haptoglobin, hemopexin (Figure 1.8) to limit the acquisition of iron and its 




Figure 1.8 The sequestration of iron and its moieties. Source: Adapted from Parrow et al.202 
 
1.9.12 Dysregulation of Iron Homeostasis 
 
For the reasons stated above, iron homeostasis needs to be maintained at all times. Iron 
supplementation is widely regarded as one of the most critical public health interventions in 
low and middle incoming countries, reducing the morbidity and mortality linked to iron 
deficiency and anaemia.42 However, reports have suggested that iron supplementation in 
areas with high burdens of infectious disease can increase the risk of severe bacteria 
morbidity and mortality.203 We suggest that a study conducted by our team (and led by the 
candidate) partly explains the mechanism. In the previous FeVir study,204 we collected the 
blood of 48 adult male Gambian subjects immediately before and four hours after taking 400 
mg ferrous sulphate orally. We then performed full blood counts and analysis of serum 
biochemical parameters, including serum iron, transferrin, ferritin, and transferrin saturation 
(TSAT). Additionally, we inoculated these paired serum samples with different sepsis 
causing organisms such as Staphylococcus aureus, Staphylococcus epidermidis, 
Salmonella enterica serovar Typhimurium and Escherichia coli in an ex vivo bacterial growth 
assay. This study concluded that ex vivo bacterial growth over twelve hours (36h for Y. 
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enterocolitica) was significantly increased by supplemental iron and strongly correlated with 
TSAT and serum iron concentration (Annex 1.16).  
 
A clinical study by Barry et al. showed similar results in a different context.205 Barry et al. 
discovered that Polynesian neonates were twenty-fold more likely to have neonatal sepsis 
compared to European neonates. This research uncovered that this was due to 
intramuscular iron dextran injections given to the neonate if they were thought to be 
anaemic. Barry et al. also described that there was not only a difference in the incidence of 
sepsis and mortality between those given iron dextran injections but additionally, a 
difference in the type of causative organism. Further data showed that iron dextran had 
impaired the nutritional immunity of the newborns and changed the causative organism from 
S. aureus to E. coli. This finding associates closely with the differences in growth seen 
between S. aureus and E. coli isolates in response to TSAT level seen in our previous FeVir 
study.204 
 
Both the ex vivo and in vivo studies suggest that lower iron concentrations in the blood are 
vital to limit the growth of bacteria and severity of sepsis caused by common neonatal 
sepsis-causing pathogens. 
 
1.9.13 Pre-Analytical Effects on Hepcidin Measurement 
 
As hepcidin is the master regulator of iron homeostasis, its measurement can be crucial to 
the diagnosis of several iron-related disorders. However, its accurate measurement is 
complicated. Hepcidin is at the centre of the iron, infection and inflammation axis.206 
Significant increases in hepcidin concentration occur in response to iron administration 
and/or inflammatory stimuli. Subsequently, this can cause several clinical conditions and 
treatments to confound systemic hepcidin measurements. This is observed for chronic 
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kidney disease (increase),207 erythrocyte transfusions (increase),208 alcohol abuse 
(decrease)209 and chronic hepatitis C viral infection (decrease)210 all having an effect. These 
observations result in the need for a detailed medical history to be collected when 
researching the molecular mechanisms related to iron homeostasis in the human host. 
 
Serum hepcidin concentrations also vary significantly between healthy subjects, as 
evidenced by the published reference ranges.211,212 Itkonen et al. noted that reference values 
for adult females (18–50 yrs) ranged between 0.4–9.2 nmol/L, 0.7–16.8 nmol/L for females 
>50 yrs and for adult males (≥ 18 yrs) between 1.1–15.6 nmol/L.212 These results suggest 
lower hepcidin levels are observed in pre-menopausal women, as well as a significant 
difference between sexes (i.e. higher concentrations in men). In-subject variation is also 
detected, with fasting and diurnal rhythm both found to play a role.213,214 This is seen with 
serum hepcidin concentrations being found to be lowest in the early morning, increase over 
the day, followed by a return to more moderate levels by evening. 
 
Further complications of measuring hepcidin concentration in human urine, serum and 
plasma come from laboratory-based issues. Of the two main methods of measuring 
hepcidin, mass spectrometry-based methods (MS) are expensive but are accurate, more 
reproducible and measure only the native complete form of hepcidin, hepcidin-25.215 
Enzyme-linked immunosorbent assay-based methods (ELISA) are more cost-effective; 
however, these methods additionally measure the other isoforms of hepcidin, hepcidin-20 
and hepcidin-22.215 The effect of these different test attributes on the clinical diagnosis of 
iron-related disorders is still unclear. The measurement of hepcidin by ELISA-based 
methods is further hindered by hepcidin being a relatively small size (i.e. 25 amino acids) 
with few antigenic epitopes.216 Antibody generation required for the production of the ELISA-
based method is hampered by the high degree of genetic conservation between animal 
species, making it a challenge to produce viable antibodies from exposure to the protein in 
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the host animal.217 Production of synthetic alternatives is also challenging due to hepcidin's 
complex hairpin-like conformation with four disulphide bonds.218 
 
An essential aspect of the laboratory handling process of samples requiring serum hepcidin 
measurement is the monitoring of freeze-thaw cycles. Serum hepcidin is reported to only 
remain stable for two to four freeze-thaw cycles, dependent on the analysis method.219,220 
Additionally, Itkonen et al. has noted that hepcidin concentration starts to decrease after 24-
48 hours storage at room temperature, six days at 4°C, 42 days at −20°C, and over two 
years at −80°C.212 This is not bettered by hepcidin's ability to aggregate and adhere to 
plastic laboratory test tubes and pipette tips.221 
 
Previously, the analysis of hepcidin concentration has been hindered by the lack of a 
commutable calibrator, a reference material, and a reference method.221 Subsequently, 
analysis of serum hepcidin levels from various publications share correlation; however, 
absolute values regularly vary considerably between the ELISA test kits used (Chapter 3) 
This is observed with low values being associated with the use of DRG ELISA kits, and high 
values linked with the use of Intrinsic Lifesciences and Bachem ELISA kits. To combat this 
Van der Vorm et al. produced a commutable candidate reference material that was a native, 
lyophilized plasma with cyrolyoprotectant.34 This material was refined and is now freely 
available for purchase.222 However, this product was not available at the time of laboratory 
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Summary of Chapter 
 
This chapter provides a brief geographical and economic overview of the Kanifing region 
and The Gambia as a whole. This is then followed by a description of the work environment 
at the study hospital, Kanifing General Hospital. Lastly, I describe the environment in which 
community visits take place around the Kanifing and Kombo regions, in the homes of study 




















2.1 PhD Study Setting 
 
2.1.1 The Republic of The Gambia 
 
The Republic of The Gambia is the smallest mainland African nation, formed around the 
River Gambia. As part of West Africa, it is surrounded by Senegal and has a population of 
2.3 million people (2018).1 The population is growing at a rate of approximately 2.9% per 
year (2018).2 Islam is practised by 95% of the country’s population, with twelve main ethnic 
groups, the largest of which are Mandinka and Fula.3 The Gambia has a market-based 
economy, focused around tourism and traditional subsistence agriculture.3 
Figure 2.1 Map of The Gambia. Arrow shows study site location at Kanifing General 
Hospital. Source: © OpenStreetMap contributors. 
A countrywide political problem faced by the study was the removal of the previous 
President of The Gambia, Yahya Abdul-Aziz Jemus Junkung Jammeh. The Gambia 
experienced a contested election in December 2016, which provoked a constitutional crisis. 
The situation was resolved by military intervention from the neighbouring countries from the 
Economic Community of West African States (ECOWAS). The new Gambian president was 
inaugurated towards the end of January 2017, but even after the inauguration, the Gambian 
government and society were in a state of flux and political uncertainty. This affected the 
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timing of three aspects of the study, including ethical approvals, community sensitisation, 
and study initiation. 
 
2.1.2 Kanifing Municipality 
 
The Kanifing region is made up predominately of the large town, Serrekunda. Kanifing 
region is a peri-urban area with a population of around 370,0004 and is 10 km to the 
southwest of the capital, Banjul. Serrekunda was initially made up of nine villages that have 
merged into a sprawling urban area. 
 
2.1.3 Study Sites: Kanifing General Hospital, The Gambia 
 
Figure 2.2 Map of Kanifing, The Gambia. Source: © OpenStreetMap contributors. 
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Kanifing General Hospital, located in the Kanifing district, is one of six general hospitals in 
The Gambia. It is a public, government-run facility that first opened in 2010. Named initially 
Serrekunda General Hospital (SGH) it contains approximately 130 beds, with services and 
units such as an accident and emergency unit, out-patient unit, CT scanning department, 
maternity, antenatal and paediatric units. Recent investment has led to the formation of a 
small neonatal care unit. Complex clinical cases are commonly referred to The Edward 
Francis Small Teaching Hospital (EFSTH) in Banjul, as it is the only tertiary government 
referral hospital.3 Seven paediatricians staff the maternity and paediatric wards, along with 
sixteen senior nurses/midwives. During the study period, usually, there were four to six 
trained nurses working in the maternity ward during the day shift, with an equal number of 
nurse attendants. Staffing levels would commonly reduce during the night shift. Previously, 
the hospital has experienced periodic shortages of medicines, supplies, staff, electricity and 
water. 
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Figure 2.3 Kanifing General Hospital Maternity Ward. NeoInnate study team recruiting (top 
left), cord bleeding (top right), electronic data collecting (bottom left) at Kanifing General 
Hospital Maternity Ward (bottom right). Note: all imaged individuals have provided 
photographic consent. 
 
Annually, Kanifing General Hospital (KGH) provides antenatal care to 500–700 pregnant 
mothers (unpublished - hospital data). Mothers receiving antenatal care at other local 
primary health-care facilities increase the total number of births at the hospital to 3500–4500 
per year (unpublished - hospital data). The percentage of these that are live, low birthweight 
neonates (<2.5kg) is approximately 10% (hospital data 2016-2018, unpublished). During the 
study period, rates of stillbirth were at times poorly documented by hospital maternity ward 
staff, as seen in other institutions in low- and middle-income countries (LMICs).5  
 
The maternity ward was split into two large wards, with one being used for pre- and post-
delivery mothers and their neonates. There was also an adjacent eight-bed open-plan 
delivery ward. The delivery ward used a single partially broken neonatal resuscitator, which 
was commonly occupied by multiple neonates (1-3) at peak admission periods. The delivery 
ward also possessed limited respiratory support in the form of a single electrical oxygen 
concentrator. Thanks to the help from MRCG at LSHTM, both issues were overcome quickly 
in order to ensure service quality greatly improved. Other barriers to care included the lack 
of implementing Kangaroo mother care (KMC) in the hospital at the beginning of the study. 
As a result of a local implementation study, we were able to train several doctors and senior 
nurses on the care protocols. Infection control was also deemed to be poor quality in the 
maternity ward during the initiation of the study. As a result, we ensured new cleaning 
equipment was available on a monthly basis, in addition to investment into new waste 




A study-specific issue we experienced at Kanifing General Hospital was that mothers who 
delivered at the hospital were not always receiving antenatal care at the same health facility. 
At the beginning of the study, this resulted in many newborns being missed to recruitment. 
Anecdotal evidence suggested that mothers who were approached at antenatal visits at 
Kanifing General Hospital were often choosing to deliver at home or a primary level 
healthcare facility. Subsequently, our study team worked with local midwives and nurses to 
ensure mothers were informed of the benefits and risks associated with delivery at Kanifing 
General Hospital and being part of the NeoInnate Study. Furthermore, we also produced an 
additional recruitment route to ensure mothers receiving antenatal care outside the hospital 
could equally have their newborn recruited to the NeoInnate Study. This was a two-stage 
process, in which on arrival to the maternity ward if the mother was found to be capable, she 
would consent to the collection and storage of cord blood in the maternity ward. After a few 
hours, and when the mother was deemed to be in the right frame of mind after the delivery 
process, she was asked as to whether the cord blood sample and her neonate could be full 
recruited into the study. If at this point, the mother refused to give consent, the cord blood 
sample and her data were removed from the fridge and study server, respectively. This 
aspect of the study protocol required high-quality consent training focused on detailed 










2.1.4 Study Sites: Community Visits (West Coast Region) 
 
Figure 2.4 Community study visits to the homes of recruited newborns. Note: all imaged 
individuals have provided photographic consent. 
 
Neonates were visited at their home address between 24-192 hours post-delivery. Neonates 
originated from a wide area of villages across the Kombo region, the closest of which was 
from fifty metres away from the hospital, with the furthest coming from Faraba Banta (41.2 
km away). Gambian homes were generally made of concrete with open windows and tin 
rooftops. Occupancies were shared between large family groups, as is common in the 
region. At each visit, a physical examination of the neonate was completed, followed by the 
collection of a venous blood sample, if the neonate was born full-term, normal birthweight. 
For further details of community visit protocols, see Chapter 4.6 
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Figure 2.5 Community study visits involved a complete review of systems and the collection 
of neonatal vital signs data. Note: all imaged individuals have provided photographic 
consent.  
 
2.1.5 Study Sites: Laboratory Work (Kanifing General Hospital and MRCG 
Keneba Laboratory) 
 
During the study site setup process, we became aware that laboratory facilities on-site at the 
hospital would be required. Kanifing General Hospital provided our study team with a 
disused storeroom, which we converted into a study-specific laboratory. This fully functioning 
laboratory contained temperature control, UPS, internet, refrigeration, locked storage and 
sample processing equipment (i.e. centrifuge, full blood count machine, sample rollers, 
pipettes). Twelve Kanifing General Hospital and three MRCG laboratory technicians 
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provided round-the-clock laboratory service. This design ensured the implementation of the 
study led to direct capacity building in the hospital. Full haematological analyses, serum 
separation and sample storage were performed in this laboratory. On completing the sample 
collection phase of the NeoInnate Study, samples were transported to MRCG Keneba field 
station (Kiang region) on dry ice. Secondary laboratory analysis including glucose-6-
phosphate dehydrogenase deficiency testing (G6PD), biochemical analysis (serum ferritin, 
serum iron, unbound iron-binding capacity (UIBC), soluble transferrin receptor (sTfR), 
transferrin, C-reactive protein (CRP), haptoglobin, and alpha-1-acid glycoprotein (AGP)) and 
hepcidin ELISA testing were performed on a batch basis by two study staff members.   
Figure 2.6 Laboratory bench-top work during PhD study. Primary sample processing was 
completed in a purpose-built renovated laboratory at Kanifing General Hospital for 
NeoInnate study (right). MRC Keneba Microbiology Laboratory (bottom left) was the location 
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Chapter 3 - Hepcidin, serum iron and transferrin saturation in full 
term and premature infants during the first month of life: A review 
of existing evidence in humans (Review) 
 
 
Summary of Chapter 
 
BACKGROUND: Iron sequestration is a fundamental aspect of innate immunity. Evidence 
suggests that neonates actively regulate their iron distribution at birth and in early postnatal 
life, in order to sequester iron away from microbial pathogens. 
 
OBJECTIVE: To review existing evidence of serum iron, transferrin saturation and hepcidin 
levels in full-term and premature infants during the first month of life. 
 
METHODS: We reviewed literature retrieved from PubMed and Ovid Medline containing 
data on umbilical cord and venous blood concentrations of hepcidin, serum iron and 
transferrin saturation in human neonates from 0-1 month of age. After the standardisation of 
the hepcidin values based on inter-assay cross-calibration studies, weighted mean averages 
were produced for cord and venous blood using available data. Similar weighted means 
were produced for serum iron and TSAT. 
  
RESULTS: Data from 59 studies were used to create reference ranges for full-term 
neonates over the first month of life. In full-term neonates, venous blood hepcidin increases 
2-3-fold over the first month of life (to reach 61.1 ng/mL; CI: 20.1-102.0 ng/mL) compared to 
umbilical cord blood (29.7 ng/mL; CI: 21.1-38.3 ng/mL). Cord blood has high levels of serum 
iron (28.5 μmol/L; CI: 26.0-31.1 μmol/L) and TSAT (51.7%; CI: 46.5-56.9%). Following a 
short-lived immediate postnatal hypoferremia, iron and TSAT rebounded to approximately 
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half the levels in the cord by the end of the first month. There was insufficient data to 
formulate reference ranges for preterm babies.  
 
CONCLUSION: Evidence shows that full-term neonates experience an early postnatal 
hypoferremia as an innate immune defence, probably mediated by hepcidin. It is unclear 
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BACKGROUND: Iron sequestration is a fundamental aspect of innate immunity. Evidence 
suggests that neonates actively regulate their iron distribution at birth and in early postnatal 
life, in order to sequester iron away from microbial pathogens. 
OBJECTIVE: To review existing evidence of serum iron, transferrin saturation and hepcidin 
levels in full-term and premature infants during the first month of life. 
METHODS: We reviewed literature retrieved from PubMed and Ovid Medline containing 
data on umbilical cord and venous blood concentrations of hepcidin, serum iron and 
transferrin saturation in human neonates from 0-1 month of age. After the standardisation of 
the hepcidin values based on inter-assay cross-calibration studies, weighted mean averages 
were produced for cord and venous blood using available data. Similar weighted means 
were produced for serum iron and TSAT. 
RESULTS: Data from 59 studies were used to create reference ranges for full-term 
neonates over the first month of life. In full-term neonates, venous blood hepcidin increases 
2-3-fold over the first month of life (to reach 61.1 ng/mL; CI: 20.1-102.0 ng/mL) compared to 
umbilical cord blood (29.7 ng/mL; CI: 21.1-38.3 ng/mL). Cord blood has high levels of serum 
iron (28.5 μmol/L; CI: 26.0-31.1 μmol/L) and TSAT (51.7%; CI: 46.5-56.9%). Following a 
short-lived immediate postnatal hypoferremia, iron and TSAT rebounded to approximately 
half the levels in the cord by the end of the first month. There was insufficient data to 
formulate reference ranges for preterm babies. 
CONCLUSION: Evidence shows that full-term neonates experience an early postnatal 
hypoferremia as an innate immune defence, probably mediated by hepcidin. It is unclear 
whether preterm babies are able to elicit the same defence. 
WORD COUNT ABSTRACT: 260/300 
KEYWORDS: Nutritional immunity, host-pathogen interaction, hepcidin, neonates, 





Iron homeostasis during pregnancy 
Three important mediators of hepcidin synthesis: iron status, inflammation, and 
erythropoiesis, are all altered during pregnancy.1–4 Iron demand on the mother increases 
significantly to support expanded maternal erythropoiesis and iron requirements of the 
growing fetus.5–9 During pregnancy, the placenta transfers ~270mg of iron from the mother 
to the fetus via the placenta.10,11  Syncytiotrophoblasts in the placental villi take up 
transferrin-bound iron from the maternal circulation by endocytosis via transferrin receptor 1 
(TFR1) (Figure 1).12–14 As reviewed in Fisher et al.,15 iron is released from TFR1 and 
transferred from clathrin-coated vesicles into the syncytiotrophoblast cytoplasm by DMT-1,16 
Zrt/Irt-like protein ZIP8,17 and ZIP14,18 collectively. Ferroportin transports iron out of 
placental syncytiotrophoblasts, and then ceruloplasmin, hephaestin, and zyklopen may all 
play a role19–21 in helping the iron pass through the endothelium to reach the fetal circulation 
and bind to fetal transferrin.13 
 
Maternal control of fetal and early neonatal iron metabolism 
Increases in maternal and fetal iron absorption occur in the second and third trimester,22,23 
when maternal hepcidin decreases to trigger increased duodenal iron absorption,24 splenic 
macrophage iron recycling, and the release of maternal hepatic iron stores.25–27 The 
resulting increased circulating maternal iron is then freely available for transfer to the fetus. 
Factors that are thought to contribute to maternal hepcidin suppression in the second and 
third trimester include maternal iron deficiency, erythropoiesis in the mother or fetus,27 
oestrogen,28 and progesterone receptor membrane component-1.29 Conflicting evidence now 





Fetal control of fetal and early neonatal iron metabolism 
Eighty percent of all the iron transferred from the mother to the fetus occurs in the last 
trimester.31 An illustration of the fetal demand for iron (amounting to 1.6-2.0 mg/kg per day32) 
is that umbilical cord blood contains a higher serum iron concentration than in the maternal 
circulation and at delivery babies have higher total body iron per kilo than that measured in 
their mothers or in healthy adults.33–44 This pattern is seen even in anaemic mothers and 
their babies.32,43,45,46 The relative roles of maternal and fetal hepcidin levels in controlling 
placental iron transport are unclear and may change during the course of 
gestation.25,26,30,42,45,47–55 As iron becomes more available in the last months of pregnancy, 
the fetus synthesizes hepcidin probably to control the rate of placental iron transfer and 
thereby to protect itself from iron-overload.15,30,56 Evidence showing the importance of fetal 
hepcidin includes: 1) umbilical cord hepcidin concentrations at birth are higher than maternal 
levels before and during delivery26,44,57–60 and 2) in pregnancies with multiple gestations, 
differences in cord hepcidin between siblings explained a greater fraction of variability in 
cord hemoglobin, serum ferritin, sTfR, and EPO than maternal hepcidin levels.49  
 
Placental control of fetal and early neonatal iron metabolism 
The placenta may also independently regulate iron transfer to the fetus in some scenarios.61  
A reduction of ferroportin expression on the apical fetal-facing membrane of placental 
syncytiotrophoblasts during maternal iron deficiency, in addition to increased expression of 
TFR1 on the maternal-facing side supports this hypothesis.30 Sangkhae et al. propose that 
during maternal iron deficiency, iron is held in the placenta to ensure that its metabolic 
homeostasis is maintained. Placental protein synthesis and critical transfer mechanisms can 
then continue, ensuring the more detrimental condition of placental dysfunction does not 
occur. These findings were observed in murine and in vivo human trophoblast models, but 





Impact of labour and delivery on hepcidin 
Childbirth is an intensely stressful event. Inflammatory pathways (including IL-6) are induced 
at the onset of human labor, even in the absence of intrauterine infection.62–69 Initiating 
stimuli for IL-6 production and release could involve the endocrine events of labor,68–70 
mechanical distension of the membranes and cervix (smooth muscle),62,70–73 placental 
hypoxia and/or hypo-perfusion,70,74 fetal hypoxia-acidemia,75 pain 76 or exposure to infective 
agents.67,69,70,77 The production of IL-6 leads to an increase in hepcidin levels along with a 
massive influx of immune cells (predominantly neutrophils) into the cervix, decidua, 
myometrium, chorioamnionic membranes and amniotic fluid.68,78 This further exacerbates the 
rise in IL-6 and other cytokines.76,79 The increase in post-delivery maternal hepcidin 
concentrations is larger with caesarean section deliveries (5.5-fold increase) as compared to 
standard vaginal deliveries (3-fold increase).80 This is most likely due to the surgical 
procedure and the subsequent inflammation. Similar increases in serum hepcidin are seen 
postoperatively during other abdominal surgeries.81 The effect of this maternal rise in 
hepcidin before, during and immediately after childbirth on the late fetal/early neonatal iron 
status is unknown, though like IL-6,82 hepcidin is not thought to cross the placenta.83  
 
Effects of infection on neonatal serum hepcidin levels 
Intra-amniotic infections can cause an increase in fetal hepcidin.84 Multiple studies have 
documented an association between chorioamnionitis, perinatal acidosis and neonatal 
sepsis with high umbilical cord hepcidin concentrations.84–89 For example, an extremely high 
cord concentration (437.6 ng/mL) was found in a neonate with confirmed Enterococcus 
faecalis early-onset sepsis.87 Similarly, very-low birth weight, premature neonates with late-
onset culture-confirmed sepsis, exhibit elevated levels of hepcidin.90 Nevertheless, despite 
the well-documented regulatory pathways of infection and inflammation on iron regulation, it 
is important to note that multiple publications have shown a lack of correlation between 
hepcidin, IL-6 and CRP in sick neonates.87,91 This is likely due to differences in the 
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biochemical kinetics of these molecules. IL-6 concentrations spike very early in the course of 
perinatal infection, whereas the rise of CRP is delayed.  
 
Standardising hepcidin measurements 
Multiple assays, including mass spectrometry (MS) and immunochemistry ELISA methods, 
are available to quantify hepcidin in various body fluids (urine, serum and plasma).92 
However, in the studies included in this review, none of these methods are calibrated using 
the same standards and, as a result, there are significant differences in hepcidin values 
between studies.93,94  
  
In 2016, Van der Vorm et al. harmonized many of the available hepcidin ELISA assays using 
native, lyophilized plasma with cyrolyoprotectant as a commutable candidate reference 
material.93 Linear equations were formulated to standardize the hepcidin assays.93 These 
equations can now be used to conduct post-hoc standardization of non-calibrated test 
results, aiding the retrospective comparison of data from previous publications. We have 
used these equations in this review to generate standardized hepcidin values 
(Supplementary Table 1). The production of standardized reference material, which was 
refined in 2019, is available for purchase allowing hepcidin measurements to be 
standardized in all laboratories.94 
   
3.3 METHODS 
 
In March 2019, we reviewed the literature searching two databases: PubMed and Ovid 
Medline with no restrictions on language or the year of publication. The original search was 
for human studies only. Corresponding authors of extracted publications were not contacted. 
One individual carried out the inclusion/exclusion process of the retrieved studies, and there 
was no assessment of bias or the quality of studies as seen in a systematic review process. 
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Table 1 displays the search strategy used. Figure 2 shows the flow diagram of the literature 
search. The search generated publications containing data on cord and venous 
concentrations of hepcidin, serum iron and transferrin saturation in the neonatal period. 
Studies that analyzed healthy neonates were included. Mean, median or range of the 
gestational age of the study population was a requirement for inclusion. Neonates >37 
weeks at delivery were regarded as full-term neonates (FTB). Studies or study groups with a 
gestational <37 weeks were classed as premature (PTB) neonates. Retrieved publications 
had to report a mean time of bleed 0-720 hours post-delivery to be analysed. Mean (SD or 
95% CI), or median (range, IQR, or 95% CI) data were extracted from the included 
publications. Studies reporting mean (95% CI) were included in the calculation of weighted 
means (95% CI) and the associated Figures 2-5. Reference ranges for adults and children 
were presented for comparison.95,96 Many retrieved publications did not stratify results by 
birthweight; as a result, this variable was not recorded in Tables 2-4. Publications were not 
stratified by sample type (serum or plasma) due to the overall lack of studies. If multiple 
publications on the same study population were retrieved, only one was included in the 
analysis. This was the case with Ervasti et al.97,98 and Sweet et al.,99 as previously 
mentioned in Lorenz et al.100  
  
The standardization of hepcidin values using different ELISA assays was performed using 
the slopes and intercepts from Van der Vorm et al.93 This was performed for studies that 
used ELISA test kits from DRG (hepcidin-25 (human) EIA Kit, DRG, USA), Bachem 
(hepcidin-25 EIA Kit, Bachem, USA) and Intrinsic Lifesciences (Intrinsic Hepcidin ELISA Kit, 
Intrinsic Lifesciences, USA). It was not possible to standardize hepcidin values acquired 
using the ELISA from Hangzhou Eastbiopharm (Hangzhou Eastbiopharm Co. Ltd. 
Hangzhou, Zhejiang, China) and mass spectroscopy (MCProt Biotechnology, Kanazawa, 
Japan), used in Basu et al.52 and Ichinomiya et al.,85 respectively. Prohepcidin was not 




The software Stata IC version 15 (StataCorp LP, College Station, Texas, USA) and R (R: A 
Language and Environment for Statistical Computing, R Foundation for Statistical 
Computing, 2020, https://www.R-project.org) were used to analyse data. To calculate the 
confidence interval (CI) around the weighted mean, the weighted variance was calculated 
using the wtd.var function from the R package Hmisc. The standard error derived from this 
weighted variance was then used to calculate the t-statistic (i.e. weighted mean divided by 
weighted standard error), from which the 95% CI was derived. GraphPad Prism version 8 
(GraphPad Software, San Diego, California, USA) software was used to produce the 
graphical representation of the results. 
 
3.4 RESULTS  
 
The initial search of two electronic databases for three different iron markers yielded 13,931 
publications. After the exclusion of duplicated studies and selection criteria filtering, 20 
publications were included in the analysis for hepcidin, 23 publications for TSAT and 51 
publications for serum iron. Many of these studies were found to contain information on 
multiple parameters of interest. Overall, we identified 59 publications containing data on 
hepcidin, serum iron or TSAT in FTB neonates. Sixteen publications were found to contain 
data on PTB neonates.  
  
In publications detailing the effects of cord clamping interventions, all retrieved cord blood 
values were from groups that underwent 60 seconds of delayed cord clamping. This is 
consistent with current WHO policy.107 Cord blood weighted mean values are generated 
in Tables 2-7, and are represented by a dashed line in Figures 3-5 and a (95% CI) 






Standardized weighted mean umbilical cord blood hepcidin levels were higher in FTB 
neonates (29.7 ng/mL; CI: 21.1-38.3 ng/mL) vs PTB neonates (8.4 ng/mL; CI: 2.0-14.7 
ng/mL) (Figure 3A and 3B and Tables 2 and 3). Full-term cord blood hepcidin levels were 
2-fold higher than in adult male (13.1 ng/mL; CI: 1.4-43.2 ng/mL) and female (10.6 ng/mL; 
CI: 1.4-43 ng/mL) references ranges (Table 2). FTB standardized venous hepcidin levels 
increased (61.1 ng/mL; CI: 20.1-102.0 ng/mL) over the first four days of life (Figure 6A). 
This trend is unclear for PTB neonates due to the lack of studies. (Table 3 and Figure 6B). 
No studies were retrieved that assessed post-delivery venous blood samples >77 hours in 
FTB or >168 hours in PTB. 
 
TSAT 
The weighted mean TSAT in cord blood was higher in FTB neonates (51.7%; CI: 46.5-
56.9%) compared to PTB neonates (36.5%; CI: 0.8-72.1%) (Tables 4 and 5 and Figure 4). 
Cord blood TSAT in FTB neonates was double the reference levels found in adults (23.5%; 
CI: 12-38.8%) and children aged 1-5 years (19.4%; CI: 8.2-32.9%) (Table 4). The weighted 
mean average of TSAT decreased 2-fold from cord blood to venous blood in FTB neonates 
(down to 25.2%; CI: 20.1-30.3%) (Figure 7A). This hypoferremic response in FTB neonates 
was followed by a steady increase from 21.8% (CI: 18.8-24.7%) to 44.2% (CI: 32.1-
57.8%). No trend was identifiable in PTB neonates due to the lack of data (Table 
5 and Figure 7B).  
  
Serum Iron 
Unlike TSAT values, serum iron levels in cord blood were higher in PTB (46.8 μmol/L; CI: 
29.7-63.8 μmol/L) neonates compared to FTB neonates (28.5 μmol/L; CI: 26.0-31.1 μmol/L) 
(Figure 5). Like TSAT, a similar 2-fold decrease in the weighted mean average of venous 
blood compared to cord blood is seen in FTB (13.8 μmol/L; CI: 10.8-16.9 μmol/L) (Table 6), 
and PTB neonates (16.2 μmol/L; CI: 15.3-17.0 μmol/L) (Table 7). Figure 8 suggests that 
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after the initial reduction (in the first 48 hours of life), levels of serum iron remain consistent 
over the first month of life in PTB (B) and FTB neonates (A). Serum iron was lowest 
between 0-48 hours post-delivery (Table 6 and Table 7). 
 
3.5 DISCUSSION  
  
Standardization of hepcidin 
To our knowledge, this is the first review to retrospectively compare serum hepcidin 
concentrations between studies, using post-hoc standardized values to produce calculated 
weighted mean averages in umbilical cord and venous blood. Pre-standardized hepcidin 
values in cord and peripheral blood share good correlation between methods. However, 
absolute values vary considerably between the ELISA test kits used (Table 2-3). A trend of 
low values is associated with the use of DRG ELISA kits, and high values linked with the use 
of Intrinsic Lifesciences and Bachem ELISA kits.  
  
Hypoferremia in FTB neonates 
The weighted mean average for cord blood hepcidin was calculated using data from 11 
studies. Almost all included studies reported a mean value between 11-41ng/mL, apart from 
Kulik-Rechberger et al. This study reported a much higher cord blood hepcidin value 
(67.9ng/mL; CI: 59.3-76.5ng/mL) as seen in Figure 3A. In addition, this study also recorded 
higher hepcidin levels in venous samples collected at 72 hours (92.9ng/mL; CI: 83.3-
102.3ng/mL),26 compared to those collected by Prentice et al. at 77 hours (55.6ng/mL; CI: 
47.1-65.5ng/mL).108 
 
When all the data are reviewed together (Figure 6A), hepcidin increases from within the first 
2-11 hours of life108 and then continues to increase up to 82 hours post-delivery. At all times 
the hepcidin levels are much higher than those recorded in adults. This excess hepcidin 
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production may provide a quick, comprehensive and relatively long-lasting (0-3 days) 
hypoferremic response to aid protection during this vulnerable period108. After the first few 
days, TSAT gradually increases as do serum iron levels, eventually reaching a plateau at 
approximately 1 month of age.  
  
Iron metabolism biomarker data gaps in first month of life in full-term babies 
Gaps in the time course of the concentration of hepcidin, TSAT and serum iron in the first 
month of life in full-term neonates still exist. This hinders our understanding of neonatal iron 
metabolism, particularly because hepcidin, TSAT and serum iron are transient and dynamic 
iron parameters. At the point in which hypoferremia is believed to be maximal, publications 
detailing the concentration in early (<12 hours) venous samples are lacking in both groups 
(FTB n=2, PTB n=1). Further research at this time point is required to fully elicit the strength 
and consistency of this response, as well as understanding the process in greater detail.  
 
Lack of data on preterm neonates during the first 24 hours 
After analysis of the current literature, the extent of the role that hypoferremia plays in 
neonates with a gestational age less than 37 weeks is still unclear. This is primarily due to 
the limited number of publications documenting hepcidin (n=5), TSAT (n=6) and serum iron 
(n=13) in the first month of life in preterm neonates. The variability between the studies is 
vast and further complicated by the complex, intensive and inconsistent care of premature 
neonates worldwide.  
 
Data analysis of the retrieved publications suggests that preterm neonates have lower cord 
hepcidin than in full-term neonates, infants and healthy adults. Weighted cord mean values 
are 3-fold higher in full-term (29.7ng/mL; CI: 21.1-38.3ng/mL) neonates compared to preterm 
(8.4ng/mL; CI: 2.0-14.7ng/mL) neonates. We speculate that this could be due to very early 
preterm neonates (<30 weeks’ gestation) possessing circulatory monocytes with decreased 
surface expression of TLR4, lower mRNA expression of TLR4 and reduced cytokine 
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production.109 An effect on the production of IL-6 at delivery, might then lead to a reduced 
ability to stimulate hepcidin expression as suggested in full-term babies.  
  
Our analysis proposes that peripheral venous hepcidin values in preterm neonates increase 
to 44ng/mL at 168 hours. However, decreases in TSAT between the cord and venous 
samples are not observed (36.5% to 45.6%). We propose that this is due to a lack of data on 
TSAT levels in preterm neonates over the first hours of life, potentially due to the complex 
ethical questions around bleeding preterm neonates so early in postnatal life. This results in 
the collection of skewed data, focusing only on later time points in the first month of life.  
 
Limitations  
The aim of this review was to evaluate our current knowledge on neonatal iron homeostasis 
in preterm and full-term neonates. As a result of the dearth of publications detailing the 
parameters of interest during this period, our review has several limitations. Firstly, many 
studies do not stratify their study groups by gestational age (preterm: <37 weeks, full term: 
>37 weeks). Subsequently, we have had to assign each study group or population by the 
mean gestational age. This will result in a reduction of any natural variation potentially 
caused by gestational age between the reviewed populations. This is also the case with 
respect to birth weight.  
 
Similarly, the studies on preterm neonates are made up of multiple small sample size 
subgroups with different gestational ages. Due to the lack of preterm studies, we have had 
to combine these study groups to formulate weighted means and figures. This in itself, could 
distort the impact of gestational age on our results, since data from the very early preterm 




The retrieval of gestational age was a crucial aspect of the search strategy; however, few 
studies document the method used. There are large differences in the accuracy of different 
techniques.110  
  
Post-hoc standardization of different hepcidin ELISA kits has, to our knowledge, never been 
completed before with retrospective data. However, care should be given to the accuracy of 
the standardized values, as standardization was only possible for DRG, Bachem and 
Intrinsic Lifesciences ELISA test kits. Studies that used alternative methods111 were not 
included in summary statistics.  
  
An essential criterion of inclusion in this publication was that all neonatal data came from 
healthy newborns. However, documentation of labor practices and postnatal care, along with 
postnatal medication lack detail in the publications retrieved. Vaginal delivery is commonly 
referred to as the method of delivery; however, the use of inflammation-inducing forceps or 
vacuum delivery is not widely reported.  
 
Conclusion 
Currently available data suggests that hepcidin, serum iron and TSAT levels for adults and 
infants are much lower than those found in cord blood and venous blood from neonates 
during the first month of life. We have strengthened the evidence that full-term neonates 
possess the ability to produce a hepcidin-mediated hypoferremic response post-delivery. 
Whether this mechanism is found in PTB neonates is still unclear. This is predominately due 
to the lack of studies on healthy preterm neonates during the first hours of life. If premature 
or low birthweight neonates are unable to mount a hypoferremic response, this could 
enhance their risk of early neonatal infections. Conversely, if the hypoferremic response is 
seen in both preterm and full-term neonates, it will further support the hypothesis that 




In summary, serum hepcidin is likely triggered by the inflammatory effect of labor and 
delivery. We suggest that this intrinsic mechanism of protection protects newborns with 
immature immune systems to transition from a semi-allogeneic, protected fetal setting to a 
microbe-rich extrauterine environment.112,113 Hepcidin-induced hypoferremia then potentially 
provides a broad action innate bacteriostatic action to invading micro-organisms, when 
physiological adaption to postnatal life is so critical for survival.  
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Table 1: Literature Search Strategy. Searches conducted via PubMed and Ovid Medline. 
 
Table 2: Hepcidin (ng/mL) in full-term newborns over the neonatal period. Values from 
Basu et al111 were not standardized because the study used the Hangzhou Eastbiopharm 
ELISA, which was not part of the Van der Vorm et al. analysis.93 Extracted standard 
deviations were converted to 95% confidence intervals. Median (IQR or 95% CI) were not 
included in weighted means. Reference ranges were obtained from Hepcidin Analysis 
(Radboundumc).96 
 
Table 3: Hepcidin (ng/mL) in preterm newborns over the neonatal period. Ichinomiya et 
al85 was not standardized because the study used a mass spectrometry based method that 
was not part of the Van der Vorm et al. analysis.93 Extracted standard deviations were 
converted to 95% confidence intervals. Median (IQR or 95% CI) were not included in 
weighted means. Reference ranges were obtained from Hepcidin Analysis 
(Radboundumc).96  
 
Table 4: Transferrin saturation (%) in full-term newborns over the neonatal period. 
Extracted standard deviations were converted to 95% confidence intervals. Median (IQR or 
95% CI) were not included in weighted means. Reference ranges are taken from the 
National Health and Nutrition Examination Survey, 1999–2000.114 
 
Table 5: Transferrin saturation (%) in preterm newborns over the neonatal period. 
Extracted standard deviations were converted to 95% confidence intervals. Median (IQR or 
95% CI) were not included in weighted means. AGA groupa and SGA groupb can be 
identified in Figure 3B using the superscripted letters. Reference ranges were obtained from 
the National Health and Nutrition Examination Survey, 1999–2000.114 
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Table 6: Serum iron (μmol/L) in full-term newborns over the neonatal period. Extracted 
standard deviations were converted to 95% confidence intervals. Median (IQR or 95% CI) 
were not included in weighted means. Reference ranges are generated from the National 
Health and Nutrition Examination Survey, 1999–2000.114 
 
Table 7: Serum iron (μmol/L) in preterm newborns over the neonatal period. Extracted 
standard deviations were converted to 95% confidence intervals. Median (IQR or 95% CI) 
were not included in weighted means. AGA groupc, SGA groupd, 30-36 wksg and 24-29 wksh 
can be identified in Figure 4B using the superscripted letters. Ru et al, 2018115 is referenced 
as e . Ru et al, 2018116 is referenced as f . Reference ranges are generated from the National 
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Table 2: Hepcidin concentration (ng/mL) in full-term newborns over the neonatal period. 
Reference Year Location n Test Type Type of Sample 
Hepcidin (ng/mL) Standardized Hepcidin (ng/mL) 
Mean (95% CI) Median (IQR or 95% CI) Mean (95% CI) Median (IQR or 95% CI) 
Armitage et al. (VPM) 2019 The Gambia 114 ELISA (Bachem) Cord (Plasma)  46.0 (31.3-55.1)  29.4 (20-35.2) 
Armitage et al. (VA) 2019 The Gambia 193 ELISA (Bachem) Cord (Plasma)  41.9 (26.3-56.6)  26.8 (16.8-36.1) 
Basu et al. 2015 India 15 ELISA (Hangzhou Eastbiopharm) Cord (Serum) 124.0 (115-133) 
 N/A  
Briana et al. 2013 Greece 104 ELISA (DRG) Cord (Serum)  17.85 (4.75-69.2)  24.1 (3.1-44.2) 
Cao et al. 2014 USA 57 ELISA (Intrinsic) Cord (Serum) 131.8 (109-155)  41.7 (34.5-48.9)  
Cao et al. 2016 USA 98 ELISA (Intrinsic) Cord (Serum) 121.5 (105-138)  38.3 (33.2-43.6)  
Delaney et al. 2019 USA 108 ELISA (Intrinsic) Cord (Serum) 92.13 (91.9-92.3)  29.2 (29.1-29.2)  
Dosch et al. 2016 USA 47 ELISA (DRG) Cord (Plasma) 13.4 (11.7-15.1)  17.8 (15.4-20.2)  
Garcia-Valdes et al. 2015 Spain 52 ELISA (DRG) Cord (Serum) 18.01 (15.1-20.9)  24.3 (20.2-28.4)  
Hoppe et al. 2018 Sweden 15 ELISA (Bachem) Cord (Serum)  30.5 (21.7-38.8)  19.5 (13.9-24.8) 
Kulik-Rechberger et 
al. 2016 Poland 44 ELISA (DRG) Cord (Serum) 48.98 (42.9-55.1) 
 67.9 (59.3-76.5)  
   44  Venous - 72 hours (Serum) 66.79 (60-73.5)  92.9 (83.3-102.3)  
Lee et al. 2016 USA 104 ELISA (Intrinsic) Cord (Serum) 87.4 (74.4-103)  27.7 (23.6-32.6)  
Lorenz et al. 2014 Germany 100 ELISA (Intrinsic) Cord (Plasma)  103.9 (61.4-149.2)  32.9 (19.6-47.1) 
Prentice et al. 2019 The Gambia 81 ELISA (Bachem) Cord (Serum) 43.8 (36.8-52.3)  27.9 (23.5-33.4)  
   53  Venous - 6 hours (2-11) (Serum) 79.4 (68.1-92.4)  50.7 (43.5-58.9)  
   21  Venous - 29 hours (26-34) (Serum) 45.9 (36.5-57.8)  29.3 (23.3-36.9)  
   33  Venous - 77 hours (74-82) (Serum) 87.1 (73.8-102.7)  55.6 (47.1-65.5)  
Rehu et al. 2010 Finland 116 ELISA (Intrinsic) Cord (Serum) 71.6 (60.8-84.4)  22.8 (19.4-26.77)  
Ru et al. 2018 USA 50 ELISA (Bachem) Cord (Serum) 17 (12-24.2)  10.9 (7.7-15.5)  
Slomka et al. 2013 Poland 54 ELISA (DRG) Cord (Serum)  18.50 (2.75-35.13)  25 (2.8-48.4) 
Young et al. 2011 USA 19 ELISA (Intrinsic) Cord (Serum) 61.0 (26.4-95.6)  19.4 (8.6-30.3)  
Weighted Mean (Cord)     73.2 (48.1-98.3) N/A 29.7 (21.1-38.3) N/A 
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Weighted Mean (Venous)     72.7 (48.3-97.2) N/A 61.1 (20.1-102.0) N/A 
Adults (Median (95% CI))     Men: 13.1 (1.4-43.2) ng/mL | Women: 10.6 (1.4-43) ng/mL (hepcidinanalysis.com, 2019) 



















Table 3: Hepcidin concentration (ng/mL) in preterm newborns over the neonatal period. 
Reference Year Location n Test Type Type of Sample Study Group 
Hepcidin (ng/mL) Standardized Hepcidin (ng/mL) 
Mean (95% CI) Median (IQR or 95% CI) Mean (95% CI) Median (IQR or 95% CI) 
Delaney et al. 2019 USA 126 ELISA (Bachem) Cord (Serum)  13.78 (13.6-14)  8.8 (8.7-9)  
Ichinomiya et al. 2017 Japan 92 Mass Spec (MCProt) Cord (Serum)   7.3 (2.85-16.38)  N/A 
Lorenz et al. 2014 Germany 40 ELISA (Intrinsic) Cord (Plasma) 24-29 wks  26.9 (13.5-63.1)  8.7 (4.5-20.1) 
   81 ELISA (Intrinsic) Cord (Plasma) 30-36 wks  45.9 (24.7-74.5)  14.7 (8.0-23.7) 
Ru et al. 2018 USA 92 ELISA (Bachem) Cord (Serum)  12.1 (9.2-15.7)  7.8 (5.9-10.1)  
Uijterschout et al. 2015 Netherlands 85 ELISA (Bachem) Venous - 168 hours (Serum)  69.6 (14.6-180.1)  44.4 (9.4-114.8)  
Weighted Mean (Cord)      13.1 (2.4-23.7) N/A 8.4 (2.0-14.7) N/A 
Weighted Mean (Venous)      69.6 (14.6-180.1) N/A 44.4 (9.4-114.8) N/A 
Adults (Median (95% CI))      Men: 13.1 (1.4-43.2) ng/mL | Women: 10.6 (1.4-43) ng/mL (hepcidinanalysis.com, 2019) 












Table 4: Transferrin saturation (%) in full-term newborns over the neonatal period. 
Reference Year Location n Type of Sample 
TSAT (%) 
Mean (95% CI) Median (IQR or 95% CI or Range) 
Al-Tawil et al. 2012 Egypt 90 Venous - 24 hours 25 (24.6-25.4)  
Ali et al. 2016 USA 64 Cord 59.2 (53.9-64.5)  
Anderson et al. 2011 Sweden 162 Venous - 48 hours 23 (21.9-24.1)  
Balogh et al. 2007 Hungary 20 Cord  60.5 (14-90) 
   20 Venous - 39 hours (18-114)  22.5 (11-42) 
Basu et al. 2015 India 15 Cord 61.8 (54.7-68.9)  
El-Farrash et al. 2012 Egypt 30 Cord 49.5 (42.5-56.5)  
Ervasti et al. 2007 Finland 199 Cord 55 (52.4-57.6)  
Haga et al. 1980 Norway 21 Cord 55 (33.8-76.2)  
Kalem et al. 2019 Turkey 380 Cord 55.87 (54.8-56.9)  
Kelly et al. 1978 Scotland 115 Cord 58.8 (55.6-62)  
Kitajima et al. 2010 Japan 8 Cord  15.1 (8.3-27.5) 
   8 Venous - 720 hours  44.2 (32.1-57.8) 
Kleven et al. 2007 USA 26 Cord 42 (32.4-51.6)  
Mashako et al. 1991 DRC 166 Cord 32.3 (30.1-34.5)  
Milman et al. 1987 Denmark 74 Cord  48 (32-71) 
   47 Venous - 120 hours  33 (21-48) 
Prentice et al. 2019 The Gambia 81 Cord 47.6 (43.7-51.5)  
   53 Venous - 6 hours (2-11) 24.4 (21.2-27.6)  
   21 Venous - 29 hours (26-34) 21.8 (18.8-24.7)  
   33 Venous - 77 hours (74-82) 30.9 (26.9-34.8)  
Puolakka et al. 1980 Finland 47 Cord 53 (49-57)  
Rehu et al. 2010 Finland 116 Cord 50.6 (44.5-57.5)  
Rois et al. 1975 USA 26 Cord 61.2 (55.9-66.5)  
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Slomka et al. 2013 Poland 49 Cord  58.1 (51.7-73.6) 
Yamada et al. 2014 Brazil 21 Cord 47.7 (40.2-55.2)  
   21 Venous - 720 hours 39.8 (34.7-44.9)  
Weighted Mean (Cord)    51.7 (46.5-56.9) N/A 
Weighted Mean (Venous)    25.2 (20.1-30.3) N/A 
Adults (Median (95% CI))    23.5 (12-38.8) % (10-90th percentiles) - NHNES 
















Table 5: Transferrin saturation (%) in preterm newborns over the neonatal period. 
Reference Year Location n Type of Sample Study Group 
TSAT (%) 
Mean (95% CI) Median (IQR or 95% CI or Range) 
Celik et al. 2015 Turkey 42 Venous - 648 hours (288-1872)  46.5 (41.2-51.8)  
Haga et al. 1980 Norway 23 Cord AGA Groupa 48 (39.8-56.2)  
   6 Cord SGA Groupb 41 (23.4-58.6)  
Ichinomiya et al. 2017 Japan 92 Cord   87.2 (68.3-100) 
Kitajima et al. 2010 Japan 13 Cord   64.3 (15.8-88.9) 
   13 Venous - 720 hours   33.2 (17.1-79.5) 
Lackmann et al. 1998 Germany 15 Venous (<1 hour) <32 wks  39 (5-83) 
   22 Venous (<1 hour) 33-34 wks  36 (7-87) 
   26 Venous (<1 hour) 35-36 wks  31 (13-60) 
Yamada et al. 2014 Brazil 25 Cord  24.8 (18.5-31.1)  
   25 Venous - 720 hours  44.1 (37.3-50.9)  
Weighted Mean (Cord)     36.5 (0.8-72.1) N/A 
Weighted Mean (Venous)     45.6 (30.4-60.9) N/A 
Adults (Median (95% CI))     23.5 (12-38.8) % (10-90th percentiles) - NHNES 








Table 6: Serum iron concentration (μmol/L) in full-term newborns over the neonatal period. 
Reference Year Location n Type of Sample 
Serum Iron (μmol/L) 
Mean (95% CI or Range) Median (IQR or 95% CI or Range) 
Ahlsten et al. 1989 Sweden 20 Cord 38 (34.9-41.1)  
Ali et al. 2016 USA 64 Cord 26.8 (24.4-29.2)  
Amarnath et al. 1989 USA 15 Cord 24.1 (21-27.2)  
Anderson et al. 2011 Sweden 162 Venous - 48 hours 9.9 (9.5-10.3)  
Armitage et al. (VA) 2019 The Gambia 193 Cord  18.8 (15.4-22.3) 
Armitage et al. (VPM) 2019 The Gambia 114 Cord  16.0 (12.7-18.7) 
Awadallah et al. 2004 Jordan 92 Cord 20.7 (20.1-21.3)  
Balogh et al. 2007 Hungary 20 Cord  25.5 (8-43) 
   20 Venous - 39 hours (18-114)  9.5 (5-20) 
Bastida et al. 2000 Spain 70 Cord 41.5 (38.3-44.7)  
Basu et al. 2016 India 15 Cord 23.8 (22.2-25.4)  
Basu et al. 2015 India 142 Cord 26.5 (25.5-27.5)  
Bermudez et al. 2015 Spain 30 Cord 6.26 (5.37-7.15)  
Briana et al. 2013 Greece 104 Cord 24.14 (22.4-25.9)  
Busarira et al. 2019 Libya 126 Cord 23.69 (23.5-23.9)  
Cao et al. 2016 USA 68 Cord 39.73 (35-44.4)  
Chong et al. 1984 UK 20 Cord 41.1 (29.6-52.6)  
Delaney et al. 2019 USA 108 Cord 40.8 (37.3-44.3)  
El-Farrash et al. 2012 Egypt 30 Cord 28.29 (25.6-31)  
Ertekin et al. 2015 Turkey 76 Cord 26.1 (24.1-28.1)  
Ervasti et al. 2007 Finland 199 Cord 27.4 (26.3-28.5)  
Gruccio et al. 2014 Argentina 99 Cord 27.03 (25.7-28.4)  
Haga et al. 1980 Norway 21 Cord 27.1 (24.2-30)  
Kelly et al. 1978 Scotland 115 Cord 27.0 (25.6-28.4)  
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Kleven et al. 2007 USA 26 Cord 44.1 (32.2-56)  
Kocylowski et al. 2017 Poland 64 Cord 35.1 (33.2-37)  
Lao et al. 1991 Hong Kong 77 Cord 35.8 (32.7--38.9)  
Lee et al. 2006 South Korea 19 Cord 31.3 (28.4-34.2)  
Lee et al. 2016 USA 104 Cord 35.4 (32-39.2)  
Mezdoud et al. 2017 Algeria 97 Cord 20.1 (19-21.3)  
Milman et al. 1987 Denmark 74 Cord  28 (19-39) 
   47 Venous - 120 hours  19 (13-31) 
Mukhopadhyay et al. 2011 India 50 Cord 29 (25.8-32.2)  
Murata et al. 1989 Japan 45 Cord 28.5 (26.7-30.3)  
Oliveria et al. 2014 Brazil 144 Cord 24.6 (23.5-25.7)  
Ozkiraz et al. 2011 Turkey 16 Venous - 216 hours (96-336) 16.4 (13.8-19)  
Patidar et al. 2013 India 50 Venous - 8 hours (1-23) 19.4 (17.2-21.6)  
Prentice et al. 2019 The Gambia 81 Cord 24.7 (22.5-26.9)  
   53 Venous - 6 hours (2-11) 13.6 (12.0-15.2)  
   21 Venous - 29 hours (26-34) 11.6 (10.1-13.1)  
   33 Venous - 77 hours (74-82) 14.5 (13.1-16.0)  
Puolakka et al. 1980 Finland 47 Cord 28.8 (26.2-31.4)  
Rois et al. 1975 USA 26 Cord 6.19 (6.18-6.20)  
Ru et al. 2018 USA 49 Cord 48.3 (39.3-59.1)  
Slomka et al. 2013 Poland 49 Cord 22.4 (20.5-24.3)  
Sweet et al. 2001 UK 68 Cord 26 (24.2-27.8)  
Szabo et al. 2001 Hungary 10 Cord 23.2 (16.3-30.1)  
   10 Venous - 47 hours 7.2 (6.15-8.25)  
Tiker et al. 2006 Turkey 16 Venous - 209 hours (96-288) 19.9 (12.7-28.4)  
Tsuzuki et al. 2013 Japan 30 Cord 31.1 (27.3-34.9)  
   30 Venous - 120 hours 19.5 (16.4-22.6)  
Yamada et al. 2014 Brazil 21 Cord 23.9 (19.4-28.4)  
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   21 Venous - 720 hours 16.7 (14.9-18.5)  
Yapakci et al. 2009 Turkey 16 Venous - 211 hours (±46) 19.9 (17.9-21.9)  
Weighted Mean (Cord)    28.5 (26.0-31.1) N/A 
Weighted Mean (Venous)    13.8 (10.8-16.9) N/A 
Adults (Median (95% CI))    15.2 (8.1-24.5) μmol/L (10-90th percentiles) - NHNES 

















Table 7: Serum iron concentration (μmol/L) in preterm newborns over the neonatal period. 
Reference Year Location n Type of Sample (Cord or Venous) Study Group 
Serum Iron (μmol/L) 
Mean (95% CI or Range) Median (IQR or 95% CI) 
Celik et al. 2015 Turkey 42 Venous - 648 hours (288-1872)  15.6 (13.3-17.9)  
Delaney et al. 2019 USA 126 Cord  53.1 (49.8-56.4)  
Haga et al. 1980 Norway 24 Cord AGA Groupc 16.8 (13.2-20.4)  
   7 Cord SGA Groupd 18.3 (11.2-25.4)  
Ichinomiya et al. 2017 Japan 92 Cord   23.27 (15.2-32.4) 
Lackmann et al. 1998 Germany 15 Venous - <1 hour <32 wks  14 (2-41) 
   22 Venous - <1 hour 33-34 wks  12 (2-32) 
   26 Venous - <1 hour 35-36 wks  15 (6-28) 
Ru et al. 2018 USA 91 Cord e 73.4 (57.3-93.1)  
Ru et al. 2018 USA 140 Cord f 53.7 (50.1-60.8)  
Schiza et al. 2007 Greece 181 Venous - 336 hours  16.1 (15.5-16.7)  
Sweet et al. 2001 UK 50 Cord 30-36 wksg 20.8 (18.4-23.2)  
   26 Cord 24-29 wksh 17.4 (13.3-21.5)  
Tiker et al. 2006 Turkey 14 Venous - 67 hours (24-144) 26-32 wks 15.81 (4.83-33.48)  
   12 Venous - 65 hours (24-96) 33-36 wks 19.26 (6.8-39.2)  
Tsuzuki et al. 2013 Japan 14 Cord  27.5 (21.9-33.1)  
    Venous - 120 hours  16.47 (13.1-19.8)  
Yamada et al. 2014 Brazil 25 Cord  8.8 (6.97-10.6)  
    Venous - 720 hours  15.54 (14.1-17)  
Yapakci et al. 2009 Turkey 17 Venous - 336 hours (96-720)  17.22 (14.2-20.3)  
Weighted Mean (Cord)     46.8 (29.7-63.8) N/A 
Weighted Mean (Venous)     16.2 (15.3-17.0) N/A 
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Adults (Median (95% CI))     15.2 (8.1-24.5) μmol/L (10-90th percentiles) - NHNES 





















Figure 1: Placental iron transfer between mother and fetus. Fe2+ = ferrous iron, Fe3+ = ferric iron, Tf = transferrin, Apo-Tf = unsaturated 
transferrin, Fetal Tf = fetal-derived transferrin, NTBI = non-transferrin bound iron. Syncytiotrophoblasts in the placental villi take up transferrin-
bound iron from the maternal circulation by endocytosis via transferrin receptor 1 (TFR1). Iron is released from TFR1 in acidified endosomes 
and transferred into the syncytiotrophoblast cytoplasm by DMT-1, Zrt/Irt-like protein ZIP8, and ZIP14, collectively. Ferroportin transports iron 
out of placental syncytiotrophoblasts, and then ceruloplasmin, hephaestin, and zyklopen oxidise Fe2+ to Fe3+ helping it pass through the 
endothelium to reach the fetal circulation. It is still unclear as to whether newly transported iron enters the fetal circulation as NTBI or bound to 
fetal transferrin. Fetal-derived hepcidin is believed to regulate ferroportin expression on the fetal basal-side of placental 
syncytiotrophoblasts.13,117 Maternal-derived hepcidin is believed to play a role in regulating TFR1 expression on the maternal-side of the 
placental syncytiotrophoblasts118. This figure is adapted from Sangkhae and Nemeth et al, 2018.119 
 
Figure 2: Flow diagram of the literature search and selection criteria. Retrieving publications on hepcidin, TSAT or serum iron in neonates 
over the first month of life.  
 
Figure 3: Hepcidin (ng/mL) in cord blood: (A) full term neonates, (B) preterm neonates. Standardized means from each publication are 
plotted with error bars showing 95% confidence intervals. Dashed line shows the weighted mean of all publications found in the figure. Median 




Figure 4: Transferrin saturation (%) in cord blood: (A) full term neonates, (B) preterm neonates. Means from each publication are plotted 
with error bars showing 95% confidence intervals. Dashed line shows the weighted mean of all publications found in the figure. a shows Haga et 
al, AGA group.120 b shows Haga et al SGA group.120 Median values were not included in this figure.  
 
Figure 5: Serum iron (μmol/L) in cord blood: (A) full term neonates, (B) preterm neonates. Means from each publication are plotted with 
error bars showing 95% confidence intervals. Dashed line shows the weighted mean of all publications found in the figure. c shows AGA 
neonates in Haga et al.120 d shows SGA neonates in Haga et al.120 Ru et al, 2018115 is referenced as e. Ru et al, 2018116 is referenced as f. g 
shows 30-36 wks neonates in Sweet et al.121 h shows 24-29 wks neonates in Sweet et al.121 Median values were not included in this figure.  
 
Figure 6: Hepcidin (ng/mL) over the neonatal period: (A) full term neonates, a shows the weighted mean (95%CI) for all studies seen in 
Figure 2A. b, c and e shows Prentice et al.108 d shows Kulik-Rechberger et al.26 (B) preterm neonates, a shows the weighted mean (95%CI) for 
all studies seen in Figure 2B. b shows Uijterschout et al.122 
 
Figure 7: Transferrin saturation (%) over the neonatal period: (A) full term neonates, a shows the weighted mean (95%CI) for all studies 
seen in Figure 3A. b shows Prentice et al.108 c shows Al-Tawil et al.123 d shows Prentice et al.108 e shows Balogh et al.101 f shows Anderson et 
al.124 g shows Prentice et al.108 h shows Milman et al.40 i shows Kitajima et al.125 j shows Yamada et al.126 (B) preterm neonates, a shows the 
 
 132 
weighted mean (95%CI) for all studies seen in Figure 3B. b shows Lackmann et al.127 c shows Celik et al.128 d shows Yamada et al.126 e shows 
Kitajima et al.125 All values are mean (95%CI), unless marked with ° median (range) and • median (95%CI). Lackmann et al, 1998 (b) data from 
the three study groups (<32 wks, 33-34 wks and 35-36 wks) was averaged as all groups are classed as PTB neonates and are bled at the 
same time of life.127 
 
Figure 8: Serum iron (μmol/L) over the neonatal period: (A) full term neonates, a shows the weighted mean (95%CI) for all studies seen in 
Figure 2A. b shows Prentice et al.108 c shows Patidar et al.129 d shows Prentice et al.108 e shows Balogh et al.101 f shows Szabo et al.130 g 
shows Anderson et al.124 h shows Prentice et al.108 i shows Milman et al.40 j shows Tsuzuki et al.131 k shows Tiker et al.132 l shows Yapakci et 
al.133 µ shows Ozkiraz et al.134 n shows Yamada et al.126 (B) preterm neonates, a shows the weighted mean (95%CI) for all studies seen in 
Figure 2B. b shows Lackmann et al.127 c shows Tiker et al.132 d shows Tiker et al.132 e shows Tsuzuki et al.131 f shows Schiza et al.135 g shows 
Yapakci et al.133 h shows Celik et al.128 i shows Yamada et al.126 All values are mean (95%CI), unless marked with * mean (range), ° median 
(range) and • median (95%CI). Lackmann et al, 1998 (b) data from the three study groups (<32 wks, 33-34 wks and 35-36 wks) was averaged 











Figure 2: Flow diagram of the literature search. 
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Figure 5: Serum iron concentration (μmol/L) in cord blood 
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Figure 6: Hepcidin concentration (ng/mL) over the neonatal period  
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Figure 8A - Serum iron in FTB neonates




Hepcidin, serum iron and transferrin saturation in full term and premature infants 
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3.7 SUPPLEMENTARY MATERIAL 
 
SUPPLEMENTARY METHODS 
Supplementary Table 1 - Post-hoc hepcidin standardisation 
Test ID  Kit Slope (95% CI)  Intercept (95% CI) 
IC-4 Bachem Hepcidin-25 1.569 (1.523-1.614) -0.10 (-1.95 to 1.85) 
IC-5 Instrinsic Lifesciences Hepcidin IDx 3.184 (3.086-3.281) -0.85 (-2.91 to 1.21) 
IC-6 DRG Hepcidin-25 0.711 (0.674-0.748) 0.73 (-0.05 to 1.52) 
 
Supplementary Table 1: Previously documented regression relationships used to conduct 
post-hoc hepcidin standardisation. These regression relationships were extract from Table 2 
of van der Vorm et al.1  
 
SUPPLEMENTARY REFERENCES 
1. van der Vorm LN, Hendriks JCM, Laarakkers CM, Klaver S, et al. Toward Worldwide 
Hepcidin Assay Harmonization: Identification of a Commutable Secondary Reference 
Material. Clin Chem. Clinical Chemistry; 2016;62:993–1001. 
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Chapter 4 - Neonatal iron distribution and infection susceptibility in 
full term, preterm and low birthweight babies in urban Gambia: 
study protocol for an observational study (Methodology) 
 
 
Summary of Chapter 
 
BACKGROUND: Neonatal infection is the third largest cause of death in children under-five 
worldwide. Nutritional immunity is the process by which the host innate immune system 
limits nutrient availability to invading organisms. Iron is an essential micronutrient for both 
microbial pathogens and their mammalian hosts. Changes in iron availability and distribution 
have significant effects on pathogen virulence and on the immune response to infection. Our 
previously published data shows that, during the first 24 hours of life, full-term neonates 
have reduced overall serum iron. Transferrin saturation decreases rapidly from 45% in cord 
blood to ~20% by six hours post-delivery. 
 
METHODS: To study neonatal nutritional immunity and its role in neonatal susceptibility to 
infection, we will conduct an observational study on 300 full-term normal birthweight 
(FTB+NBW), 50 preterm normal birthweight (PTB+NBW), 50 preterm low birthweight 
(PTB+LBW) and 50 full-term low birthweight (FTB+LBW), vaginally-delivered neonates born 
at Kanifing General Hospital, The Gambia. We will characterize and quantify iron-related 
nutritional immunity during the early neonatal period and use ex vivo sentinel bacterial 
growth assays to assess how differences in serum iron affect bacterial growth. Blood 
samples will be collected from the umbilical cord (arterial and venous) and at serial time 
points from the neonates over the first week of life. 
 
DISCUSSION: Currently, little is known about nutritional immunity in neonates. In this study, 
we will increase understanding of how nutritional immunity may protect neonates from 
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infection during the first critical days of life by limiting the pathogenicity and virulence of 
neonatal sepsis causing organisms by reducing the availability of iron. Additionally, we will 
investigate the hypothesis that this protective mechanism may not be activated in preterm 
and low birthweight neonates, potentially putting these babies at an enhanced risk of 
neonatal infection. 
 
*NOTE: The secondary study objective (III) of assessing the bacterial growth of common 
neonatal pathogens in neonatal sera was not achieved due to the lack of sufficient blood 
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PTB = Preterm birth
FTB = Fullterm birth
LBW = Low birthweight
NBW = Normal birthweight
WHO = World Health Organisation
TSAT = Transferrin saturation
MDG = Millennium development goal
GBS = Group B Streptococci 
EONS = Early onset neonatal sepsis
YICSS = Young Infants Clinical Signs Studies
KGH = Kanifing General Hospital
MRCG = Medical Research Council Unit The Gambia at LSHTM
KMC = Kanifing Municipal Council
UIBC = Unbound iron-binding capacity
IL6 = Interleukin 6
IL22 = Interleukin 22
sTfR = Soluble transferrin receptor
CRP = C-reactive protein
AGP = Alpha 1-acid glycoprotein
HIV = Human immunodeficiency virus
TB = Tuberculosis
EDTA = Ethylenediaminetetraacetic acid
V1 = Venous bleed 1
V2 = Venous bleed 2
IM = Intramuscular
ELISA = Enzyme-linked immunosorbent assay
ID = Identification
CRF = Case report form
eCRF = Electronic case report form
ANOVA = Analysis of variance
IDE = Integrated development environment
CyTOF = Cytometry by time of flight
STAT3 = Signal transducer and activator of transcription 3
TLR = Toll-like receptor
SOP = Standard operating procedure
OD = Optical density
WBC = White blood cell
LPS = Lipopolysaccharide
Introduction
Neonatal infections – challenges in low-income settings
Neonatal infection is the third largest cause of death in chil-
dren under-five worldwide and is an ongoing major global 
public health challenge (Sustainable Development Goal 3.2)1. 
Between 1990 and 2016 maternal and under-five child mortal-
ity has decreased by half2. However, the proportion of neonatal 
deaths among under-five deaths increased from 37% (1990) to 
44% (2013)3,4. Today, approximately 2.8 million children die 
annually during the neonatal period – the first 28 days of life. 
Of these, 73% die within the first six days of life3. An increas-
ing proportion of child deaths are in sub-Saharan Africa5, with 
60–80% of newborn deaths occurring in low birthweight (LBW) 
neonates (<2500g at birth)6. 95% of all LBW neonates are born 
in low-income countries7. However, the situation is likely to be 
worse than documented, as neonatal deaths in developing 
countries are commonly under reported and the records 
commonly contain errors8,9. It is estimated that about one third of 
deaths in the first month of life, are caused by infections includ-
ing bacterial sepsis, meningitis, pneumonia, neonatal tetanus, and 
diarrhoea10.
Evidence is lacking on the aetiology of neonatal infections in 
developing countries, especially from community settings11,12. 
However, the limited data suggests that Klebsiella species, 
Escherichia coli, and Staphylococcus aureus are common causes 
of early onset sepsis (EONS)13–15. The available antibiotic suscep-
tibility data suggests that pathogens associated with neonatal sepsis 
in developing countries are often resistant to WHO-recommended 
empiric antibiotics13,16. Antibiotic resistance has emerged with 
potency over the last few decades due to a multitude of com-
plex reasons. Antibiotic overuse, inappropriate prescribing, inad-
equate diagnostics, extensive agricultural use, availability of 
few new antibiotics, and the ease of transportation of resistant 
bacteria are among the factors contributing to the rise. Equally, 
bacteria have the ability to rapidly mutate (with or without drug 
selection pressure) and horizontally transfer genetic mate-
rial between species (i.e. non-human pathogens) of bacteria17,18. 
Neonates are particularly at risk from antibiotic resistant 
organisms because they generally succumb before alternative 
antibiotic regimes can be tried.
Diagnosis of neonatal sepsis with high specificity remains chal-
lenging in developing countries. A widely used tool developed 
by the World Health Organization Young Infants Clinical Signs 
Studies (YICSS), which includes seven clinical signs to aid 
diagnosis, has only a 85% sensitivity and 75% specificity for 
severe bacterial infection during the first week of life19. Microbio-
logical identification of a pathogen isolated from blood cultures 
often has higher specificity, but microbiological laboratory facili-
ties are frequently lacking in low-income settings19. With this 
all in mind, there is an immediate need to improve our under-
standing of neonatal blood-borne infections and develop novel 
therapies that could enhance immunological protection possibly 
via boosting innate immune mechanisms.
Nutritional immunity
Iron is critical for the human host and most pathogens. Iron 
is one of the most important factors in the host-pathogen battle 
for resources. Bacteria and other pathogens have evolved a wide 
variety of mechanisms to acquire iron from the nutrient rich 
host (e.g. siderophores and iron specific channels)20 to aid 
growth and virulence, with a number of iron acquisition genes 




Nutritional immunity describes the normal physiological innate 
processes used by the host to combat infection by limiting 
nutrient availability. Key among these processes is the abil-
ity to rapidly decrease the circulating concentration of iron (and 
other transition metals) in response to an infection22. The hypof-
erremia of inflammation is mediated by the hormone, hepcidin. 
Research completed in 2000–2001 by three independent 
research groups led to the discovery of the hepcidin hormone, 
and the important function it plays in many aspects of iron 
metabolism23–25. Hepcidin is now understood to be the master 
regulator of iron homeostasis. Unlike any other micronutrient, 
iron is regulated by a hormone that responds to both infection 
and nutritional status. The host inflammatory mediators, IL626, 
IL2227 and Type 1 interferon28, have been found to increase tran-
scription of hepcidin through several Toll-like receptor (TLR) 
ligands29 and STAT3 signalling30,31 resulting in decreased sys-
temic iron concentrations in the circulation. This multifaceted 
mechanism limits nutrient availability to extracellular invad-
ing microorganisms32. The system is well documented in 
mouse models33–35, but less so in human studies. However, it is 
clear that humans with excessive levels of serum iron (e.g. due 
to hemochromatosis) are predisposed to infection with iron- 
dependent species of bacteria36,37.
Neonatal hypoferremia
Although iron metabolism in adults and older children is well 
studied, the kinetics of iron handling in the early neonatal period, 
a time of intense physiological change, are poorly understood38. 
Childbirth results in a neonate moving from a semi-allogeneic, 
protected and nearly sterile environment to one that is abundant 
in a diverse array of microbes. The delivery process is the initial 
focal point for the mass bacterial colonisation of the skin and gas-
trointestinal tract of the neonate39,40. Neonates are known to have 
very low levels of immunological memory and possess an imma-
ture immune system41. Post-natal iron metabolism in neonates 
is controlled by an array of different signals, such as hypoxia, 
erythropoietic drive, maternal and foetal iron stores42. A number 
of studies have investigated serum iron, transferrin saturation 
(TSAT), ferritin and haemoglobin levels at the time of birth using 
cord blood as a proxy for early neonatal blood43,44. A recent pro-
spective study showed neonates born preterm compared to early-
term had higher serum iron concentrations in umbilical blood, 
which was inversely correlated with levels of serum hepcidin45. 
A similar study has also shown that small-for-gestational-age 
neonates and neonates born by elective caesarean have lower 
levels of hepcidin44. Previous work has shown that serum iron 
and TSAT decreases between birth and the first 6–12 hours post- 
partum in full term, healthy vaginally delivered newborns46,47.
The study described here will shed light on the effects of pre-
maturity and birthweight on body iron distribution immedi-
ately after birth and during the first week of life. Free ferric 
and ferrous iron (i.e. transferrin bound iron), haem-based iron 
molecules and their chaperone proteins (haem-hemopexin and 
haemoglobin-haptoglobin) will also be investigated.
Study objectives
The primary study objective is to characterize in detail how full 
term, preterm and low birthweight neonates modulate serum 
iron in the first 24 hours of life. We hypothesize that prema-
ture and/or low birthweight babies have a defect in their ability 
to sequester iron at 6–24 hours after birth in comparison to 
full term neonates with normal birthweight.
The secondary objectives are:
I.      Characterise how iron metabolism, handling and 
recycling differs between full term, preterm and low 
birthweight neonates at birth and during the first 
24 hours of life.
II.     Describe iron metabolism, handling and recycling in full 
term neonates at birth and during the first 7 days of life.
III.    Determine if sera from preterm and low birthweight 
neonates supports a greater level of ex-vivo growth 
of microorganisms that are common causes of neo-
natal sepsis in Africa and The Gambia (Staphylococ-
cus aureus, Klebsiella pneumoniae, Escherichia coli, 
Group B Streptococcus, Streptococcus pneumoniae and 
Salmonella enterica serovar Typhimurium (S. Typhimu-
rium hereafter)) in comparison to sera from full term, 
normal birthweight neonates.
IV.    Characterize frequencies and functionality of neu-
trophils, monocytes, dendritic cells, NK cells, B cells and 
T cells (D8 and CD4) in cord blood from full term, 
premature and low birthweight neonates.
Protocol
Study site
Study participants will be recruited from Kanifing General 
Hospital (formally Serrekunda General Hospital), in the Kanifing 
region of The Gambia, West Africa. Serrekunda is a large 
town, forming a peri-urban area with a population of around 
340,000, and is 13km to the southwest of the capital, Banjul. 
Serrekunda was originally made up of nine villages that have 
merged into a sprawling urban area. Annually, Kanifing General 
Hospital (KGH) provides antenatal care to 500–700 pregnant 
mothers. Mothers receiving antenatal care at other local health-
care facilities increase the total number of births at the hospital 
to 3500–4500 per year. The percentage of these that are live, low 
birthweight neonates (<2.5kg) is approximately 10%. Speci-
men samples will be subjected to primary processing on-site at 
KGH, followed by transport to Medical Research Council Unit 
The Gambia at LSHTM (MRCG) for storage and analysis.
Participants
In total, 450 healthy newly born neonates will be identified dur-
ing delivery at the Kanifing General Hospital Maternity Ward 
(Figure 1) starting in July 2017. Pregnant mothers must be over 
the age of eighteen years. After informed consent is obtained, 
neonates who meet the inclusion criteria will be enrolled 
into the study. For inclusion in the study, neonates must be 
healthy, medically stable, greater than 32 weeks gestational age 
and weigh more than 2000g. To be considered preterm (PTB) the 
neonates will be < 37 weeks gestational age (assessed by New 
Ballard Score48) and q 32 weeks gestational age. All neonates 
with a gestational age q37 weeks will be considered full term 




Figure 1. Main study flow chart of all study procedures and exclusion criteria. Group A will contain neonates characterised by preterm 
birth and low birthweight (PTB+LBW); Group B will contain neonates characterised by preterm birth and normal birthweight (PTB+NBW); 
Group C will contain neonates characterised by full term birth and low birthweight (FTB+LBW); Groups D1, D2 and D3 will all contain 
babies characterised by full term birth and normal birthweight (FTB+NBW). In this study, preterm is defined <37 weeks gestation and low 
birthweight is <2500g. Exclusion criteria (α): Father refused, mother refused, family/escort refused, communication not possible or mother 
with severe disabilities. Exclusion criteria (β): Antibiotics or antimalarials given before delivery (<24 hours), referred to tertiary level health 
facility, absconded, known HIV-positive, severe pre-eclampsia, receiving TB treatment, antepartum haemorrhage, recent blood transfusion 
(within the last month), no foetal heartbeat, mother <18 years, refusal, recruited to another study and emergency caesarean section. 
Exclusion criteria (γ): Recruited to another study on-site, refusal, blood transfusion given in labour, antibiotics or antimalarials given during 
labour, neonate requires resuscitation (1 min APGAR), neonatal weight <2000g, neonate born breech, neonate born via vacuum delivery, 
neonate born caesarean section, foetal stillbirth, macerated stillbirth and major congenital malformations. Exclusion criteria (δ): Failed cord 
blood collection (serum tubes), failed cord blood collection (EDTA), cord blood processed >3 hours, neonate requires resuscitation (10 min 
APGAR), absconded and route 2B refusal. Exclusion criteria (ε): Mother birth check refusal, father birth check refusal, family escort birth 
check refusal, mother <18 years, recruited to another study on-site, antibiotics or antimalarials given to mother before delivery (<24 hours), 
neonate has had surgery, neonates sibling twin was recruited, neonate given antibiotics (other than tetracycline eye ointment), neonate 
given iron supplementation, neonatal sickness (tone, activity, feeding, heart rate, respiratory rate, abnormal anterior fontanelle), neonatal 
temperature (<36.5°C or >37.5°C), major congenital malformations (neonate), New Ballard Score (<32 weeks), failed V1 (serum), failed V1 
(EDTA), failed V1 (both EDTA and serum), mother V1 bleed refusal, father V1 bleed refusal, and family/escort V1 bleed refusal. Exclusion 
criteria (ζ): neonatal sickness (tone, activity, feeding, heart rate, respiratory rate, abnormal anterior fontanelle), neonatal temperature (<36.5°C 
or >37.5°C), neonate has had surgery, neonate given antibiotics (other than tetracycline eye ointment), neonate given iron supplementation, 




neonates will weigh < 2500g. All neonates weighing q 2500 g will 
be considered normal birthweight (NBW).
The study groups are:
Group A (PTB+LBW): Neonates who are both preterm and low 
birthweight.
Group B (PTB+NBW): Neonates who are preterm and normal 
birthweight.
Group C (FTB+LBW): Neonates who are full term but low 
birthweight.
Group D (FTB+NBW): Neonates who are full term and normal 
birthweight.
In addition to the main study, 300 FTB neonates of the 450 
neonates will also be included into a sub-study, which aims 
to describe serum iron markers in full term babies (Group D, 
FTB+NBW only) over the first week of life.
Study design
This is a proof-of-concept, observational cohort study (Groups 
A, B, C and D) with an embedded short prospective cohort 
study (Group D divided into D1, D2 and D3).
Entry evaluation
Consent and enrolment. There are two routes into the study enrol-
ment (Figure 2). Pregnant mothers who are receiving antena-
tal care on-site at KGH, will be approached at an antenatal visit 
and voluntarily sensitised to the study requirements and proto-
col (Route 1). Pregnant women, who are sensitised will not be 
required at that point to give written or verbal consent. This 
group will be provided with study information sheets and encour-
aged to discuss study participation with their family. When the 
pregnant woman returns to KGH Maternity Ward to deliver 
(some mothers will choose to deliver at other healthcare facili-
ties), she will be asked to read the full study information sheet 
(or have it read to her by a study nurse if she is not literate) 
and provide formal written consent to the study involvement 
for their neonate (see Extended data49–51).
Route 2 will provide an alternative route of enrolment for preg-
nant mothers, that would like their neonate to be part of the 
study but have been receiving antenatal care at another facil-
ity before delivering at KGH maternity ward. In route 2, healthy, 
pregnant women will enter the KGH ward to deliver and will be 
approached to provide written formal consent to umbilical cord 
blood collection and storage only. No testing or laboratory proc-
esses will be conducted on their sample, until full study consent 
is gained post-delivery. The cord blood sample will be stored at 
4°C (within the maternity ward), until the mother’s pain and 
discomfort subside (2–6 hours post-delivery). At this point, 
the mother and/or father will be invited to provide written formal 
consent on full study enrolment. If, at this point, mother and/or 
father refuse full study consent post-delivery, the previously col-
lected personal information and umbilical cord sample will be 
safely discarded.
Pre-delivery screening
In both Route 1 and Route 2 enrolment, mothers must provide 
written consent before assessment of personal information (ante-
natal card) and questioning can begin. After consenting, mothers 
will be asked for their demographic information and their per-
sonal contact details. Pregnant mothers will be excluded from 
the study if they are below the age of 18 years, have no foetal 
heartbeat detected upon admission, known to be HIV-positive, 
in receipt of Mycobacterium tuberculosis therapy, taken antibiot-
ics in the last 24 hours, had a blood transfusion in the last month, 
suffering from severe pre-eclampsia or antepartum haemor-
rhage, or in another research study. Mothers can refuse to be part 
of the study at any stage of the study protocol. Pregnant women 
that are referred at this point to a tertiary level healthcare facility, 
will be excluded from the study.
Delivery procedures, post-delivery screening and umbilical 
cord blood collection
Delivery procedures and screening. Study nurses will assist 
clinical KGH maternity ward staff in the delivery process and 
collect data via electronic case report form (eCRF) on their 
designated study tablets. Neonates will be excluded at the delivery 
stage of the study for the following reasons: major congenital 
malformations (not including polydactylism), blood transfusions 
given to mother or neonate, severe birth asphyxia (requiring 
resuscitation), neonates born via breech, vacuum or via caesarean 
section, or a birthweight <2000g. After the delivery stage of the 
study protocol, neonates can be excluded from the study follow-
ing the detection of infection or illness (information gained from 
full blood count analysis or review of systems). Neonates will 
also be removed from the study protocol, if medication is 
given (not including intramuscular vitamin K, tetracycline eye 
ointment or any immunisations). All medication that is given 
to mothers and neonates will be recorded. Mothers will be able 
to refuse study participation at any stage. Mothers that deliver 
multiple newborns will only be invited to consent and enrol 
one of their neonates into the study.
Umbilical cord blood collection. Once the neonate is fully deliv-
ered, one-minute delayed cord clamping will be used (following 
World Health Organisation (WHO) policy52). During the one-
minute delay, the one-minute APGAR score will be conducted. 
If the neonate requires resuscitation, the neonate will be excluded 
from the study. After the umbilical cord has been removed and 
cleaned, a trained study nurse will identify the umbilical arter-
ies and the umbilical vein. Blood will be collected from both. 
The tubes will be placed in the cool box for 1-3 hours before 
transfer to the study laboratory for primary processing. If the 
mother is enrolled by route 2, the mother will be asked to 
provide written consent to full study recruitment before the 
sample is sent for primary laboratory processing.
Hospital assessment and 1st venous blood draw
Hospital health assessment (study recruitment and group 
allocation). At 6–24 hours post-delivery, recruited mothers 
and their neonates will be invited to a private consultation with 




Figure 2. NeoInnate Study enrolment route and blood draw design. Group A contains neonates characterised by preterm birth and low 
birthweight (PTB+LBW); Group B contains neonates characterised by preterm birth and normal birthweight (PTB+NBW); Group C contains 
neonates characterised by full term birth and low birthweight (FTB+LBW); Groups D1, D2 and D3 all contain babies characterised by full term 




be collected, along with a photograph of the antenatal card to 
gather gestational age data (fundal height, last menstrual period 
and ultrasound), mother’s last haemoglobin level before deliv-
ery (dated), known sickle cell status, neonate immunisations, and 
medication given to the mother (pre, during and post-delivery) 
and the neonate. A complete review of systems of the mother 
and neonate plus anthropometric data on the newborn will then 
be collected. Neuromuscular and physical maturation of each 
neonate will be assessed using the New Ballard Score48.
Neonates will be excluded if they score less than 32 weeks of 
gestation. From this assessment, the neonate will be assigned 
to a specific study group. If the neonate is allocated to the 
Group D (FTB+NBW) group, the neonate will be allocated to a 
randomised bleed group (q24 hours - <80 hours (Group D1); 
q80 hours - <136 hours (Group D2); and q136 - <192 hours 
(Group D3). Failure to meet the inclusion criteria at this stage 
of the study protocol, will result in exclusion from the study.
1st venous blood draw (all neonates). A blood sample will 
be collected from all neonates that have passed the inclusion 
criteria in the hospital health assessment. Immediately after the 
health assessment, a venous blood draw will be performed (6–24 
hours post-delivery). PTB and/or LBW neonates will donate 
2ml of venous blood. FTB+NBW neonates will donate 3.5ml 
of venous blood. All samples will reach the laboratory within 
three hours post collection for primary processing.
Community health assessment and 2nd venous blood draw
Community health assessment. Study nurses will visit all moth-
ers or enrolled neonates at their homes at least once. At that 
visit, a physical examination of the neonate will be completed. 
The following information will also be collected: neonatal 
immunisation history, a complete review of systems of the 
mother and baby, and any medication given to the mother or 
neonate since delivery. Mothers will also be provided with health 
education and study contact details (should the neonate become 
unwell).
2nd venous blood draw Group D (FTB+NBW) only. At this point, 
if the mother and neonate are deemed to have passed the screen-
ing process and the neonate is in Group D, then the neonate 
will have its second and last venous blood draw (3.5ml). All 
samples will reach the laboratory within three hours post collection 
for primary processing.
Laboratory evaluations
Blood samples. Whole blood samples will be assessed for: full 
haematology panel (using a Medonic M20M GP), glucose-6-
phosphate dehydrogenase deficiency and sickle trait. All serum 
samples collected will be assessed by ELISA for the follow-
ing: IL6, IL22, free haem, hepcidin, hemopexin, lipocalin-2, 
lactoferrin, and foetal haemoglobin. Additionally, serum ferri-
tin, serum iron, UIBC, soluble transferrin receptor (sTfR), trans-
ferrin, C-reactive protein (CRP), haptoglobin, and alpha 1-acid 
glycoprotein (AGP) will be assessed using a fully automated 
biochemistry analyser (Cobas Integra 400 plus) Additionally, 
umbilical WBC will be processed and analysed for exploratory 
secondary analysis 4.
Bacterial growth assays. Ex vivo growth of bacteria (includ-
ing clinical and laboratory isolates of Staphylococcus aureus, 
Klebsiella pneumoniae, Escherichia coli, Enterobacter spp., 
Enterococcus spp., and Salmonella Typhimurium) in participant 
serum as in Cross et al. (2015)53 will be performed.
Study outcomes
The primary outcome variables will be TSAT (transferrin 
saturation) and serum iron.
The secondary outcome variables will be hepcidin; hemo-
pexin; haptoglobin; IL22; free serum haem and haemoglobin; 
foetal haemoglobin; lactoferrin; lipocalin-2; IL6; C-reactive 
protein; alpha-1-acid glycoprotein; transferrin concentration; 
soluble transferrin receptor; unbound iron-binding capacity; 
ferritin; haemoglobin; WBCs types and numbers in cord blood 
samples and ex vivo bacterial growth.
Data entry, handling, storage and security
All protocol-required field data will be captured electroni-
cally on an electronic eCRF or a paper case report form (CRF) 
that will be completed for each included participant. After giv-
ing written consent the pregnant women will be given a study 
identification number, which will be used in all future data-
sets for subject anonymity. Field data will be collected ver-
bally and from antenatal cards by study nurses. Collected data 
will be entered in real time using eCRFs developed on top of a 
REDCap (Research Electronic Data Capture) database and pub-
lished on Samsung Galaxy Tab 3 SM-T111 handheld devices. 
Collected data will be transported to the database via a direct 
secure connection over the 4G mobile network. Laboratory related 
data will be extracted directly from laboratory equipment and 
uploaded to the database. Any data collected on the paper format 
will be double entered by a trained data entry clerk. The local 
co-investigator will review all forms and identify any errors 
prior to data entry or to marking data as complete. The study 
data will also be validated through automated and manual vali-
dation methods implemented in the study database applica-
tion system. The study database will be custom-developed. All 
paper CRF will be stored in a locked file archive. Electronic 
data will be stored on the local dedicated server maintained at 
MRCG. The study will be conducted in compliance with Good 
Clinical Practice. Study personal security measures will include 
controlled access limited to authorised users only, physi-
cal security, remove identifiable information (anonymization), 
avoidance of third-party cloud storage and password protection.
Sample size and power
This study will target recruitment of 150 ‘’exposed” neonates 
which will include a target of 50 neonates in each Group A, 
B and C. 300 neonates will be recruited for Group D (“unex-
posed”). The study will have constraints from time, budget, 
loss to follow up, haemolysis during sample collection, insuf-
ficient blood volume and the distribution of new births in each 
group at the Kanifing General Hospital. 
Based on this, we have run simulations (Stata/IC 15.1) to 
calculate the power to detect a range of differences comparing 




outcomes TSAT and serum iron. We did not calculate power 
for the secondary outcomes, which are considered exploratory. 
The simulation was run using a linear regression model assum-
ing a lognormal distribution for the response variables TSAT and 
serum iron levels 6–24 hours after birth. Data from a previous 
study (Prentice S, personal communication) was used to obtain 
mean and SD estimates for TSAT and serum iron both at base-
line and 6–24 hours after birth. The predictor variables were 
the Groups (A–D) with Group D as the reference. The model 
was adjusted for the baseline (cord blood levels). We also 
examined the power assuming a normal distribution for TSAT 
(i.e. without log transformation). The significance level consid-
ered was 0.05 and the simulation was run for 100000 iterations. 
This process was repeated for the following four different sam-
ple size scenarios which we refer to as N1, N2, N3 and N4 
respectively:
N1) Group A=Group B =Group C =50 neonates
 N2) Group A=Group B =25 neonates and Group C =50 neonates
 N3) Group A=Group B =10 neonates and Group C =50 neonates
 N4) Group A=Group B =50 neonates and Group C =10 neonates
For all the above four cases, D=300.
The simulation results for the baseline adjusted model with 
log transformation show that for sample size scenario N1, the 
minimum mean differences that can be detected with 80% 
power were about 4% and 2.5 µmol/L for TSAT and serum iron 
respectively (Figure 3A and 3B). These correspond to effect 
sizes of 0.35 and 0.39 respectively. The power drops substan-
tially if smaller numbers were to be recruited as in scenarios N2 
(A=B=25) and N3 (A=B=10). Under N2 and N3, the minimum 
mean differences that can be detected with 80% would increase 
to about 5.8% and 9.1% for TSAT (Figure 3A) and 3.3 µmol/L 
and 5 µmol/L for serum iron (Figure 3B). The results for 
scenario N4 can be considered as subset of N1-N3 by 
rearranging Groups A, B and C.
Statistical analysis
The primary research objective is to examine if preterm and/or 
low birthweight neonates (“Exposed”) have a reduced ability 
to sequester iron at 6-24 hours after birth in comparison 
to full term neonates with normal birthweight (“Unexposed”)?
We hypothesize that FTB+NBW (Group D) neonates on 
average will have lower values of TSAT and serum iron 
compared to “Exposed” (PTB or LBW babies) (Figure 4). Ini-
tially, we will analyse all “Exposed” (Groups A+B+C) vs “Unex-
posed” (Group D). Each neonate will be further classified by his 
or her gestational age (premature vs. full term) and birthweight 
(low vs. normal) in a 2x2 table (Table 1). Linear regression 
models will be used in order to evaluate the difference in 
mean between each Group A-C and D; that is where D will be 
the reference group. TSAT and serum iron levels will be log 
transformed before fitting the models (if necessary). Both the 
unadjusted and adjusted (for the cord blood level) mean 
differences together with the 95% CI will be calculated.
In the second stage of analysis, we will assess the effect of poten-
tial confounding variables using the regression models. Covari-
ates to be considered include the specific time of measurement, 
demographic and health variables. The time effect may not be 
linear, and this will be investigated in the further regression 
models. To reduce the effects of multiple testing, data analy-
sis will be driven by a predefined primary study hypothesis. Any 
exploratory analyses conducted (in the absence of predefined 
study hypotheses) will be considered hypothesis-generating, rather 
than confirmatory. In order to reduce the levels of missing and 
inaccurately entered data into the database, all clinical, demo-
graphic and laboratory data will be entered in real time via elec-
tronic data capture, with automated and manual validation methods 
implemented. The study design does not provide for the recruit-
ment of equal numbers of subjects in each month of the 
year (or during the dry vs wet seasons). The Gambia has a 
higher birth rate during the months of September–December in 
comparison to other months54.
In order to remove this potential source of bias, we will adjust 
for month of birth and/or season in the regression analysis. If the 
missing data rates is more than 5%, we will consider imputa-
tion. The follow-up duration is relatively short. Thus, we expect 
little bias from loss to follow-up. If loss to follow-up rate is 
considerably different between groups, we will perform sensi-
tivity analyses to examine the robustness of results. We will also 
consider sensitivity analysis fitting a multivariate regression model 
where the main outcomes of interest (including TSAT, serum 
iron and hepcidin) will be jointly regressed to the same set of 
predictors.
The analysis for the secondary objectives are described below:
I.    Characterise how iron metabolism, handling and 
recycling differs between full term, preterm and low 
birthweight neonates at birth and during the first 
24 hours of life.
A similar strategy will be used as for the primary objective. Regres-
sion modelling will be used to evaluate the difference in means 
between each Group A-C and D; D will be the reference (“Unex-
posed”) group. The effects of potential confounding variables 
will also be assessed using further regression modelling.
II.    Describe iron metabolism, handling and recycling in 
full term neonates at birth and during the first 7 days 
of life.
Analysis of the longitudinal data will involve generalised esti-
mating equations incorporating time of measurement. We will 
include spline terms at each time point to evaluate the change in 
the outcomes (all primary and secondary outcome parameters) 
over time during the transition period from cord to 24–79; 80–135; 
136–192 hours after birth. Note that this will only include data 
collected from Group D neonates and will not be a comparison 
between Groups A–C and D neonates.
III.    Determine if sera from preterm and low birthweight 




Figure 3. Estimated power to detect a given difference between Groups A vs D based on simulation using a linear regression 
model adjusted for baseline for three sample size scenarios. N1 (Group A=Group B=Group C=50 neonates); N2 (Group A=Group 
B =25 neonates and Group C=50 neonates); N3 (Group A=Group B =10 neonates and Group C=50 neonates); N4 (Group A=Group B=50 
neonates and Group C =10 neonates).
Figure 4. An example of hypothetical scenario for TSAT 
values between the groups to be compared. In this example: 
(i) Time 0 refers to average cord blood levels (ii) Time 6-24 refers 
to the mean level in the 6-24 hour period after birth. (iii) T1, T2, 
represent TSAT in 1 and 2 above and $T=T2-T1 for full term, normal 
birthweight (Group D) (iv.) T1’, T2’and $T’=T2’-T1’ same as above 
but for the premature, low birthweight (Group A). Hypothesis: H0: 
T2=T2’ vs. HA: T2wT2’.
Table 1. Four combinations 
in total for exposure: a: Pre, 
Low; b: Pre, Normal; c: Full, 




Term Pre A B
Full C D
microorganisms that are common causes of neona-
tal sepsis in Africa and The Gambia (Staphylococcus 
aureus, Klebsiella pneumoniae, Escherichia coli, Entero-
bacter spp., Enterococcus spp., and S. Typhimurium) 
in comparison to sera from FTB+NBW neonates.
The bacterial growth will be analysed in a similar method 
as described in Cross et al. (2015)53 in order to determine if 
changes in iron availability modulate the growth. Growth 














Here, the population size at the beginning of the growth 
curve is given by N0. The carrying capacity is given by K. 
The intrinsic growth rate of the population is r. We will gener-
ate the best fitting values of K, r and N0 for the growth curve 
data. Additionally, for each bacterium, we compare the time 
at which the population density reaches 1
2
K (inflection point), 
the fastest possible generation time (doubling time) and the 
area under the logistic curve obtained by taking the integral 
of the logistic equation. This will be used to assess growth 
curves from different sample types (Cord vs V1) and between 
the four study groups.
IV. Characterize frequencies and functionality of neutrophils, 
monocytes, dendritic cells, NK cells, B cells, T cells (D8 





Exploratory analysis will be conducted using linear regressions 
modelling.
Statistical analyses will be performed using STATA (Stata-
Corp. 2017. Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LLC); R (R Foundation for Statistical 
Computing, Vienna, Austria.) and Data Desk (Data Description 
Inc Ithaca NY). All files used will have an accompanying data 
dictionary. Annotated STATA do-files or R files will be used to 
describe any data transformations and statistical tests used.
Dissemination of findings
The study results will be published in relevant peer-reviewed 
journals and key findings will be presented at international sci-
entific meetings. Data sharing will be in agreement with the 
sponsor policy on research data sharing and with the Bill & 
Melinda Gates Foundation Global Access requirements.
Study status
The study is in the data collection phase.
Discussion
Humans and bacteria are involved in an on-going tug of war over 
iron. Each side has evolved complicated and varied iron-acquisition 
mechanisms in an effort to turn the tide of war in their 
own favour55. Nutritional immunity describes the processes 
by which the human host tries to starve invading organisms of 
nutrients, especially iron.
This study aims to determine if premature and low birthweight 
babies have a defect in their ability to sequester iron during the 
first 24 hours of life. The study design will produce a detailed 
and extensive picture of iron metabolism in neonates. To our 
knowledge, no other study has tried to analyse such a large 
and diverse collection of iron and infection variables in 
neonates born in Sub Saharan Africa. The study will enrol sub-
jects who are all at an increased risk of neonatal infection, and 
subsequent sepsis and death.
A potential limitation of this study is the inadequacy of using 
the New Ballard Score as the only method of gestational aging. 
Original and New Ballard Score are reported to overestimated 
gestational age compared to ultrasound and in particular, misclas-
sify preterm infants as term newborns56. Additionally, newborn 
clinical assessments as a whole, tend to underestimate gesta-
tional age in growth-restricted neonates56. The gold standard of 
gestational aging is an ultrasound in the first trimester57. 
However, this procedure is rarely correctly completed in this 
study population. If it is documented on the mother’s antenatal 
records, care will be taken to record it. Limits of the study also 
include that HIV status, TB status and iron supplementation 
given are all gained from the antenatal records of the mother. 
Furthermore, antenatal records will not contain all information 
on medication given in every mothers’ pregnancy. As a result, 
care will be made to extensively question participants mother’s 
during verbal one-to-one consultation with our study research 
clinician.
In conclusion, our overarching study goal is to evaluate the likeli-
hood that novel products designed to induce hypoferremia (poten-
tially via mini-hepcidins58) may be useful in the future for the 
prevention of neonatal sepsis in high risk babies. This could be 
produced by a transient redistribution of iron away from the cir-
culation, thus applying a bacteriostatic brake on any bacteria that 
have crossed into the baby’s systemic circulation and hence 
boosting host survival in vulnerable newborns. We hope this may 
ultimately help reduce the use of antibiotics in maternal and 
neonatal wards worldwide.
Ethical approval
This study has been approved by The Gambia Government/MRC 
Joint Ethics Committee (no. SCC1525) and Ethics Commit-
tee of London School of Hygiene and Tropical Medicine (ref no. 
14316). The study procedures will be explained to the neonate’s 
mother/guardians orally or in writing. A neonate is only recruited 
into the study after the consent form has been signed/thumb 
printed by the mother/guardian.
This study was registered with clinicaltrials.gov (NCT03353051) 
on 27 November 2017.
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Underlying data
No data are associated with this article.
Extended data
Figshare: Cross et al. GatesOpen Research SCC1525v2__NeoIn-
nate_Participant Info&Consent form Route 1. https://doi.
org/10.6084/m9.figshare.8069195.v449
This project contains the following extended data:
•  SCC1525v2__NeoInnate_Consent form Route 1_v3 
Approved8Nov17.docx (Route 1 consent and informa-
tion sheet)
Figshare: Cross et al. GatesOpenResearch SCC1525v2_NeoInnate_
Consent form Route 2_Part 1_ (Umbilical Cord Blood Collection) 
- Labour Ward_v1.1-Approved 8Nov17. https://doi.org/10.6084/
m9.figshare.8069246.v150
This project contains the following extended data:
•  SCC1525v2_NeoInnate_Consent form Route 2_Part 
1_ (UCB Collection) - Labour Ward_v1.1-Approved 
8Nov17.docx (Route 2 consent and information sheet 
part 1)
Figshare: Cross et al. Gates Open Research SCC1525v2__NeoIn-




Outside SGH v1-Approved 8Nov17. https://doi.org/10.6084/
m9.figshare.8069243.v151
This project contains the following extended data:
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Attribution 4.0 International license (CC-BY 4.0).
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Chapter 5 – Early postnatal hypoferremia in low birthweight and 
preterm babies: A prospective cohort study in hospital-delivered 
Gambian neonates (Main Paper) 
 
 
Summary of Chapter 
 
BACKGROUND: Neonates, particularly those born preterm (PTB) and with low birthweight 
(LBW), are especially susceptible to bacterial and fungal infections that cause an estimated 
225,000 deaths annually globally. Iron is a vital nutrient for the most common organisms 
causing septicaemia. Full-term babies elicit an immediate postnatal hypoferremia assumed 
to have evolved as an innate defence. We tested whether PTB and LBW babies are capable 
of the same response. 
 
METHODS: We conducted an observational study of 152 babies who were either PTB (born 
≥32 to <37weeks gestational age) and/or LBW (<2500g) (PTB/LBW) and 278 term, normal-
weight babies (FTB/NBW). Blood was sampled from the umbilical cord vein and artery, and 
matched venous blood samples were taken from all neonates between 6-24 hrs after 
delivery. We measured haematological, iron and proinflammatory biomarkers.  
 
FINDINGS: In both PTB/LBW and FTB/NBW babies, serum iron decreased 3-fold within 
12hrs of delivery compared to umbilical blood (7·5±4·5 vs 23·3±7·1ng/ml, P<0·001, n=425). 
Transferrin saturation showed a similar decline with a consequent increase in unsaturated 
iron-binding capacity. C-reactive protein levels increased over 10-fold (P<0·001) and 
hepcidin levels doubled (P<0·001). There was no difference in any of these responses 




INTERPRETATION: Premature or low birthweight babies are able to mount a very rapid 
hypoferremia that is indistinguishable from that in normal term babies. The data suggest that 
this is a hepcidin-mediated response triggered by acute non-infective inflammation at birth, 
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Research in context: 
Evidence before this study: 
We searched PubMed and Ovid Medline for publications that detail hepcidin, serum iron and 
TSAT concentrations in umbilical cord blood or venous blood taken in the neonatal period 
that were published before July 1, 2019 with restriction to publications in the English 
language. We used the search terms “neonate”, “hepcidin”, “TSAT” and “serum iron”. We 
excluded studies on non-humans, in medically unstable neonates or studies that did not 
provide details of gestational age for the study population. We identified 20 studies on 
hepcidin, 23 on TSAT and 51 on serum iron. Collectively, 59 publications contained research 
on full-term (FTB) neonates, and 16 on premature (PTB) neonates. Many of the retrieved 
publications focused on maternal-fetal iron endowment, where umbilical cord blood was 
used as a proxy for early neonatal blood. Very few publications have documented iron and 
inflammatory variables in matched umbilical and neonatal blood samples taken in the 
immediate hours (0-24h) after delivery. Analysis of the retrieved publications leads to the 
conclusion that neonatal hypoferremia may exist in all neonates, however the evidence is 
sparse and unclear, particularly in PTB newborns.  
 
Added value of this study: 
To our knowledge, this observational non-blinded study is the first to assess the independent 
effects of gestational age and birthweight on iron and infection parameters in healthy 
Gambian newborns in the first hours of life. Our findings confirm that a very rapid 
hypoferremia occurs in the early hours of postnatal life with evidence that it is mediated by 
an increase in hepcidin. Premature and low birthweight babies exhibited almost identical 





Implications of all the available evidence: 
There is now clear evidence that neonates, including those with PTB or LBW, elicit a rapid 
and transient hypoferremia probably induced, at least in part, by hepcidin. The strength and 
consistency of this effect indicates that it may have evolved as an innate immune response 
designed to protect neonates from bacterial septicaemia. This suggests the possibility that a 
further enhancement or prolongation of hypoferremia (for instance by mini-hepcidins), might 





BACKGROUND: Neonates, particularly those born preterm (PTB) and with low birthweight 
(LBW), are especially susceptible to bacterial and fungal infections that cause an estimated 
225,000 deaths annually globally. Iron is a vital nutrient for the most common organisms 
causing septicaemia. Full-term babies elicit an immediate postnatal hypoferremia assumed 
to have evolved as an innate defence. We tested whether PTB and LBW babies are capable 
of the same response. 
METHODS: We conducted an observational study of 152 babies who were either PTB (born 
≥32 to <37weeks gestational age) and/or LBW (<2500g) (PTB/LBW) and 278 term, normal-
weight babies (FTB/NBW). Blood was sampled from the umbilical cord vein and artery, and 
matched venous blood samples were taken from all neonates between 6-24 hrs after 
delivery. We measured haematological, iron and proinflammatory biomarkers.  
FINDINGS: In both PTB/LBW and FTB/NBW babies, serum iron decreased 3-fold within 
12hrs of delivery compared to umbilical blood (7·5±4·5 vs 23·3±7·1ng/ml, P<0·001, n=425). 
Transferrin saturation showed a similar decline with a consequent increase in unsaturated 
iron-binding capacity. C-reactive protein levels increased over 10-fold (P<0·001) and 
hepcidin levels doubled (P<0·001). There was no difference in any of these responses 
between PTB/LBW and FTB/NBW babies.  
INTERPRETATION: Premature or low birthweight babies are able to mount a very rapid 
hypoferremia that is indistinguishable from that in normal term babies. The data suggest that 
this is a hepcidin-mediated response triggered by acute non-infective inflammation at birth, 
and likely to have evolved as an innate immune response against bacterial and fungal 
septicaemia. 
 
Trial registration: clinicaltrials.gov (NCT03353051). Registration date: November 27, 2017.  
FUNDING: Bill & Melinda Gates Foundation (OPP1152353).  
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Neonatal sepsis is the third highest cause of death globally, accounting for 225,000 deaths 
each year.1 It is projected that these numbers will increase as a consequence of the 
increasing global prevalence of antimicrobial resistance.2 
 
Physiological adaption to the postnatal environment in the first hours of life is critical for 
survival. At birth, babies transition from a semi-allogeneic, protected fetal setting to a 
microbe-rich extrauterine environment.3 The initial mass bacterial colonisation of mucosa in 
the digestive, respiratory and urogenital tracts, as well as the skin, occurs during the very 
early neonatal period.4 The maternal gut is the source of the majority of transmitted bacterial 
strains to the neonatal microbiome and common strains are also seeded from the maternal 
skin and the vaginal microbiome.5 The acquisition of symbionts can positively affect gut 
maturation, metabolic homeostasis and immune function in early life and beyond,6 but 
pathogenic bacteria and fungi pose an immediate risk unless contained. Adaptive immune 
responses require priming in neonates, and hence innate defence mechanisms play an 
important role in containment.  
 
Similarly, just before delivery or during the intrapartum period babies can be infected by 
micro-organisms, which may lead to early-onset neonatal sepsis (EONS) especially if the 
mother is colonised with pathogenic bacteria.7 Aspiration or ingestion of infected amniotic 
fluid in utero or infected secretions at birth are the common routes of infection. 
 
Iron is an important commodity in the host-pathogen battle for resources.8 It is a cofactor in 
numerous metabolic pathways that are critical for the human host as well as most 
pathogens. Therefore, systemic iron distribution is strictly regulated by the host.9 For many 
human pathogens, the acquisition of iron via a variety of molecular mechanisms can 
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enhance growth and virulence.8 Individuals with chronically high iron states (e.g. 
haemochromatosis) have an enhanced risk of bacterial infection,10 as well as increased free 
radical redox damage.11 Historic studies administering parenteral iron to Polynesian 
neonates infamously increased mortality rates by promoting Escherichia coli septicemias,12 
underlining the critical role that iron plays in the neonatal period. 
  
Cord blood, which has high levels of serum iron and transferrin saturation,13 has frequently 
been used as a proxy for neonatal iron status. However, previous work by our group and 
others has shown that healthy, vaginally-delivered, full-term babies profoundly decrease 
their serum iron and TSAT levels in the first 24h after birth- an adaptation that may have 
evolved as an innate defence against iron-requiring microorganisms.14 In the current study, 
we hypothesised that the greater susceptibility of preterm and low birthweight babies to 
neonatal infections might be because they are less able to elicit this defence. We 
prospectively tested this in hospital-delivered Gambian neonates. 
 
5.3 PARTICIPANTS AND METHODS 
 
Full details of the methods of this study can be found in the published protocol paper.15 
 
Study Design 
This observational study recruited well, hospital-delivered neonates into four different groups 
characterised according to birthweight and gestational age as shown in Figure 1. The 
primary analysis compares all babies exhibiting preterm birth (PTB), low birthweight (LBW) 
or both (PTB/LBW) versus full-term (FTB), normal birthweight (NBW) newborns 





Ethics, standards and informed consent 
The study was approved by the Medical Research Council Unit The Gambia at London 
School of Hygiene and Tropical Medicine (MRCG at LSHTM) Scientific Coordinating 
Committee, the Joint Gambia Government/MRCG Ethics Committee (SCC1525) and the 
London School of Hygiene and Tropical Medicine Ethics Committee (Ref:14316). The study 
was conducted according to Good Clinical Practice (GCP) standards. All participants gave 
written, informed consent. 
 
Study setting 
Study participants were recruited from Kanifing General Hospital (formerly Serrekunda 
General Hospital), in the urban Kanifing region of The Gambia, West Africa. 
 
Recruitment, screening and enrolment 
In total, we planned to identify 450 healthy newly born babies during delivery at the Kanifing 
General Hospital (KGH) Maternity Ward. After informed consent was obtained, neonates 
who met the inclusion criteria were enrolled. For inclusion in the study, neonates were 
medically stable (no birth asphyxia nor signs of sepsis as judged by the attending study 
physician), ≥32 weeks gestational age and weighed  ≥2000g. Preterm babies (PTB) were 
<37 completed weeks gestational age (assessed by New Ballard Score16). Term babies 
(FTB) had a gestational age ≥37 completed weeks. Low birthweight (LBW) was defined as 
<2500g in line with the usual WHO definition. Neonates who weighed ≥2500g were defined 
as normal birthweight (NBW). The observational period began at delivery and lasted until the 
end of the 7th day of life. Data collection started on the 5th July 2017 and ended on 1st 
February 2019. 
 
Pregnant mothers were excluded from the study if they were below the age of 18 years, had 
no fetal heartbeat detected upon admission, were known to be HIV-positive, were in receipt 
of Mycobacterium tuberculosis therapy, had taken antibiotics in the last seven days, had a 
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blood transfusion in the last month, were suffering from severe pre-eclampsia or antepartum 
haemorrhage, or were in another research study.  
 
Babies were excluded at the delivery stage for the following reasons: major congenital 
malformations (not including polydactylism), blood transfusions given to mother or neonate, 
severe birth asphyxia (requiring resuscitation), neonates born via breech, vacuum or via 
caesarean section, or a birthweight <2000g (in order to avoid the additional burden of a 
blood draw in these vulnerable neonates as guided by the Joint Gambia Government/MRCG 
Ethics Committee).  
 
After the delivery stage, babies were excluded following the detection of infection or illness 
(information gained from a venous bleed or review of systems). Neonates were also 
removed from the study protocol if any medication other than intramuscular vitamin K, 
tetracycline eye ointment or immunisations were given. All medications given to mothers and 
neonates during the study period were recorded. Mothers who delivered multiple newborns 
were invited to enrol one of their neonates into the study. 
 
Sample collection 
Once the neonate was fully delivered, one-minute delayed cord clamping was used 
(following World Health Organisation (WHO) policy17). After the umbilical cord was removed 
and cleaned, a trained study nurse identified the umbilical arteries and umbilical vein. Blood 
was collected from each using separate blood draw equipment.  
 
At 6-24h post-delivery, recruited mothers and their neonates were invited to a private 
consultation with the study research clinician. Further demographic data were collected, 
along with a complete review of systems of the mother and neonate. Anthropometric data on 
the newborn was also collected at this point. Neuromuscular and physical maturation of 
each neonate was assessed using the New Ballard Score.16 Immediately after passing the 
 
 173 
health assessment, a venous blood draw was performed on all neonates (2 ml for PTB/LBW 
neonates and 3·5 ml for FTB/NBW neonates). 
 
Laboratory analyses 
A full haematology panel (using a Medonic M20M GP, Boule Diagnostics, Spanga, Sweden) 
and glucose-6-phosphate dehydrogenase deficiency test (R&D Diagnostics Limited, 
Papagos, Greece) were conducted on whole blood. Serum was separated and stored at -
20oC prior to analysis of ferritin, iron, unsaturated iron-binding capacity (UIBC), soluble 
transferrin receptor (sTfR), transferrin, c-reactive protein (CRP), haptoglobin and alpha-1-
acid glycoprotein (AGP) using a fully automated biochemistry analyser (Cobas Integra 400 
plus, Roche Diagnostic, Switzerland). Transferrin saturation (TSAT) was calculated. Serum 
samples were assessed for hepcidin concentration by ELISA (hepcidin-25 (human) EIA Kit, 
DRG, USA) with a dynamic range of 0·135-81 ng/mL. Hepcidin reference material refined by 
Diepeveen et al18 was not used due to the lack of availability at the time of conducting 
laboratory analyses.  
 
In order to ensure a consistent assessment of haemolysis in all serum samples, batches of 
samples were thawed before entering the biochemistry analyser and visually scored by a 
single operator. A previously published specimen integrity chart for haemolysis was used as 
reference.19 Samples were scored 0 (yellow 0 g/L) to 6 (dark red 8 g/L). Samples scoring ≥5 
were removed from the analysis. All serum samples experienced one freeze-thaw cycle 
before biochemical analyses was conducted.  
 
Sample size determination 
This study targeted recruitment of 50 neonates in each of the 3 groups PTB, LBW and 
PTB/LBW and 300 FTB/NBW newborns. Sample size calculations for the primary outcomes 
of change in serum iron and TSAT between cord and the first neonatal samples were based 
on data from a previous study14 and are summarised in the published protocol paper.15 All 
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The primary analysis compared responses in the PTB and/or LBW babies combined 
(PTB/LBW) versus FTB/NBW. Further subgroups of the PTB/LBW group (groups A-C as 
summarised in Figure 1) were also examined in the secondary analyses (see 
Supplementary Material). For continuous variables, baseline characteristics are presented 
as means (± SD) for normally distributed variables. All skewed data were transformed using 
the ladder command in STATA. The ladder command searches a subset of the ladder of 
powers for a transformation that converts the variable of interest into a normally distributed 
variable. Results were confirmed graphically by the gladder command. Categorical variables 
are reported as proportions. The rate of missing data was small (<5%), thus we did not 
impute missing data. Participant characteristics and iron status indicators were compared 
using 2-tailed t-tests or χ2 tests. Multiple regression was used to explore relationships 
between iron status indicators, participant characteristics, inflammatory and haematology 
markers. The relative strength of associations was assessed using standardised coefficients, 
which represent the effect on the outcome variable (expressed as a fraction of a standard 
deviation) caused by a one standard deviation difference in the predictor variable. Changes 
between cord and postnatal blood samples were assessed by paired t-tests. Comparisons of 
continuous variables between groups A-D were produced using repeat measures one-way 
analysis of variance. We examined the association between covariates and the three 
outcomes iron, TSAT and hepcidin status using linear regression models with backward 
elimination for variable selection. All models were adjusted for baseline (cord blood) levels. 
Unless otherwise stated, all hypothesis tests were two-sided at significance level of 0.05. All 
analyses were performed using DataDesk (Data Description Inc., Ithaca, USA) and STATA 






Figure 2 is the CONSORT diagram summarising subject recruitment. Baseline 
characteristics for the 430 neonates completing the study are shown in Table 1. As per 
protocol, there was a large difference in birthweight between NBW (3199±376g) and LBW 
(2338±118g) newborns, with associated differences in length and head circumference. 
Gestational age was also lower in the PTB babies (35·6±0·7) than FTB (39·4±1·3wk). When 
the LBW and PTB babies were combined as PTB/LBW, their weight and gestational ages 
were significantly lower than the FTB/NBW newborns. Mothers of low birthweight babies 
were younger (26·8±6·6y) than FTB/NBW mothers (29·7±6·9y), but there were no other 
differences in maternal or neonatal characteristics (Table 1 and Supplementary Table 1 & 
2). 
 
Neonatal hypoferremia  
Figure 3 illustrates a profound hypoferremia occurring in the first day after parturition. There 
were no babies that failed to show a hypoferremic response and very few in whom the 
response was only moderate. Figure 4 shows that the decline had already occurred by the 
beginning of our sampling window at 6h post-delivery. Contrary to our initial hypothesis, 
there was no difference in the hypoferremic response between any of the PTB, LBW or 
PTB/LBW groups and the controls. For all the babies combined, serum iron decreased over 
3-fold from 23·3±7·1 to 7·5±4·5μmol/L (P<0·001) and TSAT decreased from 51·7±17·3 to 
15·0±6·9% (P<0·001) (Table 2). The mean decrease in serum iron from cord to postnatal 
blood was remarkably consistent across all groups (between 15·2 and 16·5μmol/L), 
equivalent to a range from 2·9 to 3·1-fold decrease (Table 3). Likewise, the spread of the 
decreases in TSAT between groups was very tight (between 35 and 39%), equivalent a 3·4 
to 3·5-fold reduction. Correspondingly there was a substantial increase in UIBC in all groups 
indicating an enhanced ability to sequester any free iron (22·9±10·5 to 43·5±15·9μmol/L, 
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P<0·0001 for all babies combined). Notably, ferritin, TIBC and haemoglobin levels increased 
from cord to the first neonatal bleed, and there was no change in transferrin; thus confirming 
that the decrease in serum iron was an active adaptation not related to altered 
haemodynamics. 
 
Figure 5 shows that all groups had similar hepcidin levels (20·9±13·8 in PTB/LBW vs 
19·4±14·4 ng/mL in FTB/NBW, P=0.3) in their cord blood. However, the cord blood from 
PTB neonates had slightly higher TSAT values (54·8±17·7 vs 50·2±16·9%, P=0·017) and 
serum iron (24·4±7·3vs 22·7±7·0 μmol/L, P=0·01) in comparison to FTB neonates. In the 
postnatal venous blood samples, all groups had similar hepcidin levels (37·4±23·5 in 
PTB/LBW vs 38·9±23·9ng/ml in FTB/NBW, P=0.5). The venous blood from PTB and LBW 
neonates had slightly higher TSAT values (16·1±8·4% and 16·2±5·3% vs 14·4±6·0%, both 
P=0.01) in comparison to FTB neonates. There is no evidence that these small differences 
in TSAT will translate into a clinically important difference in susceptibility to neonatal sepsis 
or infection. Additional comparisons can be seen in Supplementary Tables 3 & 4.  
 
Comparisons of further iron, infection and haematological parameters in umbilical cord and 
venous blood can be seen in Supplementary Table 5. Analysis of the babies subdivided 
into groups A-D is listed in Supplementary Tables 6, 7 and 8. As anticipated, based upon 
the lack of difference in hypoferremia between PTB, LBW and FTB/NBW neonates, there 
were no differences between the additional subgroupings of A-D. 
 
Factors associated with the decline in serum iron and TSAT 
CRP levels increased by over 10-fold between cord and postnatal blood (0·17±0·6 to 
2·16±4·0mg/L, P<0·001) and hepcidin levels doubled (19·9±14·2 to 38·4±23·7ng/ml, 




Table 3 lists the results of the regression analysis of factors associated with Day 1 serum 
iron. Use of standardised coefficients permits ranking in order of the effect size per standard 
deviation of the predictor variable. In univariate analysis CRP, hepcidin and transferrin were 
most strongly associated with serum iron. Note that CRP was entered as the reciprocal of 
the square root, so the direction of the coefficient is reversed (i.e. a high CRP was 
associated with a low serum iron). Haptoglobin, age of mother and birthweight were also 
significantly associated with serum iron. In multivariable analysis, CRP and hepcidin were 
the strongest correlates. The parallel analysis for TSAT showed broadly similar associations 
(Table 3). 
 
Factors associated with postnatal hepcidin levels 
Based on the pre-hoc assumption that hepcidin orchestrates the postnatal hypoferremia, we 
examined the factors associated with neonatal hepcidin levels on Day 1 (Table 4).  The 
strongest predictor was time of bleed with a negative coefficient. Examination of Figure 4C 
suggests that this was because hepcidin rose very fast at, or immediately after, parturition 
and was already starting to decline by 6h. Ferritin was positively associated with hepcidin, 
and serum iron was negatively correlated. Surprisingly there was no evidence of a cross-




The rapid and profound postnatal hypoferremia demonstrated in this study closely matches 
our prior findings in full-term, vaginally-delivered rural Gambian babies14 and the results of 
studies elsewhere.20,21 The 3·4-fold decrease recorded here is towards the top end of the 2-
4-fold range recorded in prior studies.14,20,21 We have previously proposed that this may 
represent an evolved innate immune response designed to deprive blood-stream bacteria of 
iron and hence create a hostile bacteriostatic environment.14 The current study was 
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designed to test the hypothesis that immature or growth-restricted neonates might have a 
lesser ability to trigger this innate defence and that this might explain their greater 
susceptibility to septicemias.22 Our hypothesis was firmly refuted. We showed that the 
premature and low birthweight neonates all exhibited a profound hypoferremia during the 
first 24h of life, with no detectable differences from the full-term, normal birthweight 
newborns. In fact, there was a remarkable similarity in the hypoferremic response across all 
the study groups that underscores the efficiency of the process and supports the likelihood 
that it occurs by the process of evolution.  
 
The host-pathogen battle for iron has been extensively studied23 and it has long been 
assumed that the hypoferremia of the acute phase response acts as an innate defence 
against iron-requiring organisms. Hepcidin is a key, though not necessarily the only,24 
regulator of this response.25 Inflammatory cytokines including IL-6, IL-22 and Type-1 
interferon rapidly upregulate hepcidin expression and release from the liver.26 Hepcidin 
causes hypoferremia by inhibiting the action of the transmembrane iron-exporter ferroportin 
in enterocytes and macrophages, thus blocking iron absorption and recycling.27 Injection of 
recombinant hepcidin results in the very rapid induction of hypoferremia in mice28 and 
humans.29  
 
In both univariate and multivariate analysis neonatal serum iron and TSAT levels were most 
strongly correlated with CRP and hepcidin (Table 3) suggesting that the hypoferremia is, at 
least partly, driven by an inflammatory response to the stress of the birth process and/or the 
exposure of the newborn to vaginal and/or gastrointestinal micro-organisms not previously 
encountered in utero. The modest proportion of variance explained in the full multivariate 
model (29% for serum iron and 22% for TSAT) might reflect the fact that both measures 
have been suppressed too close to their physiological lower limit and hence display a limited 
range. It is also possible that hepcidin-independent mechanisms, driven by effector 
molecules unmeasured in this study, are playing an additional role.24 A full examination of 
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the mechanism responsible for the hypoferremia would probably require studies in an animal 
model. Neonatal piglets may be a suitable model due to their low iron endowment at birth, 
low iron milk30, fast growth rate31 and similarities to human anatomy and physiology.32 These 
factors result in young porcine models often becoming iron deficient and anaemic without 
the need for low-iron diets (i.e. as seen in murine models).33 
 
Using ex vivo assays with sentinel bacteria, we have previously demonstrated that low TSAT 
values in serum from adults34 and neonates14 exerts a powerful bacteriostatic effect. In the 
neonatal study, growth rates of Escherichia coli, Streptococcus pneumoniae, Streptococcus. 
agalactiae and Staphylococcus aureus, were highly significantly lower in neonatal serum 
than in cord serum and for each organism growth rates were significantly associated with 
TSAT. S. aureus was least responsive, possibly reflecting its ability to utilise haem iron, 
though it was still clearly influenced by transferrin saturation. E. coli was most responsive, 
which may explain why intramuscular iron administration to Polynesian neonates increased 
septicaemia rates with a major shift towards E. coli as the most frequently identified cause.12 
The hypoferremia observed in the current hospital-based study (in both PTB/LBW and 
FTB/NBW babies) was more profound than we previously observed in rural home 
deliveries14 (TSAT declined to 15% versus 24% in rural babies) and hence the bacteriostatic 
effect would be expected to be even greater. 
 
There are several strengths and limitations to our study. The large sample size allows us to 
confidently exclude any clinically-meaningful differences in the postnatal response of 
preterm and low birthweight babies compared to the full-term normal birthweight neonates. 
By protocol, we did not recruit mothers with complex medical histories (e.g. pre-eclampsia, 
antepartum haemorrhage or antenatal infection) or sick babies (e.g. with birth asphyxia or 
suspected sepsis). We did not recruit newborns born <32 completed weeks gestation and/or 
<2000g birthweight, or those delivered via c-section, vacuum or forceps. We cannot 
speculate whether similar hypoferremic responses would occur in such cases, but 
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reciprocally we can conclude that the responses we observed are a characteristic feature of 
normal human birth and were not elicited by pathological circumstances. In order to allow 
mothers to recover from their delivery and the neonates to be stabilised and checked for 
inclusion, we constrained our first postnatal blood draw to after 6h post-delivery. With many 
samples collected soon after this point, we have demonstrated that the reduction in 
circulating iron levels occurs very rapidly, but we cannot state how rapidly. We did not 
measure pro-inflammatory cytokines (e.g. IL-6 and IL-22) which might have provided 
additional insights into the mechanisms eliciting hypoferremia. Similarly, we did not attempt 
to address any possible hepcidin-independent mechanisms because the putative mediators 
remain unknown. Such studies may require animal models. 
 
In conclusion, our results suggest that the innate postnatal iron restriction strategy in the first 
hours of life has evolved as an intrinsic mechanism to protect neonates from common 
pathogens and/or free-radical damage, and occurs regardless of gestational age or 
birthweight. This hypoferremia is at least partly mediated by the hormone, hepcidin. The 
trigger mechanism, relation to maternal iron status, and its effect on susceptibility to 
systemic bacterial infections require further investigation.  
 
Our results highlight the importance of hypoferremia as a conserved mechanism of 
protection, and prompt further research into the use of iron restriction as a transient 
bacteriostatic mechanism to limit bacterial growth and virulence in other instances of 
infection. Hypoferremia can slow the multiplication of bacterial pathogens,34 which in 
combination with antibiotics, could allow enough time for the adaptive immune system to 
fight the infection. Augmentation of innate immunity in neonates and other at-risk groups 
(elderly or immunocompromised) might be achieved by the use of small molecule orally-






AGP = Alpha-1-acid glycoprotein 
CRP = C-reactive protein 
ELISA = Enzyme-linked immunosorbent assay 
EONS = Early-onset neonatal sepsis 
FTB = Full-term birth 
G6PD = Glucose-6-phosphate dehydrogenase 
GCP = Good Clinical Practice 
IL-6 = Interleukin 6 
IL-22 = Interleukin 22 
KGH = Kanifing General Hospital 
KMC = Kanifing Municipal Council 
LBW = Low birthweight 
MRCG = Medical Research Council Unit The Gambia at LSHTM 
NBW = Normal birthweight 
PI = Principal investigator 
PTB = Preterm birth  
SCC = Scientific Coordinating Committee 
sTfR = Soluble transferrin receptor 
TIBC = Total iron-binding capacity 
TLR = Toll-like receptor 
TSAT = Transferrin saturation 
UIBC = Unbound iron-binding capacity 
V1 = Venous bleed 1 







We thank Kanifing Municipal Council (KMC) and Kanifing General Hospital (KGH) for their 
support during the study.   
 
Funding:  
The research was undertaken with a research grant provided by the Bill & Melinda Gates 
Foundation (OPP1152353). The funding agency had no role in the design and conduct of 
the study, and did not have any in the collection, management, analyses or interpretation of 
the data nor in the preparation, review, or approval of the manuscript. The Nutrition Theme 
of the MRC Unit The Gambia at LSHTM are supported by core funding MC-A760-5QX00 to 
the MRC Unit The Gambia/MRC International Nutrition Group by the UK MRC and the UK 
Department for the International Development (DFID) under the MRC/DFID Concordat 
agreement. 
 
Availability of Data and Materials:  
All data will be made available to researchers upon reasonable request to the study PI and 
clearance by the MRCG Scientific Coordinating and Ethics Committees.  
 
Authors’ Contributions: 
JHC is PhD student with MRCG at LSHTM. He contributed to the development of the 
protocols, study management, field data collection, development of the data analysis plan, 
conducting the data analysis and drafting of the manuscript. 
OJ is a research clinician with MRCG at LSHTM. He contributed to the development of the 
protocols, study management, field data collection and patient care.  
NIM is a statistician at MRCG at LSHTM. He wrote the data analysis plan in consultation 
with JC, CC and AMP.  
SRG was a visiting B.Sc. student from Cardiff University. He contributed to the laboratory 
analyses and field data collection. 
 
 183 
BJBT is a laboratory technician with MRCG at LSHTM. He contributed to the laboratory 
analyses and field data collection. 
AMP is a Professor of International Nutrition at LSHTM and Nutrition Theme Leader at 
MRCG at LSHTM. He conceived the study, obtained the funding, contributed to the 
development of the protocols, the data analysis plan, conducting the data analysis and the 
drafting of the manuscript. 
CC is Senior Investigator Scientist at MRCG at LSHTM and Group Leader for Iron, Infection 
and Anaemia. She was the PI on the trial, conceived the study, and obtained the funding.  
She was responsible for the overall development of the protocols, the data analysis plan, 
conducting the data analysis and the drafting of the manuscript. 
All authors reviewed the final manuscript prior to submission. 
 
Competing Interests:  
The authors declare that they have no competing interests. 
 
Consent for Publication:  
Not applicable. 
 
Ethics Approval and Consent to Participate:  
This study has been approved by The Gambia Government/MRC Joint Ethics Committee 
(no. SCC1525) and London School of Hygiene and Tropical Medicine Ethics Committee (ref 
no. 14316). The study was conducted according to Good Clinical Practice (GCP) standards. 
The study procedures were explained to the neonate’s mother/guardians orally and in 
writing. A neonate was only recruited into the study after the written, informed consent was 






Author Details:  
1Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical 
Medicine, Atlantic Boulevard, Fajara, P.O. Box 273, Banjul, The Gambia 
2Cardiff University, Cardiff, Wales, CF10 3AT, United Kingdom 
 
5.6 REFERENCES  
 
1 GBD 2016 Causes of Death Collaborators M, Abajobir AA, Abbafati C, et al. Global, 
regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: 
a systematic analysis for the Global Burden of Disease Study 2016. Lancet  2017; 
390: 1151–210. 
2 Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global 
solutions. Lancet Infect Dis 2013; 13: 1057–98. 
3 Moore RE, Townsend SD. Temporal development of the infant gut microbiome. Open 
Biol 2019; 9: 190128. 
4 Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the 
acquisition and structure of the initial microbiota across multiple body habitats in 
newborns. Proc Natl Acad Sci 2010; 107: 11971–5. 
5 Ferretti P, Pasolli E, Tett A, Huttenhower C, Correspondence NS. Mother-to-Infant 
Microbial Transmission from Different Body Sites Shapes the Developing Infant Gut 
Microbiome. Cell Host Microbe 2018; 24: 133–45. 
6 Dominguez-Bello MG, Godoy-Vitorino F, Knight R, Blaser MJ. Role of the microbiome 
in human development. Gut 2019; 68: 1108–14. 
7 Chan GJ, Lee AC, Baqui AH, Tan J, Black RE. Prevalence of early-onset neonatal 
infection among newborns of mothers with bacterial infection or colonization: a 
systematic review and meta-analysis. BMC Infect Dis 2015; 15: 118. 




9 Pigeon C, Ilyin G, Courselaud B, et al. A New Mouse Liver-specific Gene, Encoding a 
Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed 
during Iron Overload. J Biol Chem 2001; 276: 7811–9. 
10 Khan FA, Fisher MA, Khakoo RA. Association of hemochromatosis with infectious 
diseases: expanding spectrum. Int J Infect Dis 2007; 11: 482–7. 
11 Pietrangelo A. Hereditary hemochromatosis. Biochim Biophys Acta - Mol Cell Res 
2006; 1763: 700–10. 
12 Barry DM, Reeve AW. Increased incidence of gram negative neonatal sepsis with 
intramuscular iron administration. Pediatrics 1977; 60: 908-12. 
13 Lorenz L, Peter A, Poets CF, Franz AR. A Review of Cord Blood Concentrations of 
Iron Status Parameters to Define Reference Ranges for Preterm Infants. Neonatology 
2013; 104: 194–202. 
14 Prentice S, Jallow AT, Sinjanka E, et al. Hepcidin mediates hypoferremia and reduces 
the growth potential of bacteria in the immediate post-natal period in human neonates. 
Sci Rep 2019; 9: 16596. 
15 Cross JH, Jarjou O, Mohammed NI, Prentice AM, Cerami C. Neonatal iron distribution 
and infection susceptibility in full term, preterm and low birthweight babies in urban 
Gambia: study protocol for an observational study. Gates Open Res 2019; 3: 1469. 
16 Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New Ballard 
Score, expanded to include extremely premature infants. J Pediatr 1991; 119: 417–
23. 
17 WHO | Delayed umbilical cord clamping for improved maternal and infant health and 
nutrition outcomes. WHO. 2019. Available at: 
https://www.who.int/nutrition/publications/guidelines/cord_clamping/en/. 
18 Diepeveen LE, Laarakkers CMM, Martos G, et al. Provisional standardization of 
hepcidin assays: creating a traceability chain with a primary reference material, 
candidate reference method and a commutable secondary reference material. Clin 
 
 186 
Chem Lab Med 2019; 57: 864–72. 
19 Dugan L, Leech L, Speroni KG, Corriher J. Factors Affecting Hemolysis Rates in 
Blood Samples Drawn From Newly Placed IV Sites in the Emergency Department. J 
Emerg Nurs 2005; 31: 338–45. 
20 Szabo M, Vasarhelyi B, Balla G, et al. Acute postnatal increase of extracellular 
antioxidant defence of neonates: the role of iron metabolism. Acta Paediatr 2001; 90: 
1167–70. 
21 Balogh Á, Szabó M, Kelen D, et al. Prohepcidin levels during human perinatal 
adaptation. Pediatr Hematol Oncol 2007; 24: 361-8 
22 Schrag SJ, Farley MM, Petit S, et al. Epidemiology of invasive early-onset neonatal 
sepsis, 2005 to 2014. Pediatrics. 2016; 138: e20163013. 
23 Skaar EP. The battle for iron between bacterial pathogens and their vertebrate hosts. 
PLoS Pathog 2010; 6: e1000949. 
24 Enculescu M, Metzendorf C, Sparla R, et al. Modelling Systemic Iron Regulation 
during Dietary Iron Overload and Acute Inflammation: Role of Hepcidin-Independent 
Mechanisms. PLoS Comput Biol 2017; 13: e1005322. 
25 Michels K, Nemeth E, Ganz T, Mehrad B. Hepcidin and Host Defense against 
Infectious Diseases. PLoS Pathog. 2015; 11: e1004998. 
26 Ganz T. Systemic iron homeostasis. Physiol Rev 2013; 93: 1721–41. 
27 Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by 
binding to ferroportin and inducing its internalization. Science 2004; 306: 2090–3. 
28 Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin 
causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-
containing organs. Blood 2005; 106: 2196–9. 
29 Protagonist Therapeutics. Protagonist Therapeutics announces final phase 1 study 
results with novel hepcidin mimetic, PTG-300. https://www.prnewswire.com/news-
releases/protagonist-therapeutics-announces-final-phase-1-study-results-with-novel-
hepcidin-mimetic-ptg-300-300571268.html. (accessed Sept 18, 2019). 
 
 187 
30 Starzyński RR, Laarakkers CMM, Tjalsma H, et al. Iron Supplementation in Suckling 
Piglets: How to Correct Iron Deficiency Anemia without Affecting Plasma Hepcidin 
Levels. PLoS One 2013; 8: e64022. 
31 Ventrella D, Dondi F, Barone F, et al. The biomedical piglet: establishing reference 
intervals for haematology and clinical chemistry parameters of two age groups with 
and without iron supplementation. BMC Vet Res 2016; 13: 23. 
32 Moughan PJ, Birtles MJ, Cranwell PD, Smith WC, Pedraza M. The piglet as a model 
animal for studying aspects of digestion and absorption in milk-fed human infants. 
World Rev. Nutr. Diet. 1992; 67: 40-113  
33 Li Y, Hansen SL, Borst LB, Spears JW, Moeser AJ. Dietary Iron Deficiency and 
Oversupplementation Increase Intestinal Permeability, Ion Transport, and 
Inflammation in Pigs. J Nutr 2016; 146: 1499-505. 
34 Cross JH, Bradbury RS, Fulford AJ, et al. Oral iron acutely elevates bacterial growth 
in human serum. Sci Rep 2015; 5: 16670. 
35 Vifor Pharma. Vifor Pharma ferroportin inhibitor enters phase-I clinical trial. 
http://www.viforpharma.com/en/media/press-releases/201802/2167159 (accessed 
Sept 18, 2019). 
 
 188 
Figure and Table Legends: 
 
Figure 1: Schematic diagram of all study groupings and the generation of subgroups. 
PTB = preterm birth, FTB = full-term birth, LBW = low birthweight and NBW = normal 
birthweight. FTB/NBW neonates are FTB+NBW. PTB/LBW neonates are FTB+LBW, 
PTB+NBW and PTB+LBW neonates. 
 
Figure 2: CONSORT diagram for participant flow. PTB/LBW are displayed in GREEN, 
and FTB/NBW in ORANGE.  
 
Figure 3: Analysis of serum iron (A), TSAT (B) and hepcidin (C) in umbilical cord 
(BLUE) and post-natal venous blood (RED) based on all study groupings. Horizontal 
lines represent the arithmetic group means. FTB/NBW are FTB+NBW. PTB/LBW are 
FTB+LBW, PTB+NBW and PTB+LBW neonates. *** = all group comparisons between cord 
and venous blood are statistically significant (P<0·001). Hepcidin displayed as log10. 
 
Figure 4: Timecourse of the changes in serum iron (A), TSAT (B), hepcidin (C) and 
CRP (D) in the first day of life. Means ± 95% CI. PTB/LBW are RED columns and 
significance lines. FTB/NBW are BLUE columns and significance lines. Columns are plotted 
according to mean time of bleed for the categories 0, 1-8, 9-16 and 17-24 hours. **** = 
P<0·0001, *** = P<0·001, ** = P<0·01, * = P<0·05. No significance line = P>0·05. 
 
Figure 5: Comparisons of serum iron (A = cord, B = venous), TSAT (C = cord, D = 
venous) and hepcidin (E = cord, F = venous) in cord and post-natal venous blood. 
Means ± 95% CI. FTB/NBW are BLUE columns. PTB/LBW are RED columns. PTB are 
DARK GREY columns. LBW are LIGHT GREY columns. Significance lines represent the 
comparison of PTB/LBW, PTB or LBW groups to the FTB/NBW group. ** = P<0·01, * = 
P<0·05. No significance line = P>0·05. 
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Table 1: Participant Characteristics. Demographic, clinical and pregnancy outcome 
characteristics of the women and their newborns. Data are presented as arithmetic mean (± 
SD) and analysed by one-way analysis of variance or as a proportion (%) and analysed 
by Pearson χ2 test. P values in bold font are considered significant based on P<0·05.  
 
Table 2: Iron Parameters (cord vs venous sample) for FTB/NBW, PTB/LBW, PTB and 
LBW neonates. Data are presented as mean (± SD) and analysed by one-way analysis of 
variance. P values in bold font are considered significant based on P<0·05. Skewed 
variables were transformed as follows: log10 (serum iron), 1/sqrt (TIBC), sqrt (ferritin), 1/sqrt 
(CRP), log10 (hepcidin). 
 
Table 3: Linear regression of factors associated with postnatal serum iron and TSAT.  
All regressions were adjusted for 4 grades of visually assessed haemolysis. Ranked 
according to their standardized coefficients calculated in STATA. a 1/sqrt(CRP), b log10 
(hepcidin).  
 
Table 4: Linear regression of factors associated with postnatal serum hepcidin.  
All regressions were adjusted for 4 grades of visually assessed haemolysis. Ranked 
according to their standardized regression coefficients calculated in STATA. a sqrt(ferritin), b 




Figure 1  
 
 191 




























Table 1 – Participant characteristics 
 Whole Population FTB/NBW PTB/LBW P value FTB PTB P value NBW LBW P value 
Number of participants (n) 430 278 152 ·· 289 141 ·· 377 53 ·· 
Characteristic Mean (± SD) 
Gestational age (Weeks) 38·1 (±2·1) 39·4 (±1·3) 35·8 (±1·1) <0·001 39·4 (±1·3) 35·6 (±0·7) <0·001 38·4 (±2·0) 35·9 (±1·7) <0·001 
Birth weight (g) 3092 (±453) 3299 (±368·3) 2715 (±338·5) <0·001 3264 (±402·2) 2741 (±336·9) <0·001 3199 (±376·3) 2338 (±117·7) <0·001 
Head circumference (cm) 34·0 (±1·2) 34·6 (±1·0) 33·0 (±0·1) <0·001 34·5 (±1·1) 33·1 (±0·1) <0·001 34·3 (±1·1) 32·3 (±0·8) <0·001 
Length (cm) 49·2 (±1·9) 50·0 (±1·6) 47·7 (±1·6) <0·001 49·9 (±1·7) 47·7 (±1·6) <0·001 49·6 (±1·7) 46·7 (±1·4) <0·001 
Maternal haemoglobin ≤7 days before delivery (g/dl) 11·6 (±1·8) 11·6 (±1·8) 11·4 (±1·8) 0·25 11·6 (±1·8) 11·5 (±1·8) 0·35 11·5 (±1·8) 11·8 (±1·7) 0·75 
Age of mother (Years) 29·4 (±6·9) 29·7 (±6·9) 28·7 (±6·8) 0·16 29·6 (±7·0) 28·9 (±6·8) 0·35 29·7 (±6·9) 26·8 (±6·6) 0·003 
1 min APGAR score (0-10) 9·7 (±0·7) 9·6 (±0·8) 9·7 (±0·6) 0·51 9·6 (±0·8) 9·8 (±0·6) 0·26 9·7 (±0·7) 9·6 (±0·8) 0·7 
Time from admission to birth (Hours) 3·2 (±5·1) 3·2 (±5·2) 3·2 (±4·8) 0·96 3·2 (±5·2) 3·2 (±4·8) 0·94 3·2 (±5·1) 3·3 (±5·0) 0·94 
Time from delivery to postnatal blood collection (Hours) 12·7 (±5·3) 12·7 (±5·4) 12·8 (±5·3) 0·81 12·6 (±5·3) 13·0 (±5·3) 0·47 12·8 (±5·3) 12·5 (±4·8) 0·71 
 Percentage (%) 
Percentage male (%) 53·5% (224) 54·3% (151) 52·0% (79) 0·64 54·7% (158) 51·1% (72) 0·48 53·8% (203) 50·9% (27) 0·69 
Percentage early term, ≥37-≤38 weeks (%) 19·3% (83) 27·7% (77) 3·9% (6) <0·001 28·7% (83) 0·0% (0) <0·001 20·4% (77) 11·3% (6) 0·12 
G6PD deficiency positive (%) 12·6% (54) 11·5% (32) 14·6% (22) 0·36 11·4% (33) 15·0% (21) 0·3 13·3% (50) 7·7% (4) 0·26 
Multiple births (%) 3% (13) 2·2% (6) 4·6% (7) 0·16 2·1% (6) 4·9% (7) 0·1 2·7% (10) 5·7% (3) 0·23 







Table 2 - Changes in iron status, inflammation and hepcidin between cord and postnatal blood 
 Whole Population  FTB/NBW  PTB/LBW  Preterm Birth (PTB) Low Birthweight (LBW) 
Sample Type n Cord n Venous P  value n Cord n Venous 
P  
value n Cord n Venous 
P  
value n Cord n Venous 
P  
value n Cord n Venous 
P  
value 
Serum iron  
(μmol/L) 425 23·3 (±7·1) 421 7·5 (±4·5) <0·001 275 22·7 (±7·0) 271 7·3 (±4·6) <0·001 150 24·3 (±7·3) 150 8·0 (±4·1) <0·001 140 24·4 (±7·3) 139 7·8 (±4·1) <0·001 51 24·5 (±7·7) 51 8·5 (±3·4) <0·001 
UIBC  
(μmol/L) 423 22·9 (±10·5) 420 43·5 (±15·9) <0·001 273 23·7 (±10·4) 271 44·1 (±18·0) <0·001 150 21·5 (±10·6) 149 42·2 (±10·9) <0·001 140 21·2 (±9·8) 138 42·0 (±10·9) <0·001 51 22·1 (±12·2) 50 43·8 (±10·2) <0·001 
TIBC  
(μmol/L) 423 46·1 (±8·0) 420 51·0 (±17·9) <0·001 273 46·3 (±8·1) 271 51·4 (±20·7) <0·001 150 45·8 (±7·8) 149 50·2 (±11·3) <0·001 140 45·6 (±7·4) 138 49·8 (±11·1) <0·001 51 46·6 (±9·3) 50 52·3 (±11·9) <0·001 
Transferrin  
(g/L) 426 1·96 (±0·3) 423 1·99 (±0·3) 0·003 275 1·98 (±0·3) 273 1·98 (±0·3) 0·8335 151 1·93 (±0·3) 150 2·00 (±0·3) <0·001 141 1·92 (±0·3) 139 1·99 (±0·3) <0·001 52 1·94 (±0·4) 51 2·02 (±0·4) 0·0024 
TSAT  
(%) 423 51·7 (±17·3) 420 15·0 (±6·9) <0·001 273 50·2 (±16·7) 271 14·4 (±6·1) <0·001 150 54·5 (±18·0) 149 16·2 (±8·2) <0·001 140 54·8 (±17·7) 138 16·1 (±8·4) <0·001 51 54·6 (±18·7) 50 16·2 (±5·3) <0·001 
Serum ferritin  
(ug/L) 426 210·5 (±157·8) 415 381·2 (±297·6) <0·001 275 212·6 (±157·7) 271 393·9 (±312·6) <0·001 151 206·6 (±158·5) 149 358·6 (±268·1) <0·001 141 206·8 (±154·8) 138 355·7 (±259·6) <0·001 52 192·1 (±179·5) 51 366·2 (±343·8) <0·001 
Serum AGP  
(g/L) 426 0·18 (±0·1) 423 0·24 (±0·2) <0·001 275 0·19 (±0·1) 273 0·25 (±0·2) <0·001 151 0·17 (±0·1) 150 0·23 (±0·2) <0·001 141 0·16 (±0·2) 139 0·22 (±0·2) <0·001 52 0·16 (±0·1) 51 0·21 (±0·16) <0·001 
Serum CRP  
(mg/L) 425 0·17 (±0·6) 422 2·16 (±4·0) <0·001 275 0·19 (±0·7) 273 2·27 (±4·1) <0·001 150 0·14 (±0·2) 149 1·96 (±3·8) <0·001 140 0·14 (±0·2) 138 1·99 (±3·9) <0·001 51 0·10 (±0·07) 51 1·14 (±1·8) 0·0002 
>5mg/L 2 0·5% 54 12·8% <0·001 2 0·7% 37 13·6% <0·001 0 0·0% 17 11·4% N/A 0 0·0% 16 11·6% N/A 0 0·0% 4 7·8% N/A 
>3mg/L 3 0·7% 83 19·7% <0·001 3 1·0% 59 21·6% <0·001 0 0·0% 24 16·1% N/A 0 0·0% 23 16·7% N/A 0 0·0% 6 11·8% N/A 
Serum hepcidin  
(ng/ml) 425 19·9 (±14·2) 417 38·4 (±23·7) <0·001 277 19·4 (±14·4) 270 38·9 (±23·9) <0·001 148 20·9 (±13·8) 147 37·4 (±23·5) <0·001 138 21·5 (±13·9) 136 37·7 (±23·3) <0·001 52 17·6 (±13·0) 51 33·7 (±22·2) <0·001 
Haemoglobin  





Table 3 - Factors associated with neonatal serum iron and TSAT at 6-24h post-partum 
Predictor Coefficient Standard error Standardised coefficient  P value 
R2 
(%) 
Univariate Analysis - Serum Iron 
CRP a 0·135 0·023 0·258 <0·0001 15·5 
Hepcidin b -0·139 0·025 -0·249 <0·0001 14·2 
Transferrin 0·273 0·056 0·222 <0·0001 13·7 
Haptoglobin -1·21 0·303 -0·184 <0·0001 12·2 
Age of mother -0·009 0·002 -0·152 0·001 11·1 
Birthweight -0·0001 -0·00004 -0·149 0·001 11 
Multivariate Analysis - Serum Iron 
CRP a 0·124 0·022 0·239 <0·0001 
29·2 
Hepcidin b -0·11 0·025 -0·198 <0·0001 
Transferrin 0·23 0·055 0·186 <0·0001 
Age of mother -0·008 0·002 -0·143 0·001 
Haptoglobin -0·741 0·28 -0·114 0·008 
Birthweight -0·00009 0·00003 -0·104 0·016 
Univariate Analysis - Transferrin Saturation (TSAT) 
CRP a 0·153 0·023 0·306 <0·0001 11·7 
Haptoglobin -1·14 0·302 -0·181 <0·0001 5·7 
Hepcidin b -0·085 0·025 -0·16 0·001 4·8 
Birthweight -0·0001 0·00004 -0·153 0·001 4·7 
Age of mother -0·008 0·002 -0·151 0·002 4·7 
Multivariate Analysis - Transferrin Saturation (TSAT) 
CRP a 0·139 0·022 0·285 <0·0001 
21·8 
Hepcidin b -0·093 0·024 -0·253 <0·0001 
Ferritin -0·008 0·002 0·187 <0·0001 






Table 4 - Factors associated with neonatal serum hepcidin at 6-24h post-partum 







Univariate Analysis - Serum Hepcidin 
Ferritin a 0·039 0·0005 0·354 <0·0001 14 
Time of bleed -0·0007 0·0001 -0·321 <0·0001 12 
Transferrin -0·706 0·104 -0·318 <0·0001 11·5 
Serum iron b -0·479 0·089 -0·267 <0·0001 8·2 
sTfR c -0·36 0·092 -0·189 0·001 5 
Multivariate Analysis - Serum Hepcidin 
Time of bleed -0·0008 0·00009 -0·354 <0·0001 
36·1 
Ferritin a 0·035 0·004 0·319 <0·0001 
Serum iron b -0·413 0·078 -0·232 <0·0001 
sTfR c -0·286 0·086 -0·15 0·001 
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5.7 SUPPLEMENTARY MATERIAL 
 
SUPPLEMENTARY METHODS 




Supplementary Table 1 – Participant Characteristics (Groups A-D) 
 Whole Population Group A (PTB+LBW) Group B (PTB+NBW) Group C (FTB+LBW) Group D (FTB+NBW) P value 
Number of Participants (n) 430 42 99 11 278  
Characteristic Mean (± SD) 
Gestational age (Weeks) 38·1 (±2·1) 35·1 (±0·9) 35·7 (±0·5) 38·6 (±1·3) 39·4 (±1·3) <0·0001 
Birth weight (g) 3092 (±453·9) 2326 (±122·6) 2916 (±225·9) 2380 (±89·2) 3299 (±368·3) <0·0001 
Head circumference (cm) 34·0 (±1·2) 32·2 (±0·7) 33·4 (±0·8) 32·7 (±1·0) 34·6 (±1·0) <0·0001 
Length (cm) 49·2 (±1·9) 46·6 (±1·4) 48·2 (±1·4) 47·0 (±1·5) 50·0 (±1·6) <0·0001 
Maternal hemoglobin ≤7 days before delivery (g/dl) 11·6 (±1·8) 12·2 (±1·5) 11·3 (±1·8) 10·8 (±2·0) 11·6 (±1·8) 0·29 
Age of mother (Years) 29·4 (±6·9) 26·9 (±6·6) 29·8 (±6·7) 26·4 (±6·9) 29·7 (±6·9) 0·03 
1 min APGAR score (0-10) 9·65 (±0·7) 9·6 (±0·7) 9·8 (±0·48) 9·2 (±1·3) 9·6 (±0·8) 0·03 
Time from admission to birth (Hours) 3·23 (±5·1) 3·2 (±4·9) 3·2 (±4·8) 3·7 (±5·5) 3·2 (±5·2) 0·99 
Time from delivery to V1 blood collection (Hours) 12·7 (±5·3) 13·0 (±4·9) 13·0 (±5·5) 10·5 (±3·8) 12·7 (±5·4) 0·52 
 Percentage (%) 
Percentage male (%) 53·5% (224) 47·6% (20) 52·5% (52) 63·6% (7) 54·3% (151) 0·76 
Percentage early term, ≥37-≤38 weeks (%) 19·3% (83) 0% (0) 0% (0) 54·5% (6) 27·7% (77) <0·0001 
G6PD deficiency positive (%) 12·6% (54) 7·1% (3) 18·2% (18) 9·1% (1) 11·5% (32) 0·23 
Multiple births (%) 3% (13) 7·1% (3) 4% (4) 0% (0) 2·2% (6) 0·28 
Percentage of mother on antenatal iron/folic acid (%) 82·1% (353) 76·2% (32) 87·9% (87) 63·6% (7) 81·7% (227) 0·21 
 
Supplementary Table 1: Baseline Characteristics. Demographic, clinical and pregnancy outcome characteristics of the women and their 
newborns for groups A-D. Data are presented as mean (± SD) and analysed by ANOVA or as n (%) and analysed by χ2 test. P values in bold 
font are considered significant based on P<0·05. 
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Supplementary Table 2 – Maternal Ethnicity 
Ethnic Group Whole Population FTB/NBW PTB/LBW P value Full-Term Birth (FTB) Preterm Birth (PTB) P value NBW LBW P value Group A (PTB+LBW) Group B (PTB+NBW) Group C (FTB+LBW) Group D (FTB+NBW) P value 
Aku 0·9% (4) 1·4% (4) 0% (0) 
0·13 
1·4% (4) 0% (0) 
0·1 
1·1% (4) 0% (0) 
0·73 
0% (0) 0% (0) 0% (0) 1·4% (4) 
0·65 
Balanta 0·9% (4) 0·4% (4) 2% (3) 0·4% (1) 2·1% (3) 0·8% (3) 1·9% (1) 2·4% (1) 2% (2) 0% (0) 0·4% (1) 
Fula 18·4% (79) 17·3% (79) 20·4% (31) 17% (49) 21·3% (30) 18·6% (70) 17% (9) 19·1% (8) 22·2% (22) 9·1% (1) 17·3% (48) 
Jola 13·3% (57) 14·8% (41) 10·5% (16) 14·5% (42) 10·6% (15) 13·5% (51) 11·3% (6) 11·9% (5) 10·1% (10) 9·1% (1) 14·8% (41) 
Mandinka 38·4% (165) 38·9% (108) 37·5% (57) 39·5% (114) 36·2% (51) 38·7% (146) 35·9% (19) 31% (13) 38·4% (38) 54·6% (6) 38·9% (108) 
Manjago 0·7% (3) 1·1% (3) 0% (0) 1% (3) 0% (0) 0·8% (3) 0% (0) 0% (0) 0% (0) 0% (0) 1·1% (3) 
Sarahule 5·1% (22) 3·6% (10) 7·9% (12) 3·8% (11) 7·8% (11) 4·5% (17) 9·4% (5) 9·5% (4) 7% (7) 9·1% (1) 3·6% (10) 
Serere 6·3% (27) 5·4% (15) 7·9% (12) 5·2% (15) 8·5% (12) 6·6% (25) 3·8% (2) 4·8% (2) 10·1% (10) 0% (0) 5·4% (15) 
Wollof 11·9% (51) 13% (36) 9·9% (15) 13·2% (38) 9·2% (13) 11·1% (42) 17% (9) 16·7% (7) 6% (6) 18·2% (2) 13% (36) 
Other 4·2% (18) 4·3% (12) 4% (6) 4·2% (12) 4·3% (6) 4·2% (16) 3·8% (2) 4·8% (2) 4% (4) 0% (0) 4·3% (12) 
 
Supplementary Table 2: Ethnicity of mother. Data are presented as n (%) and analysed by χ2 test. P values in bold font are considered 









Supplementary Table 3 – Comparison of iron status, inflammation and haematological parameters in cord samples  
 Whole Population PTB/LBW FTB/NBW  Full-Term Birth (FTB) Preterm Birth (PTB)  Normal Birthweight (NBW) Low Birthweight (LBW)  
Sample Type n Cord n Cord n Cord P value n Cord n Cord P value n Cord n Cord P value 
Serum iron (μmol/L) 425 23·3 (±7·1) 150 24·3 (±7·3) 275 22·7 (±7·0) 0·02 285 22·7 (±7·0) 140 24·4 (±7·3) 0·01 374 23·1 (±7·0) 51 24·5 (±7·7) 0·2 
UIBC (μmol/L) 423 22·9 (±10·5) 150 21·5 (±10·6) 273 23·7 (±10·4) 0·04 283 23·8 (±10·8) 140 21·2 (±9·8) 0·02 372 23·0 (±10·3) 51 22·1 (±12·2) 0·6 
TIBC (μmol/L) 423 46·1 (±8·0) 150 45·8 (±7·8) 273 46·3 (±8·1) 0·3 283 46·4 (±8·3) 140 45·6 (±7·4) 0·3 372 46·1 (±7·8) 51 46·6 (±9·3) 0·6 
Transferrin (g/L) 426 1·96 (±0·3) 151 1·93 (±0·3) 275 1·98 (±0·3) 0·1 285 1·99 (±0·4) 141 1·92 (±0·3) 0·05 374 1·96 (±0·3) 52 1·94 (±0·4) 0·6 
TSAT (%) 423 51·7 (±17·3) 150 54·5 (±18·0) 273 50·2 (±16·7) 0·01 283 50·2 (±16·9) 140 54·8 (±17·7) 0·01 372 51·4 (±17·0) 51 54·6 (±18·7) 0·2 
Serum ferritin (ug/L) 426 210·5 (±157·8) 151 206·6 (±158·5) 275 212·6 (±157·7) 0·7 285 212·3 (±159·6) 141 206·8 (±154·8) 0·7 374 213·0 (±154·7) 52 192·1 (±179·5) 0·4 
Serum AGP (g/L) 426 0·18 (±0·1) 151 0·17 (±0·2) 275 0·19 (±0·1) 0·2 285 0·19 (±0·1) 141 0·16 (±0·2) 0·08 374 0·18 (±0·1) 52 0·16 (±0·1) 0·3 
Serum CRP (mg/L) 425 0·17 (±0·6) 150 0·14 (±0·3) 275 0·19 (±0·7) 0·4 285 0·19 (±0·7) 140 0·14 (±0·3) 0·4 374 0·18 (±0·6) 51 0·10 (±0·07) 0·3 
     >5mg/L 2 0·5% 0 0 2 0·7% N/A 2 0·7% 0 0 N/A 2 0·5% 0 0 N/A 
     >3mg/L 3 0·7% 0 0 3 1·1% N/A 3 1·1% 0 0 N/A 3 0·8% 0 0 N/A 
Serum hepcidin (ng/ml) 425 19·9 (±14·2) 148 20·9 (±13·8) 277 19·4 (±14·4) 0·3 287 19·1 (±14·3) 138 21·5 (±13·9) 0·1 373 20·2 (±14·3) 52 17·6 (±13·0) 0·2 
Haemoglobin (g/dl) 414 15·3 (±2·5) 144 15·6 (±2·7) 270 15·1 (±2·3) 0·04 278 15·1 (±2·4) 136 15·6 (±2·6) 0·06 366 15·1 (±2·4) 48 16·3 (±3·1) 0·003 
Haematocrit (%) 414 42·7 (±7·4) 144 43·8 (±8·1) 270 42·2 (±7·0) 0·039 278 42·3 (±7·2) 136 43·7 (±7·8) 0·06 366 42·3 (±7·1) 48 45·9 (±9·2) 0·0016 
Soluble transferrin receptor (mg/L) 424 6·0 (±2·0) 151 5·94 (±1·9) 273 5·99 (±2·0) 0·79 283 6·0 (±2·1) 141 5·9 (±1·7) 0·41 372 5·92 (±1·9) 52 6·3 (±2·4) 0·19 
Haptoglobin (g/L) 426 0·02 (±0·07) 151 0·03 (±0·09) 275 0·02 (±0·06) 0·31 285 0·02 (±0·06) 141 0·03 (±0·09) 0·28 374 0·02 (±0·08) 52 0·01 (±0·02) 0·28 
     Undetectable haptoglobin (%) 182 42·7% 66 43·8% 116 42·2% 0·76 120 42·1% 63 44·6% 0·71 158 42·2% 24 46·2% 0·307 
Mean corpuscular volume (fl) 414 98·0 (±6·2) 144 98·5 (±6·1) 270 97·8 (±6·3) 0·23 278 97·7 (±6·4) 136 98·7 (±5·7) 0·11 366 97·9 (±6·0) 48 99·3 (±7·3) 0·15 
Mean corpuscular haemoglobin (pg) 414 35·1 (±2·4) 144 35·3 (±2·5) 270 35·0 (±2·4) 0·38 278 35·0 (±2·5) 136 35·4 (±2·3) 0·19 366 35·1 (±2·4) 48 35·3 (±3·0) 0·61 
Mean corpuscular haemoglobin concentration (g/dl) 414 35·8 (±1·0) 144 35·8 (±1·0) 270 35·9 (±1·0) 0·5 278 35·8 (±1·0) 136 35·8 (±1·0) 0·68 366 35·9 (±0·9) 48 35·5 (±0·9) 0·027 
White blood cell count (unit/L) 412 13·0 (±5·3) 143 12·3 (±4·6) 269 13·3 (±5·7) 0·07 277 13·3 (±5·7) 135 12·2 (±4·4) 0·033 364 13·2 (±5·4) 48 11·5 (±4·8) 0·048 
Lymphocyte count (unit/L) 412 4·73 (±3·1) 143 4·67 (±2·2) 269 4·77 (±3·5) 0·74 277 4·82 (±3·5) 135 4·54 (±2·0) 0·39 364 4·72 (±3·1) 48 4·84 (±2·4) 0·79 
Lymphocyte percentage (%) 412 36·2 (±8·3) 143 38·1 (±8·7) 269 35·2 (±7·9) 0·0006 277 35·4 (±8·0) 135 37·8 (±8·7) 0·0063 364 35·5 (±7·9) 48 42·0 (±8·8) <0·001 
MID cell count (unit/L) 412 1·02 (±0·6) 143 0·99 (±0·5) 269 1·05 (±0·6) 0·35 277 1·05 (±0·6) 135 0·97 (±0·5) 0·22 364 1·0 (±0·6) 48 1·04 (±0·6) 0·82 
MID cell percentage (%) 412 8·27 (±2·6) 143 8·52 (±3·0) 269 8·15 (±2·4) 0·17 277 8·17% (±2·5) 135 8·48 (±3·0) 0·25 364 8·12 (±2·3) 48 9·46 (±4·2) 0·0008 
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Granulocyte count (unit/L) 412 7·21 (±2·7) 143 6·68 (±2·8) 269 7·49 (±2·7) 0·0039 277 7·47 (±2·7) 135 6·66 (±2·8) 0·0047 364 7·41 (±2·7) 48 5·67 (±2·7) <0·001 
Granulocyte percentage (%) 412 55·5 (±9·1) 143 53·3 (±9·4) 269 56·6 (±8·7) 0·0004 277 56·4 (±8·8) 135 53·7 (±9·4) 0·0045 364 56·4 (±8·6) 48 48·5 (±9·8) <0·001 
Red blood cell count (unit/L) 414 4·36 (±0·7) 144 4·45 (±0·8) 270 4·32 (±0·7) 0·096 278 4·33 (±0·7) 136 4·42 (±0·8) 0·2 366 4·33 (±0·7) 48 4·63 (±0·9) 0·0066 
Red blood cell distribution width (%) 414 15·2 (±1·1) 144 15·2 (±1·0) 270 15·2 (±1·2) 0·97 278 15·2 (±1·2) 136 15·1 (±1·0) 0·64 366 15·2 (±1·1) 48 15·2 (±0·9) 0·95 
Red blood cell distribution width - absolute (fl) 414 81·0 (±8·6) 144 81·5 (±8·1) 270 80·7 (±8·9) 0·39 278 80·7 (±9·0) 136 81·6 (±7·8) 0·32 366 80·8 (±8·6) 48 82·0 (±8·7) 0·39 
Platelet count (unit/L) 414 241·4 (±86·9) 144 236·7 (±74·8) 270 243·8 (±92·8) 0·43 278 243·2 (±93·4) 136 237·5 (±72·1) 0·53 366 243·3 (±87·3) 48 225·8 (±83·1) 0·19 
Mean platelet volume (fl) 409 8·34 (±0·8) 142 8·30 (±0·8) 267 8·37 (±0·8) 0·38 275 8·36 (±0·8) 134 8·3 (±0·8) 0·45 362 8·36 (±0·8) 47 8·17 (±0·8) 0·094 
Platelet distribution width (%) 409 43·3 (±2·8) 142 43·0 (±2·5) 267 43·5 (±3·0) 0·063 275 43·4 (±3·0) 134 42·9 (±2·5) 0·091 362 43·3 (±2·8) 47 42·9 (±2·8) 0·39 
Platelet distribution width - absolute (fl) 409 11·8 (±1·2) 142 11·7 (±1·1) 267 11·8 (±1·3) 0·17 275 11·8 (±1·3) 134 11·7 (±1·1) 0·22 362 11·8 (±1·2) 47 11·5 (±1·1) 0·11 
Platelet crit (%)a 409 0·2 (±0·06) 142 0·194 (±0·06) 267 0·201 (±0·07) 0·24 275 0·2 (±0·06) 134 0·194 (±0·05) 0·36 362 0·201 (±0·06) 47 0·18 (±0·06) 0·057 
Plate large cell ratio (%) 409 17·8 (±5·3) 142 17·5 (±5·1) 267 18·0 (±5·4) 0·3 275 18·0 (±5·3) 134 17·5 (±5·1) 0·31 362 18·0 (±5·3) 47 16·8 (±4·9) 0·14 
Plate large cell count (unit/L) 409 41·4 (±14·2) 142 40·1 (±13·2) 267 42·1 (±14·6) 0·16 275 41·9 (±14·8) 134 40·2 (±12·7) 0·24 362 42·0 (±14·1) 47 36·6 (±13·7) 0·014 
Haemolysis score (0-6)                  
0 166 39·0% 54 35·8% 112 41·2% 0·27 116 41·1% 50 35·5% 0·26 149 40·2% 17 32·7% 0·3 
1 144 34·0% 53 35·1% 91 33·5% 0·73 93 33·0% 51 36·2% 0·51 132 35·6% 12 23·1% 0·074 
2 78 18·4% 29 19·2% 49 18·00% 0·6 52 18·4% 26 18·4% 0·99 62 16·7% 16 30·8% 0·014 
3 35 8·3% 15 9·93% 20 7·35% 0·4 21 7·5% 14 9·9% 0·38 28 7·6% 7 13·5% 0·15 
4 0 0·0% 0 0·00% 0 0·00% ·· 0 0·0% 0 0·0% ·· 0 0·00% 0 0·00% ·· 
 
Supplementary Table 3: Further Iron, Infection and Haematological Parameters (umbilical cord samples) for FTB/NBW, PTB/LBW, FTB, PTB, 
NBW and LBW neonates. Data are presented as mean (± SD) and analysed by ANOVA. P values in bold font are considered significant based 






Supplementary Table 4 – Comparison of iron status, inflammation and haematological parameters in venous samples 
 Whole Population PTB/LBW FTB/NBW  Full-Term Birth (FTB) Preterm Birth (PTB)  Normal Birthweight (NBW) Low Birthweight (LBW)  
Sample Type n Venous n Venous n Venous P value n Venous n Venous P value n Venous n Venous P value 
Serum iron (μmol/L) 421 7·5 (±4·5) 150 8·0 (±4·1) 271 7·3 (±4·6) 0·07 282 7·4 (±4·6) 139 7·8 (±4·1) 0·2 370 7·4 (±4·6) 51 8·5 (±3·4) 0·05 
UIBC (μmol/L) 420 43·5 (±15·9) 149 42·2 (±10·9) 271 44·1 (±18·0) 0·2 282 44·2 (±17·8) 138 42·0 (±10·9) 0·2 370 43·4 (±16·5) 50 43·8 (±10·2) 0·9 
TIBC (μmol/L) 420 51·0 (±17·9) 149 50·2 (±11·3) 271 51·4 (±20·7) 0·5 282 51·5 (±20·5) 138 49·8 (±11·1) 0·4 370 50·8 (±18·6) 50 52·3 (±11·9) 0·2 
Transferrin (g/L) 423 1·99 (±0·3) 150 2·00 (±0·3) 273 1·98 (±0·3) 0·6 284 1·99 (±0·3) 139 1·99 (±0·3) 0·8 372 1·99 (±0·3) 51 2·02 (±0·4) 0·5 
TSAT (%) 420 15·0 (±6·9) 149 16·2 (±8·2) 271 14·4 (±6·1) 0·01 282 14·5 (±6·0) 138 16·1 (±8·4) 0·01 370 14·9 (±7·1) 50 16·2 (±5·3) 0·2 
Serum ferritin (ug/L) 415 381·2 (±297·6) 149 358·6 (±268·1) 271 393·9 (±312·6) 0·3 277 393·9 (±314·5) 138 355·7 (±259·6) 0·2 364 383·3 (±291·0) 51 366·2 (±343·8) 0·7 
Serum AGP (g/L) 423 0·24 (±0·2) 150 0·23 (±0·2) 273 0·25 (±0·2) 0·2 284 0·25 (±0·17) 139 0·22 (±0·2) 0·2 372 0·25 (±0·2) 51 0·21 (±0·2) 0·1 
Serum CRP (mg/L) 422 2·16 (±4·0) 149 1·96 (±3·8) 273 2·27 (±4·1) 0·5 284 2·24 (±4·1) 138 1·99 (±3·9) 0·5 371 2·3 (±4·2) 51 1·14 (±1·8) 0·05 
     >5mg/L 54 12·8% 17 11·4% 37 13·6% 0·5 38 13·4% 16 11·6% 0·6 50 13·5% 4 7·8% 0·3 
     >3mg/L 83 19·7% 24 16·1% 59 21·6% 0·2 60 21·1% 23 16·7% 0·3 77 20·8% 6 11·8% 0·1 
Serum hepcidin (ng/ml) 417 38·4 (±23·7) 147 37·4 (±23·5) 270 38·9 (±23·9) 0·5 281 38·7 (±24·0) 136 37·7 (±23·3) 0·7 366 39·0 (±23·9) 51 33·7 (±22·2) 0·1 
Haemoglobin (g/dl) 423 19·4 (±3·1) 151 19·9 (±3·3) 272 19·1 (±2·9) 0·02 283 19·2 (±3·0) 140 19·8 (±3·3) 0·04 371 19·2 (±3·0) 52 20·7 (±3·5) 0·001 
Haematocrit (%) 423 54·7 (±9·3) 151 56·1 (±10·1) 272 53·9 (±8·9) 0·025 283 54·1 (±9·0) 140 55·9 (±9·8) 0·64 371 54·1 (±9·0) 52 59·0 (±10·7) 0·0004 
Soluble transferrin receptor (mg/L) 421 7·0 (±2·2) 150 7·03 (±2·1) 271 6·94 (±2·2) 0·7 282 7·0 (±2·3) 139 6·9 (±2·0) 0·64 370 6·87 (±2·1) 51 7·71 (±2·5) 0·0093 
Haptoglobin (g/L) 423 0·02 (±0·06) 150 0·02 (±0·04) 273 0·03 (±0·07) 0·35 284 0·03 (±0·07) 139 0·02 (±0·04) 0·41 372 0·02 (±0·07) 51 0·01 (±0·01) 0·25 
     Undetectable haptoglobin (%) 144 34·0% 43 28·7% 101 37·00% 0·083 106 37·3% 38 27·3% 0·041 129 34·7% 15 29·4% 0·46 
Mean corpuscular volume (fl) 423 98·0 (±6·1) 151 98·5 (±6·2) 273 97·7 (±6·0) 0·21 283 97·6 (±6·2) 140 98·8 (±5·8) 0·048 371 97·9 (±5·8) 52 98·9 (±7·6) 0·26 
Mean corpuscular haemoglobin (pg) 423 34·9 (±2·4) 151 35·0 (±2·4) 272 34·8 (±2·4) 0·48 283 34·8 (±2·5) 140 35·1 (±2·3) 0·13 371 34·9 (±2·4) 52 34·8 (±2·9) 0·82 
Mean corpuscular haemoglobin concentration (g/dl) 423 35·6 (±1·0) 151 35·5 (±0·9) 272 35·6 (±1·1) 0·39 283 35·6 (±1·1) 140 35·5 (±0·9) 0·59 371 35·6 (±1·0) 52 35·2 (±0·9) 0·0036 
White blood cell count (unit/L) 422 15·9 (±5·5) 151 14·9 (±4·7) 271 16·4 (±5·8) 0·0068 282 16·3 (±5·7) 140 15·0 (±4·8) 0·019 370 16·3 (±5·5) 52 13·3 (±4·1) 0·0002 
Lymphocyte count (unit/L) 422 4·1 (±2·4) 151 3·93 (±1·4) 271 4·21 (±2·9) 0·25 282 4·19 (±2·8) 140 3·95 (±1·4) 0·35 370 4·17 (±2·6) 52 3·72 (±1·2) 0·22 
Lymphocyte percentage (%) 422 26·9 (±8·8) 151 27·8 (±8·9) 271 26·5 (±8·8) 0·14 282 26·5 (±8·7) 140 27·8 (±9·0) 0·14 370 26·5 (±8·7) 52 29·7 (±9·2) 0·014 
MID cell count (unit/L) 422 1·48 (±1·0) 151 1·37 (±0·9) 271 1·55 (±1·1) 0·08 282 1·54 (±1·0) 140 1·37 (±0·9) 0·11 370 1·52 (±1·0) 52 1·27 (±0·9) 0·097 
MID cell percentage (%) 422 9·67 (±5·4) 151 9·43 (±5·0) 271 9·81 (±5·6) 0·49 282 9·79 (±5·6) 140 9·41 (±5·0) 0·49 370 9·67 (±5·4) 52 9·75 (±5·1) 0·91 
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Granulocyte count (unit/L) 422 10·3 (±4·1) 151 9·63 (±3·8) 271 10·67 (±4·2) 0·012 282 10·6 (±4·1) 140 9·68 (±3·9) 0·029 370 10·57 (±4·1) 52 8·31 (±3·3) 0·0002 
Granulocyte percentage (%) 422 63·4 (±8·6) 151 62·8 (±8·1) 271 63·7 (±8·8) 0·28 282 63·7 (±8·7) 140 62·7 (±8·2) 0·27 370 63·8 (±8·5) 52 60·5 (±8·2) 0·0095 
Red blood cell count (unit/L) 423 5·58 (±1·0) 151 5·69 (±1·0) 272 5·53 (±0·9) 0·093 283 5·55 (±1·0) 140 5·66 (±0·9) 0·28 371 5·54 (±0·9) 52 5·97 (±1·1) 0·0018 
Red blood cell distribution width (%) 423 15·4 (±1·3) 151 15·4 (±1·0) 272 15·4 (±1·4) 0·49 283 15·5 (±1·4) 140 15·3 (±1·0) 0·36 371 15·4 (±1·3) 52 15·3 (±0·9) 0·6 
Red blood cell distribution width - Absolute (fl) 423 82·2 (±8·5) 151 82·6 (±8·4) 272 82·0 (±8·6) 0·47 283 81·9 (±8·8) 140 82·8 (±8·1) 0·26 371 82·1 (8·4) 52 82·8 (±9·2) 0·58 
Platelet count (unit/L) 423 260·4 (±94·6) 151 263·4 (±96·0) 272 258·7 (±94·0) 0·62 283 257·8 (±93·6) 140 265·7 (±96·7) 0·42 371 261·6 (±95·9) 52 252·1 (±85·4) 0·5 
Mean platelet volume (fl) 419 8·47 (±0·8) 148 8·38 (±0·7) 272 8·52 (±0·8) 0·064 282 8·52 (±0·8) 137 8·37 (±0·7) 0·061 367 8·49 (±0·8) 52 8·37 (±0·8) 0·31 
Platelet distribution width (%) 419 43·7 (±3·2) 148 43·4 (±2·8) 271 43·9 (±3·3) 0·082 282 44·0 (±3·3) 137 43·3 (±2·8) 0·051 367 43·8 (±3·2) 52 42·4 (±3·0) 0·39 
Platelet distribution width - Absolute (fl) 419 12·0 (±1·3) 148 11·8 (±1·1) 271 12·1 (±1·4) 0·045 282 12·1 (±1·4) 137 11·8 (±1·1) 0·035 367 12·0 (±1·3) 52 11·8 (±1·3) 0·22 
Platelet crit (%) 419 0·22 (±0·07) 148 0·22 (±0·07) 271 0·215 (±0·07) 0·59 282 0·214 (±0·07) 137 0·221 (±0·07) 0·33 367 0·218 (±0·07) 52 0·207 (±0·06) 0·32 
Plate large cell ratio (%) 419 18·8 (±5·5) 148 18·1 (±4·9) 271 19·2 (±5·8) 0·045 282 19·2 (±5·8) 137 18·0 (±4·9) 0·032 367 18·9 (±5·6) 52 18·2 (±5·3) 0·38 
Plate large cell count (unit/L) 419 46·5 (±15·8) 148 45·9 (±13·4) 271 46·9 (±17·0) 0·55 282 46·7 (±16·9) 137 46·3 (±13·4) 0·79 367 47·0 (±16·3) 52 43·6 (±11·6) 0·15 
Haemolysis score (0-6)                  
0 0 0·0% 17 32·7% 33 12·2% <0·001 0 0·0% 0 0·0% ·· 39 10·5% 4 7·8% 0·55 
1 43 10·2% 12 23·1% 135 49·9% <0·001 34 12·1% 9 6·5% 0·075 192 51·9% 21 41·2% 0·15 
2 213 50·6% 16 30·7% 92 34·00% 0·66 138 49·0% 75 54·0% 0·33 125 33·8% 25 49·00% 0·033 
3 150 35·6% 7 13·5% 11 4·1% 0·006 99 35·1% 51 36·7% 0·75 14 3·8% 1 1·96% 0·51 
4 15 3·5% 0 0·00% 0 0·00% ·· 11 3·9% 4 2·9% 0·59 0 0·00% 0 0·00% ·· 
 
Supplementary Table 4: Further Iron, Infection and Haematological Parameters (venous samples) for FTB/NBW, PTB/LBW, FTB, PTB, NBW 







Supplementary Table 5 – Changes in further iron status and inflammation variables between cord and post-natal blood 
 Whole Population FTB/NBW PTB/LBW Preterm Birth (PTB) Low Birthweight (LBW) 
Sample Type n Cord n Venous P value n Cord n Venous P value n Cord n Venous P value n Cord n Venous P value n Cord n Venous P value 
Hematocrit (%) 414 42·7 (±7·4) 423 54·7 (±9·3) <0·001 270 42·2 (±7·0) 272 53·9 (±8·9) <0·001 144 43·8 (±8·1) 151 56·1 (±10·1) <0·001 136 43·7 (±7·8) 140 55·9 (±9·8) <0·001 48 45·9 (±9·2) 52 59·0 (±10·7) <0·001 
Soluble transferrin receptor (mg/L) 424 6·0 (±2·0) 421 7·0 (±2·2) <0·001 273 5·99 (±2·0) 271 6·94 (±2·2) <0·001 151 5·94 (±1·9) 150 7·03 (±2·1) <0·001 141 5·9 (±1·7) 139 6·9 (±2·0) <0·001 52 6·3 (±2·4) 51 7·71 (±2·5) <0·001 
Haptoglobin (g/L) 426 0·02 (±0·07) 423 0·02 (±0·06) 0·52 275 0·02 (±0·06) 273 0·03 (±0·07) 0·06 151 0·03 (±0·09) 150 0·02 (±0·04) 0·19 141 0·03 (±0·09) 139 0·02 (±0·04) 0·2 52 0·01 (±0·02) 51 0·01 (±0·01) 0·28 
     Undetectable haptoglobin (%) 182 42·7% 144 34·0% 0·009 116 42·2% 101 37·00% 0·21 66 43·8% 43 28·7% 0·006 63 44·6% 38 27·3% 0·002 24 46·2% 15 29·4% 0·08 
Mean corpuscular volume (fl) 414 98·0 (±6·2) 423 98·0 (±6·1) 0·63 270 97·8 (±6·3) 273 97·7 (±6·0) 0·29 144 98·5 (±6·1) 151 98·5 (±6·2) 0·42 136 98·7 (±5·7) 140 98·8 (±5·8) 0·24 48 99·3 (±7·3) 52 98·9 (±7·6) 0·37 
Mean corpuscular haemoglobin (pg) 414 35·1 (±2·4) 423 34·9 (±2·4) <0·001 270 35·0 (±2·4) 272 34·8 (±2·4) <0·001 144 35·3 (±2·5) 151 35·0 (±2·4) <0·001 136 35·4 (±2·3) 140 35·1 (±2·3) <0·001 48 35·3 (±3·0) 52 34·8 (±2·9) <0·001 
Mean corpuscular haemoglobin concentration (g/dl) 414 35·8 (±1·0) 423 35·6 (±1·0) <0·001 270 35·9 (±1·0) 272 35·6 (±1·1) <0·001 144 35·8 (±1·0) 151 35·5 (±0·9) 0·0001 136 35·8 (±1·0) 140 35·5 (±0·9) <0·001 48 35·5 (±0·9) 52 35·2 (±0·9) 0·01 
White blood cell count (unit/L) 412 13·0 (±5·3) 422 15·9 (±5·5) <0·001 269 13·3 (±5·7) 271 16·4 (±5·8) <0·001 143 12·3 (±4·6) 151 14·9 (±4·7) <0·001 135 12·2 (±4·4) 140 15·0 (±4·8) <0·001 48 11·5 (±4·8) 52 13·3 (±4·1) 0·008 
Lymphocyte count (unit/L) 412 4·73 (±3·1) 422 4·1 (±2·4) <0·001 269 4·77 (±3·5) 271 4·21 (±2·9) 0·0001 143 4·67 (±2·2) 151 3·93 (±1·4) 0·0001 135 4·54 (±2·0) 140 3·95 (±1·4) 0·0006 48 4·84 (±2·4) 52 3·72 (±1·2) 0·003 
Lymphocyte percentage (%) 412 36·2 (±8·3) 422 26·9 (±8·8) <0·001 269 35·2 (±7·9) 271 26·5 (±8·8) <0·001 143 38·1 (±8·7) 151 27·8 (±8·9) <0·001 135 37·8 (±8·7) 140 27·8 (±9·0) <0·001 48 42·0 (±8·8) 52 29·7 (±9·2) <0·001 
MID cell count (unit/L) 412 1·02 (±0·6) 422 1·48 (±1·0) <0·001 269 1·05 (±0·6) 271 1·55 (±1·1) <0·001 143 0·99 (±0·5) 151 1·37 (±0·9) <0·001 135 0·97 (±0·5) 140 1·37 (±0·9) <0·001 48 1·04 (±0·6) 52 1·27 (±0·9) 0·1 
MID cell percentage (%) 412 8·27 (±2·6) 422 9·67 (±5·4) <0·001 269 8·15 (±2·4) 271 9·81 (±5·6) <0·001 143 8·52 (±3·0) 151 9·43 (±5·0) 0·04 135 8·48 (±3·0) 140 9·41 (±5·0) 0·04 48 9·46 (±4·2) 52 9·75 (±5·1) 0·6 
Granulocyte count (unit/L) 412 7·21 (±2·7) 422 10·3 (±4·1) <0·001 269 7·49 (±2·7) 271 10·67 (±4·2) <0·001 143 6·68 (±2·8) 151 9·63 (±3·8) <0·001 135 6·66 (±2·8) 140 9·68 (±3·9) <0·001 48 5·67 (±2·7) 52 8·31 (±3·3) <0·001 
Granulocyte percentage (%) 412 55·5 (±9·1) 422 63·4 (±8·6) <0·001 269 56·6 (±8·7) 271 63·7 (±8·8) <0·001 143 53·3 (±9·4) 151 62·8 (±8·1) <0·001 135 53·7 (±9·4) 140 62·7 (±8·2) <0·001 48 48·5 (±9·8) 52 60·5 (±8·2) <0·001 
Red blood cell count (unit/L) 414 4·36 (±0·7) 423 5·58 (±1·0) <0·001 270 4·32 (±0·7) 272 5·53 (±0·9) <0·001 144 4·45 (±0·8) 151 5·69 (±1·0) <0·001 136 4·42 (±0·8) 140 5·66 (±0·9) <0·001 48 4·63 (±0·9) 52 5·97 (±1·1) <0·001 
Red blood cell distribution width (%) 414 15·2 (±1·1) 423 15·4 (±1·3) <0·001 270 15·2 (±1·2) 272 15·4 (±1·4) <0·001 144 15·2 (±1·0) 151 15·4 (±1·0) <0·001 136 15·1 (±1·0) 140 15·3 (±1·0) <0·001 48 15·2 (±0·9) 52 15·3 (±0·9) 0·002 
Red blood cell distribution width - absolute (fl) 414 81·0 (±8·6) 423 82·2 (±8·5) <0·001 270 80·7 (±8·9) 272 82·0 (±8·6) 0·0001 144 81·5 (±8·1) 151 82·6 (±8·4) <0·001 136 81·6 (±7·8) 140 82·8 (±8·1) <0·001 48 82·0 (±8·7) 52 82·8 (±9·2) <0·001 
Platelet count (unit/L) 414 241·4 (±86·9) 423 260·4 (±94·6) 0·0003 270 243·8 (±92·8) 272 258·7 (±94·0) 0·022 144 236·7 (±74·8) 151 263·4 (±96·0) 0·003 136 237·5 (±72·1) 140 265·7 (±96·7) 0·003 48 225·8 (±83·1) 52 252·1 (±85·4) 0·09 
Mean platelet volume (fl) 409 8·34 (±0·8) 419 8·47 (±0·8) 0·0003 267 8·37 (±0·8) 272 8·52 (±0·8) 0·0001 142 8·30 (±0·8) 148 8·38 (±0·7) 0·37 134 8·3 (±0·8) 137 8·37 (±0·7) 0·29 47 8·17 (±0·8) 52 8·37 (±0·8) 0·07 
Platelet distribution width (%) 409 43·3 (±2·8) 419 43·7 (±3·2) 0·007 267 43·5 (±3·0) 271 43·9 (±3·3) 0·021 142 43·0 (±2·5) 148 43·4 (±2·8) 0·16 134 42·9 (±2·5) 137 43·3 (±2·8) 0·26 47 42·9 (±2·8) 52 42·4 (±3·0) 0·61 
Platelet distribution width - absolute (fl) 409 11·8 (±1·2) 419 12·0 (±1·3) 0·0006 267 11·8 (±1·3) 271 12·1 (±1·4) 0·0009 142 11·7 (±1·1) 148 11·8 (±1·1) 0·24 134 11·7 (±1·1) 137 11·8 (±1·1) 0·3 47 11·5 (±1·1) 52 11·8 (±1·3) 0·21 
Platelet crit (%) 409 0·2 (±0·06) 419 0·22 (±0·07) <0·001 267 0·201 (±0·07) 271 0·215 (±0·07) 0·01 142 0·194 (±0·06) 148 0·22 (±0·07) 0·0001 134 0·194 (±0·05) 137 0·221 (±0·07) 0·0001 47 0·18 (±0·06) 52 0·207 (±0·06) 0·034 
Plate large cell ratio (%) 409 17·8 (±5·3) 419 18·8 (±5·5) 0·0001 267 18·0 (±5·4) 271 19·2 (±5·8) 0·0001 142 17·5 (±5·1) 148 18·1 (±4·9) 0·27 134 17·5 (±5·1) 137 18·0 (±4·9) 0·32 47 16·8 (±4·9) 52 18·2 (±5·3) 0·06 
Plate large cell count (unit/L) 409 41·4 (±14·2) 419 46·5 (±15·8) <0·001 267 42·1 (±14·6) 271 46·9 (±17·0) <0·001 142 40·1 (±13·2) 148 45·9 (±13·4) <0·001 134 40·2 (±12·7) 137 46·3 (±13·4) <0·001 47 36·6 (±13·7) 52 43·6 (±11·6) 0·006 
 
 207 
Haemolysis score (0-6)                          
0 166 39·0% 0 0·0% <0·001 112 41·2% 33 12·2% <0·001 54 35·8% 17 32·7% 0·69 50 35·5% 0 0·0% <0·001 17 32·7% 4 7·8% 0·001 
1 144 34·0% 43 10·2% <0·001 91 33·5% 135 49·9% <0·001 53 35·1% 12 23·1% 0·11 51 36·2% 9 6·5% <0·001 12 23·1% 21 41·2% 0·05 
2 78 18·4% 213 50·6% <0·001 49 18·00% 92 34·00% <0·001 29 19·2% 16 30·7% 0·083 26 18·4% 75 54·0% <0·001 16 30·8% 25 49·00% 0·06 
3 35 8·3% 150 35·6% <0·001 20 7·35% 11 4·1% 0·1 15 9·93% 7 13·5% 0·48 14 9·9% 51 36·7% <0·001 7 13·5% 1 1·96% 0·03 
4 0 0·0% 15 3·5% <0·001 0 0·00% 0 0·00% ·· 0 0·00% 0 0·00% ·· 0 0·0% 4 2·9% 0·042 0 0·00% 0 0·00% ·· 
 
Supplementary Table 5: Further Iron, Infection and Haematological Parameters (Umbilical cord and venous sample) for FTB/NBW, PTB/LBW, 















Supplementary Table 6 – Changes in iron status, inflammation and hepcidin between cord and post-natal blood (Groups A-D) 
 Whole Population Group A (PTB+LBW) Group B (PTB+NBW) Group C (FTB+LBW) Group D (FTB+NBW) 
Sample Type n Cord n Venous P value n Cord n Venous P value n Cord n Venous P value n Cord n Venous P value n Cord n Venous P value 
Serum iron (μmol/L) 425 23·3 (±7·1) 421 7·5 (±4·5) <0·001 41 25·0 (±7·6) 40 8·2 (±3·3) <0·001 99 24·2 (±7·2) 99 7·7 (±4·4) <0·001 10 22·6 (±7·9) 11 9·4 (±3·9) 0·0039 275 22·7 (±7·0) 271 7·3 (±4·6) <0·001 
TSAT (%) 423 51·7 (±17·3) 420 15·0 (±6·9) <0·001 41 55·6 (±17·7) 39 15·9 (±5·5) <0·001 99 54·5 (±17·7) 99 16·2 (±9·3) <0·001 10 50·4 (±23·2) 11 17·1 (±4·5) 0·0019 273 50·2 (±16·7) 271 14·4 (±6·1) <0·001 
Serum hepcidin (ng/ml) 425 19·9 (±14·2) 417 38·4 (±23·7) <0·001 42 18·8 (±13·2) 40 33·6 (±21·1) <0·001 96 22·7 (±14·1) 96 39·4 (±24·0) <0·001 10 12·7 (±11·6) 11 34·0 (±27·0) 0·023 277 19·4 (±14·4) 270 38·9 (±23·9) <0·001 
UIBC (μmol/L) 423 22·9 (±10·5) 420 43·5 (±15·9) <0·001 41 21·1 (±10·0) 39 43·4 (±10·1) <0·001 99 21·2 (±9·8) 99 41·5 (±11·2) <0·001 10 26·4 (±18·8) 11 45·2 (±10·9) 0·0006 273 23·7 (±10·4) 271 44·1 (±18·0) <0·001 
TIBC (μmol/L) 423 46·1 (±8·0) 420 51·0 (±17·9) <0·001 41 46·0 (±8·4) 39 51·6 (±11·6) 0·0014 99 45·4 (±7·0) 99 49·1 (±10·9) 0·0013 10 49·0 (±12·6) 11 54·6 (±13·5) 0·022 273 46·3 (±8·1) 271 51·4 (±20·7) <0·001 
Serum ferritin (ug/L) 426 210·5 (±157·8) 415 381·2 (±297·6) <0·001 42 189·3 (±173·1) 40 358·5 (±340·0) 0·0002 99 214·1 (±146·7) 98 354·6 (±220·7) <0·001 10 203·8 (±214·4) 11 394·3 (±372·9) 0·05 275 212·6 (±157·7) 266 393·9 (±312·6) <0·001 
Haemoglobin (g/dl) 414 15·3 (±2·5) 423 19·4 (±3·1) <0·001 40 16·4 (±2·9) 41 20·8 (±3·3) <0·001 96 15·3 (±2·4) 99 19·4 (±3·1) <0·001 8 15·8 (±4·5) 11 20·2 (±4·3) 0·021 270 15·1 (±2·3) 272 19·1 (±2·9) <0·001 
Hematocrit (%) 414 42·7 (±7·4) 423 54·7 (±9·3) <0·001 40 46·1 (±8·3) 41 59·4 (±10·1) <0·001 96 42·7 (±7·3) 99 54·5 (±9·4) <0·001 8 44·7 (±13·3) 11 57·5 (±12·9) 0·023 270 42·2 (±7·0) 272 53·9 (±8·9) <0·001 
Transferrin (g/L) 426 1·96 (±0·3) 423 1·99 (±0·3) 0·003 42 1·90 (±0·3) 40 2·00 (±0·4) 0·0034 99 1·92 (±0·3) 99 1·99 (±0·3) 0·0001 10 2·08 (±0·6) 11 2·11 (±0·5) 0·43 275 1·98 (±0·3) 273 1·98 (±0·3) 0·84 
Soluble transferrin receptor (mg/L) 424 6·0 (±2·0) 421 7·0 (±2·2) <0·001 42 6·14 (±2·0) 40 7·47 (±2·3) <0·001 99 5·74 (±1·6) 99 6·67 (±1·8) <0·001 10 7·00 (±3·7) 11 8·6 (±2·9) 0·0011 273 5·99 (±2·0) 271 6·94 (±2·2) <0·001 
Haptoglobin (g/L) 426 0·02 (±0·07) 423 0·02 (±0·06) 0·52 42 0·01 (±0·01) 40 0·01 (±0·01) 0·18 99 0·03 (±0·1) 99 0·02 (±0·05) 0·15 10 0·02 (±0·03) 11 0·02 (±0·02) 0·87 275 0·02 (±0·06) 273 0·03 (±0·07) 0·06 
     Undetectable haptoglobin (%) 182 42·7% 144 34·0% 0·009 20 47·6% 10 25·00% 0·033 42 42·4% 28 28·3% 0·037 4 40% 5 45·5% 0·8 116 42·2% 101 37·00% 0·21 
Serum AGP (g/L) 426 0·18 (±0·1) 423 0·24 (±0·2) <0·001 42 0·15 (±0·2) 40 0·19 (±0·2) <0·001 99 0·17 (±0·2) 99 0·24 (±0·2) <0·001 10 0·22 (±0·1) 11 0·27 (±0·15) 0·063 275 0·19 (±0·1) 273 0·25 (±0·17) <0·001 
Serum CRP (mg/L) 425 0·17 (±0·6) 422 2·16 (±4·0) <0·001 42 0·09 (±0·05) 40 1·01 (±1·2) <0·001 99 0·16 (±0·3) 98 2·39 (±4·5) <0·001 10 0·14 (±0·1) 11 1·63 (±3·3) 0·19 275 0·19 (±0·7) 273 2·27 (±4·1) <0·001 
     >5mg/L 2 0·5% 54 12·8% <0·001 0 0·0% 3 7·5% N/A 0 0·0% 13 13·3% N/A 0 0·0% 1 9·1% N/A 2 0·7% 37 13·6% <0·001 
     >3mg/L 3 0·7% 83 19·7% <0·001 0 0·0% 5 12·5% N/A 0 0·0% 18 18·4% N/A 0 0·0% 1 9·1% N/A 3 1·0% 59 21·6% <0·001 
Mean corpuscular volume (fl) 414 98·0 (±6·2) 423 98·0 (±6·1) 0·63 40 100·0 (±6·1) 41 100·1 (±6·5) 0·17 96 98·2 (±5·4) 99 98·3 (±5·4) 0·76 8 95·3 (±11·4) 11 94·2 (±9·8) 0·28 270 97·8 (±6·3) 272 97·7 (±6·0) 0·29 
Mean corpuscular haemoglobin (pg) 414 35·1 (±2·4) 423 34·9 (±2·4) <0·001 40 35·6 (±2·6) 41 35·2 (±2·5) 0·0001 96 35·3 (±2·2) 99 35·1 (±2·1) 0·0001 8 33·9 (±4·3) 11 33·2 (±3·8) 0·46 270 35·1 (±2·4) 272 34·8 (±2·4) <0·001 
Mean corpuscular haemoglobin concentration (g/dl) 414 35·8 (±1·0) 423 35·6 (±1·0) <0·001 40 35·5 (±0·9) 41 35·2 (±0·9) 0·0034 96 35·9 (±1·0) 99 35·7 (±0·9) 0·0031 8 35·5 (±1·1) 11 35·3 (±0·9) 0·62 270 35·8 (±0·9) 272 35·6 (±1·1) <0·001 
White blood cell count (unit/L) 412 13·0 (±5·3) 422 15·9 (±5·5) <0·001 40 10·9 (±4·2) 41 13·1 (±4·2) 0·0027 95 12·7 (±4·4) 99 15·8 (±4·8) <0·001 8 14·7 (±6·6) 11 14·0 (±3·7) 0·8 269 13·3 (±5·7) 271 16·4 (±5·8) <0·001 
Lymphocyte count (unit/L) 412 4·73 (±3·1) 422 4·1 (±2·4) <0·001 40 4·5 (±2·0) 41 3·7 (±1·2) 0·021 95 4·6 (±2·0) 99 4·0 (±1·5) 0·01 8 6·6 (±3·6) 11 3·6 (±1·1) 0·052 269 4·77 (±3·5) 271 4·21 (±2·9) 0·0001 
Lymphocyte percentage (%) 412 36·2 (±8·3) 422 26·9 (±8·8) <0·001 40 41·8 (±9·3) 41 30·5 (±9·6) <0·001 95 36·2 (±7·9) 99 26·8 (±8·5) <0·001 8 43·4 (±6·4) 11 27·0 (±7·2) 0·0048 269 35·2 (±7·9) 271 26·5 (±8·8) <0·001 
MID cell count (unit/L) 412 1·02 (±0·6) 422 1·48 (±1·0) <0·001 40 1·01 (±0·6) 41 1·25 (±0·9) 0·13 95 0·97 (±0·4) 99 1·42 (±1·0) <0·001 8 1·23 (±0·5) 11 1·32 (±1·0) 0·5 269 1·05 (±0·6) 271 1·55 (±1·0) <0·001 
MID cell percentage (%) 412 8·27 (±2·6) 422 9·67 (±5·4) <0·001 40 9·56 (±4·4) 41 9·79 (±5·2) 0·75 95 8·04 (±2·0) 99 9·27 (±4·9) 0·017 8 8·99 (±3·5) 11 9·62 (±5·3) 0·61 269 8·15 (±2·4) 271 9·81 (±5·6) <0·001 
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Granulocyte count (unit/L) 412 7·21 (±2·7) 422 10·3 (±4·1) <0·001 40 5·43 (±2·6) 41 8·12 (±3·4) <0·001 95 7·18 (±2·7) 99 10·32 (±3·9) <0·001 8 6·9 (±3·0) 11 9·02 (±2·8) 0·046 269 7·49 (±2·7) 271 10·67 (±4·2) <0·001 
Granulocyte percentage (%) 412 55·5 (±9·1) 422 63·4 (±8·6) <0·001 40 48·7 (±10·2) 41 59·8 (±8·5) <0·001 95 55·8 (±8·2) 99 64·0 (±7·8) <0·001 8 47·6 (±7·8) 11 63·3 (±6·6) 0·0013 269 56·6 (±8·7) 271 63·7 (±8·8) <0·001 
Red blood cell count (unit/L) 414 4·36 (±0·7) 423 5·58 (±1·0) <0·001 40 4·6 (±0·8) 41 5·9 (±1·0) <0·001 96 4·4 (±0·7) 99 5·5 (±0·9) <0·001 8 4·73 (±1·3) 11 6·11 (±1·2) 0·016 270 4·32 (±0·7) 272 5·53 (±0·9) <0·001 
Red blood cell distribution width (%) 414 15·2 (±1·1) 423 15·4 (±1·3) <0·001 40 15·1 (±0·8) 41 15·2 (±0·8) 0·0069 96 15·2 (±1·0) 99 15·4 (±1·0) 0·0001 8 15·8 (±1·3) 11 15·6 (±1·1) 0·096 270 15·2 (±1·2) 272 15·4 (±1·4) <0·001 
Red blood cell distribution width - absolute (fl) 414 81·0 (±8·6) 423 82·2 (±8·5) <0·001 40 82·4 (±7·8) 41 83·8 (±8·4) 0·0038 96 81·2 (±7·7) 99 82·5 (±7·9) 0·0008 8 79·8 (±12·7) 11 79·2 (±11·5) 0·38 270 80·7 (±8·9) 272 82·0 (±8·6) 0·0001 
Platelet count (unit/L) 414 241·4 (±86·9) 423 260·4 (±94·6) 0·0003 40 226·3 (±76·4) 41 256·9 (±86·1) 0·092 96 242·2 (±70·1) 99 269·4 (±101·0) 0·015 8 223·8 (±117·5) 11 234·3 (±84·3) 0·76 270 243·8 (±92·8) 272 258·7 (±94·0) 0·02 
Mean platelet volume (fl) 409 8·34 (±0·8) 419 8·47 (±0·8) 0·0003 39 8·16 (±0·8) 41 8·35 (±0·8) 0·083 95 8·36 (±0·8) 96 8·38 (±0·7) 0·99 8 8·22 (±0·8) 11 8·46 (±0·8) 0·5 267 8·37 (±0·8) 271 8·52 (±0·8) 0·0001 
Platelet distribution width (%) 409 43·3 (±2·8) 419 43·7 (±3·2) 0·007 39 43·0 (±2·9) 41 43·2 (±3·1) 0·94 95 42·9 (±2·4) 96 43·4 (±2·8) 0·17 8 42·6 (±2·4) 11 44·2 (±2·7) 0·0064 267 43·5 (±3·0) 271 43·9 (±3·3) 0·021 
Platelet distribution width - absolute (fl) 409 11·8 (±1·2) 419 12·0 (±1·3) 0·0006 39 11·5 (±1·1) 41 11·7 (±1·3) 0·33 95 11·7 (±1·2) 96 11·8 (±1·1) 0·56 8 11·6 (±1·2) 11 12·1 (±1·3) 0·026 267 11·8 (±1·3) 271 12·1 (±1·4) 0·0009 
Platelet crit (%) 409 0·2 (±0·06) 419 0·22 (±0·07) <0·001 39 0·183 (±0·05) 41 0·212 (±0·06) 0·031 95 0·199 (±0·06) 96 0·226 (±0·07) 0·0008 8 0·179 (±0·09) 11 0·190 (±0·07) 0·87 267 0·201 (±0·07) 271 0·215 (±0·07) 0·01 
Plate large cell ratio (%) 409 17·8 (±5·3) 419 18·8 (±5·5) 0·0001 39 16·6 (±5·0) 41 17·9 (±5·3) 0·1 95 17·8 (±5·2) 96 18·1 (±4·7) 0·86 8 17·6 (±4·9) 11 19·3 (±5·4) 0·062 267 18·0 (±5·4) 271 19·2 (±5·8) 0·0001 
Plate large cell count (unit/L) 409 41·4 (±14·2) 419 46·5 (±15·8) <0·001 39 36·5 (±12·2) 41 44·1 (±11·3) 0·005 95 41·7 (±12·6) 96 47·2 (±14·1) 0·0025 8 37·3 (±20·7) 11 41·8 (±13·0) 0·71 267 42·1 (±14·6) 271 46·9 (±17·0) <0·001 
Haemolysis score (0-6)                          
0 166 39·0% 0 0·0% <0·001 13 31·00% 3 7·5% 0·007 37 37·4% 6 6·1% <0·001 4 40·00% 0 0·00% 0·019 112 41·2% 33 12·2% <0·001 
1 144 34·0% 43 10·2% <0·001 10 23·8% 18 45·00% 0·043 41 41·4% 57 57·6% 0·022 2 20·00% 1 9·1% 0·48 91 33·5% 135 49·8% <0·001 
2 78 18·4% 213 50·6% <0·001 13 31·00% 18 45·00% 0·18 13 13·1% 33 33·3% <0·001 3 30·00% 3 27·3% 0·89 49 18·00% 92 34·00% <0·001 
3 35 8·3% 150 35·6% <0·001 6 14·3% 1 4·5% 0·056 8 8·1% 3 3·00% 0·12 1 10·00% 7 63·6% 0·011 20 7·4% 11 4·1% 0·098 
4 0 0·0% 15 3·5% <0·001 0 0·00% 0 0·00% ·· 0 0·00% 0 0·00% ·· 0 0·00% 0 0·00% ·· 0 0·00% 0 0·00% ·· 
 
Supplementary Table 6: Iron, Infection and Haematological Parameters (umbilical cord and venous samples) for groups A, B, C and D 







Supplementary Table 7 – Comparison of iron status, inflammation and haematological parameters in cord samples (Group A-D) 
 Whole Population Group A (PTB+LBW) Group B (PTB+NBW) Group C (FTB+LBW) Group D (FTB+NBW)  
Sample Type n Cord n Cord n Cord n Cord n Cord P value 
Serum iron (μmol/L) 425 23·3 (±7·1) 41 25·0 (±7·6) 99 24·2 (±7·2) 10 22·6 (±7·9) 275 22·7 (±7·0) 0·11 
TSAT (%) 423 51·7 (±17·3) 41 55·6 (±17·7) 99 54·5 (±17·7) 10 50·4 (±23·2) 273 50·2 (±16·7) 0·079 
Serum hepcidin (ng/ml) 425 19·9 (±14·2) 42 18·8 (±13·2) 96 22·7 (±14·1) 10 12·7 (±11·6) 277 19·4 (±14·4) 0·075 
UIBC (μmol/L) 423 22·9 (±10·5) 41 21·1 (±10·0) 99 21·2 (±9·8) 10 26·4 (±18·8) 273 23·7 (±10·4) 0·094 
TIBC (μmol/L) 423 46·1 (±8·0) 41 46·0 (±8·4) 99 45·4 (±7·0) 10 49·0 (±12·6) 273 46·3 (±8·1) 0·52 
Serum ferritin (ug/L) 426 210·5 (±157·8) 42 189·3 (±173·1) 99 214·1 (±146·7) 10 203·8 (±214·4) 275 212·6 (±157·7) 0·83 
Haemoglobin (g/dl) 414 15·3 (±2·5) 40 16·4 (±2·9) 96 15·3 (±2·4) 8 15·8 (±4·5) 270 15·1 (±2·3) 0·02 
Haematocrit (%) 414 42·7 (±7·4) 40 46·1 (±8·3) 96 42·7 (±7·3) 8 44·7 (±13·3) 270 42·2 (±7·0) 0·015 
Transferrin (g/L) 426 1·96 (±0·3) 42 1·90 (±0·3) 99 1·92 (±0·3) 10 2·08 (±0·6) 275 1·98 (±0·3) 0·18 
Soluble transferrin receptor (mg/L) 424 6·0 (±2·0) 42 6·14 (±2·0) 99 5·74 (±1·6) 10 7·00 (±3·7) 273 5·99 (±2·0) 0·22 
Haptoglobin (g/L) 426 0·02 (±0·07) 42 0·01 (±0·01) 99 0·03 (±0·1) 10 0·02 (±0·03) 275 0·02 (±0·06) 0·21 
     Undetectable haptoglobin (%) 182 42·7% 20 47·6% 42 42·4% 4 40% 116 42·2% 0·92 
Serum AGP (g/L) 426 0·18 (±0·1) 42 0·15 (±0·2) 99 0·17 (±0·2) 10 0·22 (±0·1) 275 0·19 (±0·1) 0·24 
Serum CRP (mg/L) 425 0·17 (±0·6) 42 0·09 (±0·05) 99 0·16 (±0·3) 10 0·14 (±0·1) 275 0·19 (±0·7) 0·75 
     >5mg/L 2 0·5% 0 0·0% 0 0·0% 0 0·0% 2 0·7% 0·78 
     >3mg/L 3 0·7% 0 0·0% 0 0·0% 0 0·0% 3 1·0% 0·65 
Mean corpuscular volume (fl) 414 98·0 (±6·2) 40 100·0 (±6·1) 96 98·2 (±5·4) 8 95·3 (±11·4) 270 97·8 (±6·3) 0·1 
Mean corpuscular haemoglobin (pg) 414 35·1 (±2·4) 40 35·6 (±2·6) 96 35·3 (±2·2) 8 33·9 (±4·3) 270 35·1 (±2·4) 0·25 
Mean corpuscular haemoglobin concentration (g/dl) 414 35·8 (±1·0) 40 35·5 (±0·9) 96 35·9 (±1·0) 8 35·5 (±1·1) 270 35·8 (±0·9) 0·17 
White blood cell count (unit/L) 412 13·0 (±5·3) 40 10·9 (±4·2) 95 12·7 (±4·4) 8 14·7 (±6·6) 269 13·3 (±5·7) 0·04 
Lymphocyte count (unit/L) 412 4·73 (±3·1) 40 4·5 (±2·0) 95 4·6 (±2·0) 8 6·6 (±3·6) 269 4·77 (±3·5) 0·32 
Lymphocyte percentage (%) 412 36·2 (±8·3) 40 41·8 (±9·3) 95 36·2 (±7·9) 8 43·4 (±6·4) 269 35·2 (±7·9) <0·001 
MID cell count (unit/L) 412 1·02 (±0·6) 40 1·01 (±0·6) 95 0·97 (±0·4) 8 1·23 (±0·5) 269 1·05 (±0·6) 0·49 
MID cell percentage (%) 412 8·27 (±2·6) 40 9·56 (±4·4) 95 8·04 (±2·0) 8 8·99 (±3·5) 269 8·15 (±2·4) 0·009 
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Granulocyte count (unit/L) 412 7·21 (±2·7) 40 5·43 (±2·6) 95 7·18 (±2·7) 8 6·9 (±3·0) 269 7·49 (±2·7) 0·0002 
Granulocyte percentage (%) 412 55·5 (±9·1) 40 48·7 (±10·2) 95 55·8 (±8·2) 8 47·6 (±7·8) 269 56·6 (±8·7) <0·001 
Red blood cell count (unit/L) 414 4·36 (±0·7) 40 4·6 (±0·8) 96 4·4 (±0·7) 8 4·73 (±1·3) 270 4·32 (±0·7) 0·054 
Red blood cell distribution width (%) 414 15·2 (±1·1) 40 15·1 (±0·8) 96 15·2 (±1·0) 8 15·8 (±1·3) 270 15·2 (±1·2) 0·45 
Red blood cell distribution width - absolute (fl) 414 81·0 (±8·6) 40 82·4 (±7·8) 96 81·2 (±7·7) 8 79·8 (±12·7) 270 80·7 (±8·9) 0·67 
Platelet count (unit/L) 414 241·4 (±86·9) 40 226·3 (±76·4) 96 242·2 (±70·1) 8 223·8 (±117·5) 270 243·8 (±92·8) 0·63 
Mean platelet volume (fl) 409 8·34 (±0·8) 39 8·16 (±0·8) 95 8·36 (±0·8) 8 8·22 (±0·8) 267 8·37 (±0·8) 0·41 
Platelet distribution width (%) 409 43·3 (±2·8) 39 43·0 (±2·9) 95 42·9 (±2·4) 8 42·6 (±2·4) 267 43·5 (±3·0) 0·31 
Platelet distribution width - absolute (fl) 409 11·8 (±1·2) 39 11·5 (±1·1) 95 11·7 (±1·2) 8 11·6 (±1·2) 267 11·8 (±1·3) 0·39 
Platelet crit (%) 409 0·2 (±0·06) 39 0·183 (±0·05) 95 0·199 (±0·06) 8 0·179 (±0·09) 267 0·201 (±0·07) 0·29 
Plate large cell ratio (%) 409 17·8 (±5·3) 39 16·6 (±5·0) 95 17·8 (±5·2) 8 17·6 (±4·9) 267 18·0 (±5·4) 0·47 
Plate large cell count (unit/L) 409 41·4 (±14·2) 39 36·5 (±12·2) 95 41·7 (±12·6) 8 37·3 (±20·7) 267 42·1 (±14·6) 0·11 
Haemolysis score (0-6)            
0 166 39·0% 13 31·00% 37 37·4% 4 40·00% 112 41·2% 0·62 
1 144 34·0% 10 23·8% 41 41·4% 2 20·00% 91 33·5% 0·2 
2 78 18·4% 13 31·00% 13 13·1% 3 30·00% 49 18·00% 0·067 
3 35 8·3% 6 14·3% 8 8·1% 1 10·00% 20 7·4% 0·5 
4 0 0·0% 0 0·00% 0 0·00% 0 0·00% 0 0·00% ·· 
 
 
Supplementary Table 7: Iron, infection and haematological parameters (umbilical cord samples) for groups A, B, C, and D neonates. Data are 








Supplementary Table 8 – Comparison of iron status, inflammation and haematological parameters in venous samples (Groups A-D) 
 Whole Population Group A (PTB+LBW) Group B (PTB+NBW) Group C (FTB+LBW) Group D (FTB+NBW)  
Sample Type n Venous n Venous n Venous n Venous n Venous P value 
Serum iron (μmol/L) 421 7·5 (±4·5) 40 8·2 (±3·3) 99 7·7 (±4·4) 11 9·4 (±3·9) 271 7·3 (±4·6) 0·29 
TSAT (%) 420 15·0 (±6·9) 39 15·9 (±5·5) 99 16·2 (±9·3) 11 17·1 (±4·5) 271 14·4 (±6·1) 0·68 
Serum hepcidin (ng/ml) 417 38·4 (±23·7) 40 33·6 (±21·1) 96 39·4 (±24·0) 11 34·0 (±27·0) 270 38·9 (±23·9) 0·076 
UIBC (μmol/L) 420 43·5 (±15·9) 39 43·4 (±10·1) 99 41·5 (±11·2) 11 45·2 (±10·9) 271 44·1 (±18·0) 0·53 
TIBC (μmol/L) 420 51·0 (±17·9) 39 51·6 (±11·6) 99 49·1 (±10·9) 11 54·6 (±13·5) 271 51·4 (±20·7) 0·64 
Serum ferritin (ug/L) 415 381·2 (±297·6) 40 358·5 (±340·0) 98 354·6 (±220·7) 11 394·3 (±372·9) 266 393·9 (±312·6) 0·68 
Haemoglobin (g/dl) 423 19·4 (±3·1) 41 20·8 (±3·3) 99 19·4 (±3·1) 11 20·2 (±4·3) 272 19·1 (±2·9) 0·009 
Haematocrit (%) 423 54·7 (±9·3) 41 59·4 (±10·1) 99 54·5 (±9·4) 11 57·5 (±12·9) 272 53·9 (±8·9) 0·0042 
Transferrin (g/L) 423 1·99 (±0·3) 40 2·00 (±0·4) 99 1·99 (±0·3) 11 2·11 (±0·5) 273 1·98 (±0·3) 0·65 
Soluble transferrin receptor (mg/L) 421 7·0 (±2·2) 40 7·47 (±2·3) 99 6·67 (±1·8) 11 8·6 (±2·9) 271 6·94 (±2·2) 0·017 
Haptoglobin (g/L) 423 0·02 (±0·06) 40 0·01 (±0·01) 99 0·02 (±0·05) 11 0·02 (±0·02) 273 0·03 (±0·07) 0·67 
     Undetectable haptoglobin (%) 144 34·0% 10 25·00% 28 28·3% 5 45·5% 101 37·00% 0·2 
Serum AGP (g/L) 423 0·24 (±0·2) 40 0·19 (±0·2) 99 0·24 (±0·2) 11 0·27 (±0·15) 273 0·25 (±0·17) 0·19 
Serum CRP (mg/L) 422 2·16 (±4·0) 40 1·01 (±1·2) 98 2·39 (±4·5) 11 1·63 (±3·3) 273 2·27 (±4·1) 0·26 
     >5mg/L % 54 12·8% 3 7·5% 13 13·3% 1 9·1% 37 13·6% 0·73 
     >3mg/L % 83 19·7% 5 12·5% 18 18·4% 1 9·1% 59 21·6% 0·42 
Mean corpuscular volume (fl) 423 98·0 (±6·1) 41 100·1 (±6·5) 99 98·3 (±5·4) 11 94·2 (±9·8) 272 97·7 (±6·0) 0·017 
Mean corpuscular haemoglobin (pg) 423 34·9 (±2·4) 41 35·2 (±2·5) 99 35·1 (±2·1) 11 33·2 (±3·8) 272 34·8 (±2·4) 0·08 
Mean corpuscular haemoglobin concentration (g/dl) 423 35·6 (±1·0) 41 35·2 (±0·9) 99 35·7 (±0·9) 11 35·3 (±0·9) 272 35·6 (±1·1) 0·029 
White blood cell count (unit/L) 422 15·9 (±5·5) 41 13·1 (±4·2) 99 15·8 (±4·8) 11 14·0 (±3·7) 271 16·4 (±5·8) 0·0021 
Lymphocyte count (unit/L) 422 4·1 (±2·4) 41 3·7 (±1·2) 99 4·0 (±1·5) 11 3·6 (±1·1) 271 4·21 (±2·9) 0·6 
Lymphocyte percentage (%) 422 26·9 (±8·8) 41 30·5 (±9·6) 99 26·8 (±8·5) 11 27·0 (±7·2) 271 26·5 (±8·8) 0·06 
MID cell count (unit/L) 422 1·48 (±1·0) 41 1·25 (±0·9) 99 1·42 (±1·0) 11 1·32 (±1·0) 271 1·55 (±1·0) 0·27 
MID cell percentage (%) 422 9·67 (±5·4) 41 9·79 (±5·2) 99 9·27 (±4·9) 11 9·62 (±5·3) 271 9·81 (±5·6) 0·86 
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Granulocyte count (unit/L) 422 10·3 (±4·1) 41 8·12 (±3·4) 99 10·32 (±3·9) 11 9·02 (±2·8) 271 10·67 (±4·2) 0·0017 
Granulocyte percentage (%) 422 63·4 (±8·6) 41 59·8 (±8·5) 99 64·0 (±7·8) 11 63·3 (±6·6) 271 63·7 (±8·8) 0·04 
Red blood cell count (unit/L) 423 5·58 (±1·0) 41 5·9 (±1·0) 99 5·5 (±0·9) 11 6·11 (±1·2) 272 5·53 (±0·9) 0·018 
Red blood cell distribution width (%) 423 15·4 (±1·3) 41 15·2 (±0·8) 99 15·4 (±1·0) 11 15·6 (±1·1) 272 15·4 (±1·4) 0·69 
Red blood cell distribution width - absolute (fl) 423 82·2 (±8·5) 41 83·8 (±8·4) 99 82·5 (±7·9) 11 79·2 (±11·5) 272 82·0 (±8·6) 0·39 
Platelet count (unit/L) 423 260·4 (±94·6) 41 256·9 (±86·1) 99 269·4 (±101·0) 11 234·3 (±84·3) 272 258·7 (±94·0) 0·35 
Mean platelet volume (fl) 419 8·47 (±0·8) 41 8·35 (±0·8) 96 8·38 (±0·7) 11 8·46 (±0·8) 271 8·52 (±0·8) 0·3 
Platelet distribution width (%) 419 43·7 (±3·2) 41 43·2 (±3·1) 96 43·4 (±2·8) 11 44·2 (±2·7) 271 43·9 (±3·3) 0·26 
Platelet distribution width - absolute (fl) 419 12·0 (±1·3) 41 11·7 (±1·3) 96 11·8 (±1·1) 11 12·1 (±1·3) 271 12·1 (±1·4) 0·19 
Platelet crit (%) 419 0·22 (±0·07) 41 0·212 (±0·06) 96 0·226 (±0·07) 11 0·190 (±0·07) 271 0·215 (±0·07) 0·35 
Plate large cell ratio (%) 419 18·8 (±5·5) 41 17·9 (±5·3) 96 18·1 (±4·7) 11 19·3 (±5·4) 271 19·2 (±5·8) 0·21 
Plate large cell count (unit/L) 419 46·5 (±15·8) 41 44·1 (±11·3) 96 47·2 (±14·1) 11 41·8 (±13·0) 271 46·9 (±17·0) 0·52 
Haemolysis score (0-6)            
0 0 0·0% 3 7·5% 6 6·1% 0 0·00% 33 12·2% 0·2 
1 43 10·2% 18 45·00% 57 57·6% 1 9·1% 135 49·8% 0·018 
2 213 50·6% 18 45·00% 33 33·3% 3 27·3% 92 34·00% 0·51 
3 150 35·6% 1 4·5% 3 3·00% 7 63·6% 11 4·1% <0·001 
4 15 3·5% 0 0·00% 0 0·00% 0 0·00% 0 0·00% ·· 
 
 
Supplementary Table 8: Iron, infection and haematological parameters (venous samples) for groups A, B, C, and D neonates. Data are 
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Chapter 6 – Iron homeostasis in full term, normal birthweight 
Gambian neonates over the first week of life (FTB/NBW Paper) 
 
 
Summary of Chapter 
 
BACKGROUND: Human neonates elicit a profound hypoferremia to protect against 
bacterial and fungal sepsis on their first day of life. 
 
OBJECTIVE: We examined the transience of this effect by measuring iron and its 
chaperone proteins, inflammatory and hematological parameters over the first post-partum 
week. 
 
DESIGN: We prospectively studied term (>37 completed gestational weeks), normal weight 
(>2500g) newborns at Kanifing General Hospital, The Gambia. Blood was sampled from the 
umbilical cord vein (CDV) and artery (CDA). Neonatal venous blood was sampled at 6-24h 
(V1) in all babies, who were then randomized to a second blood draw at 25-80h (V2), 81-
136h (V3) or 137-192h (V4). Hepcidin, serum iron, transferrin saturation, transferrin, 
haptoglobin, CRP, AGP, sTfR, ferritin, TIBC, UIBC and full blood count were assayed. 
 
RESULTS: Two hundred and seventy-eight neonates (278, 54.3% males, gestational age 
39.4±1.3wk, birth weight 3299±368g) were enrolled. We confirmed the profound early 
postnatal decrease in serum iron (CDV=22.7±7.0 µmol/L to V1=7.3±4.3 µmol/L, P<0.0001) 
and TSAT (50.2±16.7% to 14.4±6.1%, P<0.0001). Both variables increased steadily to reach 
16.5±3.9 µmol/L and 36.7±9.2% at V4 (P for trend <0.0001 for each). Hepcidin increased 
rapidly after birth (CDV=19.4±14.4 ng/ml to V1=38.9±23.9 ng/ml, P<0.0001) then dipped 
before rising again by V4. Inflammatory markers increased from V1 onwards. Network 
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analysis revealed a disconnect between the correlations observed in CDV and V2-V4 and 
those in V1. Surprisingly, serum iron and TSAT were only weakly influenced by hepcidin. 
 
CONCLUSIONS: Rapid anti-infective post-natal hypoferremia in human neonates is 
transient. The later rise in serum iron despite very high hepcidin indicates hepcidin 
resistance possibly caused by macrophage saturation with iron released from degradation of 
fetal erythrocytes. Pharmacological prolongation of hypoferremia might offer an ancillary tool 
in the armoury against antimicrobial resistance, however, it would need to overcome or 
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BACKGROUND: Human neonates elicit a profound hypoferremia to protect against 
bacterial and fungal sepsis on their first day of life. 
OBJECTIVE: We examined the transience of this effect by measuring iron and its 
chaperone proteins, inflammatory and hematological parameters over the first postpartum 
week. 
DESIGN: We prospectively studied term (>37 completed gestational weeks), normal weight 
(>2500g) newborns at Kanifing General Hospital, The Gambia. Blood was sampled from the 
umbilical cord vein (CDV) and artery (CDA). Neonatal venous blood was sampled at 6-24h 
(V1) in all babies, who were then randomized to a second blood draw at 25-80h (V2), 81-
136h (V3) or 137-192h (V4). Hepcidin, serum iron, transferrin saturation, transferrin, 
haptoglobin, CRP, AGP, sTfR, ferritin, TIBC, UIBC and full blood count were assayed. 
RESULTS: Two hundred and seventy-eight neonates (278, 54.3% males, gestational age 
39.4±1.3wk, birth weight 3299±368g) were enrolled. We confirmed the profound early 
postnatal decrease in serum iron (CDV=22.7±7.0 µmol/L to V1=7.3±4.3 µmol/L, P<0.0001) 
and TSAT (50.2±16.7% to 14.4±6.1%, P<0.0001). Both variables increased steadily to reach 
16.5±3.9 µmol/L and 36.7±9.2% at V4 (P for trend <0.0001 for each). Hepcidin increased 
rapidly after birth (CDV=19.4±14.4 ng/ml to V1=38.9±23.9 ng/ml, P<0.0001) then dipped 
before rising again by V4. Inflammatory markers increased from V1 onwards. Network 
analysis revealed a disconnect between the correlations observed in CDV and V2-V4 and 
those in V1. Surprisingly, serum iron and TSAT were only weakly influenced by hepcidin. 
CONCLUSIONS: Rapid anti-infective postnatal hypoferremia in human neonates is 
transient. The later rise in serum iron despite very high hepcidin indicates hepcidin 
resistance possibly caused by macrophage saturation with iron released from degradation of 
fetal erythrocytes. Pharmacological prolongation of hypoferremia might offer an ancillary tool 
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in the armoury against antimicrobial resistance, however, it would need to overcome or 
circumvent the hepcidin resistance we now report. 
Trial Registration: clinicaltrials.gov (NCT03353051). Registration date: November 27, 
2017.  
FUNDING: Bill & Melinda Gates Foundation (OPP1152353).  
WORD COUNT: 296/300 
Keywords: Nutritional immunity, host-pathogen interaction, hepcidin, neonates, 




During pregnancy, the mother increases iron absorption and turnover of erythrocytes to 
provide for the growing fetus.1 As maternal hepcidin decreases during the third trimester, 
placental iron transfer rises.2 This leads to higher cord blood TSAT and serum iron levels 
compared to those of the mother at delivery,3–5 even in anemic mothers.6 To protect the 
fetus against possible iron overload during the last trimester, fetal-derived hepcidin regulates 
iron transfer via degradation of ferroportin on placental syncytiotrophoblasts.7 As a result, 
umbilical cord hepcidin concentrations of term neonates are higher than those of the mother, 
before and during delivery.8–10  
 
Using murine and in vivo human trophoblast models, evidence also suggests that the 
placenta may independently regulate iron transfer to the fetus in specific circumstances.11 A 
reduction of ferroportin expression on the apical fetal-facing membrane of placental 
syncytiotrophoblasts and increased expression of transferrin receptor 1 (TFR1) on the 
maternal-facing side have been observed in the setting of maternal iron deficiency. Placental 
metabolic homeostasis is subsequently maintained, protecting the fetus from the more 
detrimental condition of placental dysfunction.11  
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In laboring mothers at term, cord levels of IL-6 increase 4-fold even in the absence of 
evident infection.12 Since the placenta is impermeable to IL-6,12,13 these high cord blood 
levels suggest that labour could be associated with a fetal-neonatal inflammatory response, 
potentially triggered by labour-related mechanisms or exposure to infectious agents. 
Immediately after delivery, newborns face the most complex multi-organ physiological 
adaption that they will experience in their entire lives. Increased IL-6 levels in the newborn 
are thought to assist with organ system transition at birth (e.g. cytokine-induced synthesis of 
lung surfactant proteins14) and the activation of the immune system in the newborn15. IL-6 is 
also known to activate the JAK-STAT pathway, leading to the induction of hepcidin 
synthesis.16 In previous studies we17,18 and others19–22 have demonstrated a rapid and 
profound hypoferremia occurring within the first few hours after delivery. This is assumed to 
have evolved as a defence against early-onset neonatal sepsis (EONS) and remains robust 
in premature and low-birthweight babies.18 Several studies have shown that post-natal 
peripheral hepcidin and prohepcidin (precursor) levels are higher than those in cord 
blood.9,19,20 We previously observed an initial increase in hepcidin within the first 12 hours of 
life in healthy newborns, positively correlated to raised IL-6 levels,17 and we confirmed this in 
low birth weight and premature newborns.18 Our data suggested that the IL-6-hepcidin-
ferroportin axis plays a partial, but probably not exclusive, role in orchestrating the 
hypoferremia. 
 
Here, we examine the duration of the hypoferremia and the likely regulatory influences in 







6.3 SUBJECTS AND METHODS 
 
Full details of the NeoInnate Study (clinicaltrials.gov, NCT03353051) can be found in the 
published protocol paper.23 
 
Study Design 
The NeoInnate Study tested whether preterm and/or low birthweight babies were capable of 
inducing acute hypoferremia previously noted in full-term, normal birthweight babies. Results 
of the primary outcomes have been presented elsewhere.18 Here we describe the pre-
planned secondary analysis of longitudinal changes in iron, hematological and inflammatory 
parameters over the first week of life within the term, normal weight babies from the 
FTB/NBW group. All babies were sampled from the cord artery (CDA) and vein (CDV) and 
had an early postnatal draw (V1) at 6-24h. For the longitudinal analysis over the first week of 
life and to avoid more than two blood draws per baby, the babies were then randomly 
allocated to a second blood draw at 25-80h (V2), 81-136h (V3) or 137-192h (V4) (Figure 1). 
Randomisation of second blood draw group allocation was completed using a random 
number calculator (GraphPad QuickCalcs, GraphPad Software INC, CA 92037, USA). This 
allocation was adapted according to study working hours and access to the newborn. Data 
collection started on the 5th July 2017 and ended on 1st February 2019. 
 
Ethics, standards and informed consent 
The trial was approved by the Medical Research Council Unit The Gambia at London School 
of Hygiene and Tropical Medicine (MRCG at LSHTM) Scientific Coordinating Committee, the 
Joint Gambia Government/MRC Ethics Committee (SCC1525) and the London School of 
Hygiene and Tropical Medicine Ethics Committee (Ref:14316) and conducted according to 





Study participants were recruited from Kanifing General Hospital (formerly Serrekunda 
General Hospital), in the urban Kanifing region of The Gambia, West Africa.  
 
Recruitment, screening and enrolment 
We planned to enrol 300 neonates into this longitudinal arm of the NeoInnate Study. For 
inclusion in this aim of the study, neonates were healthy, medically stable (i.e. not requiring 
resuscitation and with no signs of sepsis) with a gestational age ≥37 completed weeks 
(assessed by New Ballard Score24) and weighed ≥2500g.  
 
Pregnant mothers were excluded from the study if they were below the age of 18 years, had 
no fetal heartbeat detected upon admission, were known to be HIV-positive, were in receipt 
of TB therapy, had taken antibiotics in the last seven days, had a blood transfusion in the 
last month, were suffering from severe pre-eclampsia or antepartum haemorrhage, or were 
in another research study.  
 
Babies were excluded at the delivery stage for the following reasons: major congenital 
malformations (not including polydactylism), blood transfusions given to mother or neonate, 
severe birth asphyxia (requiring resuscitation), neonates born via breech, vacuum or via 
caesarean section. 
 
After the delivery stage, babies were excluded following the detection of infection or illness 
(i.e. information gained from a venous bleed or review of systems). Neonates were also 
removed from the study protocol if any medication other than intramuscular vitamin K, 
tetracycline eye ointment or immunisations was given. All medications given to mothers and 
neonates during the study period were recorded. Mothers who delivered multiple newborns 





Once the neonate was fully delivered, one-minute delayed cord clamping was used 
(following World Health Organisation (WHO) policy25). After the umbilical cord was removed 
and cleaned, a trained study nurse identified the umbilical arteries (CDA) and umbilical vein 
(CDV). Blood was collected from each using separate blood draw equipment.  
 
At 6-24 hours post-delivery, recruited mothers and their neonates were invited to a private 
consultation with the study research clinician. Demographic data were collected, along with 
a complete review of systems of the mother and neonate, and newborn anthropometry. 
Neuromuscular and physical maturation of each neonate was assessed using the New 
Ballard Score.24 Immediately after passing the health assessment, a 3.5ml venous blood 
draw was performed on all neonates (V1).  
 
During the community visit at the home of the neonate, a review of systems in the mother 
and child were conducted by a research nurse. This was followed by collecting data on 
medication, behaviour and immunisations of the neonate after leaving the hospital. A further 




A full haematology panel (using a Medonic M20M GP, Boule Diagnostics, Spanga, Sweden) 
and glucose-6-phosphate dehydrogenase deficiency test (R&D Diagnostics Limited, 
Papagos, Greece) were conducted on fresh whole blood. Serum was separated and stored 
at -20oC prior to analysis of ferritin, iron, unsaturated iron-binding capacity (UIBC), soluble 
transferrin receptor (sTfR), transferrin, c-reactive protein (CRP), haptoglobin, and alpha-1-
acid glycoprotein (AGP) using a fully automated biochemistry analyser (Cobas Integra 400 
plus, Roche Diagnostic, Switzerland). Transferrin saturation (TSAT) was calculated. Serum 
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samples were assessed for hepcidin concentration by ELISA (hepcidin-25 (human) EIA Kit, 
DRG, USA) with a dynamic range of 0.135-81 ng/mL. 
 
In order to ensure a consistent assessment of haemolysis in all serum samples, batches of 
samples were thawed before entering the biochemistry analyser and visually scored by a 
single operator. A previously published specimen integrity chart for haemolysis was used as 
reference.26 Samples were scored 0 (yellow 0 g/L of hemoglobin) to 6 (dark red 8 g/L of 
hemoglobin). Samples scoring ≥5 were removed from the analysis. 
 
Sample size determination 
Sample size calculations for the primary outcomes of the NeoInnate Study were based on 
data from a previous study17 and are summarised in the protocol paper.23 The secondary 
outcomes presented here were not subjected to a formal sample size analysis. 
 
Statistical analysis 
Statistical analysis and preparation of figures were conducted using STATA v15.1 (Stat-Corp 
LP, College Station, TX, USA), DataDesk version 7.0.2 (Data Description Inc) and 
GraphPad Prism (GraphPad Software INC, CA 92037, USA). For continuous variables, 
baseline characteristics are presented as means (± SD) for normally distributed variables. All 
skewed data (hepcidin, CRP, AGP, sTfR and ferritin) were transformed using the ladder 
command in STATA. The ladder command searches a subset of the ladder of powers for a 
transformation that converts the variable of interest into a normally distributed variable. 
Results were confirmed graphically by the gladder command. Categorical variables are 
reported as proportions (%). Iron and inflammation markers were compared using ordinary 
least squares analysis of variance (OLS ANOVA), using Scheffé’s post-hoc tests to control 
for multiple testing (V1 vs V2, V3 or V4). All hypothesis tests were two-sided at a 
significance level of 0.05. The rate of missing data was small (<5%), thus we did not impute 
missing data. Weighted Pearson network analysis was conducted using the Shiny Network 
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Application (https://jolandakos.shinyapps.io/NetworkApp/). The network was formatted using 
the Fruchterman-Reingold Algorithm27 only showing moderate or strong (>0.3) associations 




A CONSORT diagram summarising subject recruitment is shown in Figure 2. There were 
278 neonates with paired cord blood and V1 samples. Of these, 224 provided a second 
venous blood sample (V2, V3 or V4). 
 
Neonatal characteristics 
Baseline characteristics are shown in Table 1. Newborns were healthy vaginally delivered 
babies, with a mean gestational age of 39.4 ± 1.3wk and mean birthweight of 3299 ± 368g. 
Many of the mothers (81.7%) received iron and folic acid during pregnancy as per WHO 
guidelines. Mean anthropometric measurements of all neonates fell within the 25th and 75th 
centiles of the WHO growth charts for gestational age.28 The mean times of bleed were: V1 
= 12.7 ± 0.32h; V2 = 57.6 ± 15.6h; V3 = 105.8 ± 17.0h; and V4 = 156.7 ± 21.0h. 
 
Changes in iron and chaperone proteins in the first week of life 
Iron metabolism parameters over the first week of life can be seen in Table 2 and Figure 3. 
Following the acute hypoferremia on Day 1 (V1 = 7.3 ± 4.6µmol/L vs CDV = 22.7 ± 
7.0µmol/L, P<0.0001) there was a steady increase in serum iron to 16.5 ± 3.9μmol/L at V4 
(P for trend <0.0001) (Fig 3A). There was a slight decrease in transferrin levels (Fig 3B) but 
TIBC levels remained relatively constant (Fig 3C) and hence TSAT levels mirrored those for 
serum iron (Fig 3D). Following the acute postnatal hypoferremia (V1 = 14.4 ± 6.0% vs CDV 
= 50.2 ± 16.7%, P<0.0001) TSAT increased steadily to 36.7 ± 9.2% at V4 (P for trend 
<0.0001). UIBC consequently decreased from V1 to V4 (from 44.1 ± 18.0μmol/L to 29.5 ± 
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9.6μmol/L, P for trend <0.0001) (Fig 3E). Ferritin levels were very high at V1 (393 ± 
313μg/L) and showed a non-significant decline to 355 ± 182μg/L at V4 (Fig 3F).  
 
Changes in hepcidin and inflammatory markers in the first week of life 
Hepcidin levels in cord blood were high (19.4 ± 14.4ng/ml) and doubled immediately after 
birth to reach 38.9 ± 23.9ng/ml at V1 (P<0.0001). There was then a slight non-significant dip 
followed by a steady rise to 45.2 ± 19.1ng/ml at V4 (P for trend <0.0001) (Fig 4A). CRP 
levels were low in cord blood (0.2 ± 0.7 mg/L) and increased 10-fold immediately after birth 
(to 2.3 ± 4.1mg/L at V1, P<0.0001) followed by a further steep rise to 5.6 ± 9.3mg/L at V2 
(P<0.0001 vs V1) and then a decline to 0.9 ± 1.5 by V4 (P<0.0001 for trend)(Fig 4B). AGP 
showed a small increase after birth and then a further slow rise to V4 (P<0.0001) (Fig 4C). 
The heme-binding inflammatory-response protein haptoglobin increased between CDV and 
V1 (from 0.02 ± 0.1g/L to 0.1 ± 0.2g/L, P<0.0001) and then declined slightly to 0.08 ± 0.1g/L 
at V4 (P for trend <0.0001) (Fig 4D). 
 
Changes in hematological indices in the first week of life 
Cord hemoglobin (15.1 ± 2.3g/dl) and hematocrit (42.2 ± 7.0%) were high and there was a 
further increase by V1 (hemoglobin to 19.5 ± 2.9g/dl, hematocrit to 55.0 ± 9.7%, P<0.0001 
for both increases). This was followed by a steady decline back towards cord-like levels by 
V4 (hemoglobin to 16.9 ± 2.9g/dl, hematocrit to 46.9 ± 9.0%, P<0.0001 for trend in both 
cases) (Fig 5A,5B). Soluble transferrin receptor levels dropped markedly reflecting the fact 
that there was a net breakdown of haemoglobin during the first week of life and an 
abundance of circulating iron to supply the needs of any on-going erythropoiesis (Fig 5C). 
 
Pearson correlation network analysis of iron and inflammation markers  
Weighted Pearson correlation network analysis between the iron and inflammation markers 
in all samples (CDV, V1 and V2-4) are shown in Figure 6. The unconnected nodes for 
birthweight and gestational age reflect their lack of influence on any of the markers. As 
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expected, there were consistent associations between serum iron, TSAT, UIBC and TIBC at 
all time points, but the V1 nodes were notably separated from CDV and V2-V4 underscoring 
the unusual nature of the immediate post-natal hypoferremia. Hemoglobin and hematocrit 
followed a similar pattern, with cord values only correlating to V2-V4 values. The 
inflammatory markers CRP, AGP and haptoglobin were generally associated as would be 
expected (see lower part of the network) but ferritin, also an inflammatory marker, was 
notably separate. The most surprising feature was that hepcidin featured on the periphery of 
the network and was not associated with the inflammatory markers or serum iron. 
 
Comparisons of iron and inflammation markers in arterial (CDA) and venous cord 
blood (CDV) 
Figure 7 illustrates the comparisons between iron and inflammation markers in venous and 
arterial cord blood. For most markers there were no differences. TSAT was slightly higher in 
venous blood (50.5 ± 1.0%) than arterial cord blood (46.9 ± 1.0%, P<0.0001). Conversely, 
arterial blood had higher ferritin (276.9 ± 14.7 vs 215.7 ±10.1µg/L, P<0.0001), UIBC (27.1 ± 
0.7 vs 23.4 ± 0.7µmol/L, P<0.0001) and TIBC (49.8 ± 0.57 vs 46.1 ± 0.51µmol/L, P<0.0001).  
There were no differences in any red blood cell indices between venous and arterial cord 
blood, but white cell counts (with the exception of granulocyte count) were significantly 
higher in arterial blood (Table 3). Conversely platelet counts were significantly higher in 




This study demonstrates that, following the previously reported17,18 acute postnatal 
hypoferremia, serum iron and TSAT steadily revert towards cord-like levels over the first 
week of life. We interpret this as further evidence that the early hypoferremia has evolved to 
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help newborns navigate the hazardous journey as they progress from an almost sterile intra-
uterine existence to the heavy bacterial exposures of extra-uterine life. 
 
Our prior analyses17,18 using data from independent studies, revealed that the early 
hypoferremia was, at least in part, driven by an inflammatory response to the birth process, 
eliciting a rapid IL-6-mediated rise in hepcidin. Hepcidin blocks the release of iron from 
enterocytes and macrophages1 and thereby reduces serum iron through the dual actions of 
preventing iron absorption and recirculation. In neonates who receive insignificant amounts 
of dietary iron on Day 1, the latter mechanism dominates and the hypoferremia represents a 
temporary redistribution of iron away from the extracellular plasma where it would enhance 
the growth of any ingressing bacteria or fungi.17 It is likely that additional hepcidin-
independent mechanisms play an additional role in the hypoferremia.29 
 
A surprising element of the current data is that iron and TSAT levels start to revert to normal 
despite hepcidin levels that continue to rise over the first week reaching values that are 3-4-
fold higher than observed in healthy adults.30 Furthermore, there was no correlation between 
hepcidin and serum iron or TSAT in the V2-4 samples. This unexpected disconnect between 
the relatively high levels of serum iron and TSAT coupled with high hepcidin concentrations 
suggests that early neonatal iron metabolism is desensitised to the action of hepcidin and 
thus the sequestration of intracellular iron is not maintained. This could be because the 
intracellular iron pools are saturated in the early post-partum period. We propose that 
macrophage cellular iron pools are increased in the first hours of life, initially due to the 
physiological hemolysis of fetal erythrocytes,31 followed by the uptake of transferrin-iron 
complexes.32 Erythrophagocytosis and the recycling of iron released from the catabolism of 
heme also add to intracellular iron levels.33 This is further exacerbated by the effects of 
inflammation-induced hepcidin excess at 6-24 hours post-delivery, leading to hepcidin-
induced co-degradation34 and/or hepcidin occlusion35 of the transmembrane iron transporter, 
ferroportin. We propose the initial hepcidin levels reduce expression of ferroportin on 
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macrophage cell membranes, thus eliciting the immediate post-natal hypoferremia, but that 
complete removal of all ferroportin molecules from the cell membrane is not achieved. This 
is supported by in vivo hepcidin challenge experiments showing a halving of ferroportin 
expression within 4 hours.36 However, the complete removal of ferroportin was not achieved. 
Previous authors have suggested that excess levels of hepcidin more likely result in the 
blocking of the central cavity of ferroportin, rather than its internalization.35 We propose that 
as hepcidin levels are consistently high during the first week of life, intermittent binding and 
releasing of hepcidin to the central cavity of individual ferroportin molecules may allow for 
slow rates of iron efflux into the circulation. We hypothesize that this results in a gradual 
increase in serum iron and TSAT, even in the high hepcidin environment, as seen in 
Figures 3 and 4. Previous research suggests that a potential cause of occlusion over 
internalization and the differences between tissues in sensitivity to hepcidin could be due to 
the differing endocytic machinery present in different cell types, or differing ferroportin 
glycosylation.36,37 Further research in respect to neonatal macrophages is required. 
 
Other studies have shown that following the neonatal period, circulating hepcidin levels 
decline to those similar to or lower than those observed in cord blood.38–40 Increased 
expression of growth factors (i.e. IGF-1, HGF, EGF, PDGF-BB) is thought to be the cause of 
downregulation of hepcidin transcription.41,42 Our research shows that this trend does not 
begin until after the first week of life.  
 
Differences in hepcidin concentration between males and females are observed in adults43 
and children.44 Previous research has noted significantly lower hepcidin concentrations in 
male neonates compared to females in the first week of life.45 Though initially thought to be 
due to iron status and CRP concentration differences, it has recently been suggested that 
higher testosterone levels may be the cause. Though we did not measure testosterone 
levels in our samples, no significant difference in cord, V1 (6-24 hrs) or V2-4 (24-192 hours) 
hepcidin concentration was observed between sexes.  
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CRP levels peaked between 24-80 hours post-delivery, with again a surprising absence of 
correlation with hepcidin concentrations. This is despite the well-documented regulatory 
pathways of infection and inflammation on iron regulation.46 Previous studies have 
suggested that the lack of correlation between hepcidin, IL-6 and CRP is due to differences 
in the kinetics of these proinflammatory biomarkers during the infection process. IL-6 
concentrations spike very early in the course of infection or inflammation, hepcidin then 
follows and the rise of CRP is delayed and with a further delay to AGP release.47 
 
The great majority of mothers in this study reported that they received iron and folic acid in 
pregnancy as per Gambian government guidelines but 52% remained anaemic in the last 
week before delivery. Despite this, ferritin levels in cord blood were high (CDV: 213 ± 
158µg/L) and levels almost doubled immediately after delivery to 394 ± 313µg/L at V1. It has 
previously been suggested that this is due to the physiological hemolysis of fetal red blood 
cells, which contain ferritin in high concentrations.22 Similarly, we found elevated levels of 
haptoglobin, peaking at 0.1 ± 0.2g/L at 24-80 hours of life. We suggest this is another layer 
of nutritional immunity, as haptoglobin binds to hemoglobin, further restricting iron availability 
to invading microorganisms.48  
 
We also recorded increases in newborn hemoglobin and hematocrit taken within the first 
hours of life (6-24 hours) compared to cord blood. This is likely to be in part due to postnatal 
dehydration, as well as vasomotor instability and venous pooling.49 The decreases in 
hemoglobin and hematocrit over the first week of life are likely a response to the higher 
ambient oxygen concentration ex-utero.49 
 
We undertook the comparative analysis of iron markers and inflammation in arterial and 
venous cord blood to ensure that non-standardized sampling of ‘cord blood’ in prior studies 
did not affect the comparisons between cord and postnatal samples. Serum iron was 
identical between sampling sites, and although there were significant differences for TIBC, 
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and hence reciprocally for TSAT, the differences were only in the order of 6-7%. Transferrin 
levels were similar, suggesting that differences in non-transferrin iron-binding compounds 
account for the small difference in TIBC and TSAT.   
 
Cord arteriovenous samples show significant differences in all platelet parameters. This may 
be the result of the placenta being an active site of platelet production as previously 
suggested by Woods et al.50  
 
There are several strengths and limitations to our study. The large sample size and the 
relative homogeneity of responses across most analytes provides confidence in the trends 
observed. A limitation is that maternal iron markers in mid-gestation, parturition and after 
delivery were not measured. This would have provided information as to what effect 
maternal iron and inflammation status had on the neonatal iron marker fluctuations we 
studied. Measurement of pro-inflammatory cytokines (e.g. IL-6 and IL-22) and growth factors 
(i.e. IGF-1, HGF, EGF and PDGF-BB) may have provided additional insights into the 
regulation of postnatal iron metabolism. Variables governing the hepcidin-independent 
regulation of iron redistribution are not yet known so could not be measured in our study. 
The effects of diurnal rhythm, iron supplementation and infection were not assessed and 
could be a direction for future research.  
 
In conclusion, our results suggest that early postnatal hypoferremia is a fast-acting, yet 
short-lived adaptation likely to have evolved to protect the newborn from infection at the time 
they are most vulnerable. This is followed by a period of hepcidin desensitisation, or leaky 
intracellular iron sequestration, as iron efflux into the serum continues even in the presence 
of high serum hepcidin concentrations. The reduced need for iron for erythropoiesis during 
the first week of life could also increase the concentration of serum iron. This interpretation 
is supported by the observed decrease in sTfR levels over the first week indicating that 
erythroid tissues were not demanding iron. We have previously shown18 that, in principle, the 
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duration of postnatal hypoferremia might be extendable through the administration of mini-
hepcidins as an ancillary tool against antimicrobial-resistant infections. The new data 
presented here suggests that any such intervention would need to overcome or circumvent 
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Figure 1: Study recruitment and blood draw design. Mothers were approached on 
entering the KGH maternity ward, The Gambia. This was followed by the consenting 
process, recruitment and delivery data collection. At delivery, venous (CDV) and arterial 
(CDA) cord blood was collected after one-minute delayed cord clamping. The neonate was 
weighed after cord blood collection. At 6-24 hours post-delivery, the research study clinician 
conducted a health check of the mother and newborn. New Ballard Score was used to 
establish gestational age. If the neonate was deemed healthy, the V1 blood draw was 
completed. Follow-up in the community was conducted 24-216 hours post-delivery. This 
involved a health check of mother and newborn by the study nurse. If deemed healthy, the 
newborn was bled again (V2: ≥24 hours - <80 hours, V3: ≥80 hours - <136 hours, V4: ≥136 - 
<192 hours).  
 
Figure 2: CONSORT diagram for participant flow. Two hundred and seventy-eight full-
term, normal birthweight neonates were recruited to the study. Red outlined boxes represent 
all neonates excluded. 
 
Figure 3: Changes in iron and chaperone proteins in the first week of life 
Blood was drawn from the umbilical cord vein (CDV) at birth and from the dorsum of the 
hand at serial time points for each individual (>6-≤24hrs and >24-≤216hrs). Dots represent 
individual measurements. The blue line is a loess fit curve with 95% confidence intervals 
shaded in red. A = serum iron, B = transferrin, C = TIBC, D = TSAT, E = UIBC, F = ferritin. 
 
Figure 4: Changes in hepcidin and inflammatory markers in the first week of life 
Blood was drawn from the umbilical cord vein at birth and from the dorsum of the hand at 
serial time points for each individual (>6-≤24hrs and >24-≤216hrs). Dots represent individual 
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measurements. The blue line is a loess fit curve with 95% confidence intervals shaded in 
red. A = hepcidin, B = CRP, C = AGP, D = haptoglobin. 
 
Figure 5: Changes in hematological indices in the first week of life 
Blood was drawn from the umbilical cord vein at birth and from the dorsum of the hand at 
serial time points for each individual (>6-≤24hrs and >24-≤216hrs). Dots represent individual 
measurements. The blue line is a loess fit curve with 95% confidence intervals shaded in 
red. A = hemoglobin, B = hematocrit, C = sTfR. 
 
Figure 6: Weighted Pearson correlation network analysis of iron status and 
inflammation variables between cord and post-natal blood samples. Produced using 
the Shiny Network Application (https://jolandakos.shinyapps.io/NetworkApp/). This analysis 
is formatted into the “spring” layout that uses the Fruchterman-Reingold Algorithm 27 placing 
the more strongly correlated nodes closer together. Node colours define sample type 
(YELLOW = CDV, BLUE = V1, PINK = V2-4). The direction and size of the Pearson 
correlation between two nodes is represented using the colour (RED = Negative, GREEN = 
Positive) and thickness of an edge. Cord = umbilical cord blood. V1 = venous blood from 
dorsum of the hand at >6-≤24hrs. V2-4 = venous blood from dorsum of the hand at >24-
≤216hrs. Fer = ferritin, Hep = hepcidin, Hct = hematocrit, Hgb = hemoglobin, GA = 
gestational age, BW = birthweight, CRP = C-reactive protein, Hapt = haptoglobin, AGP = 
alpha 1-acid glycoprotein, sTfR = soluble transferrin receptor, UIBC = unbound iron-binding 
capacity, TIBC = total iron-binding capacity, Trans = transferrin, fe = serum iron, TSAT = 
transferrin saturation.  
 
Figure 7: Comparison of iron status, inflammation and hematological parameters in 
cord arterial (CDA = BLUE) and venous (CDV = RED) blood. Box plots represent the 
arithmetic mean with whiskers representing minimum and maximum values. * = P<0.05. No 
significance line = P>0.05. 
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Tables 
Table 1: Demographic, clinical and pregnancy outcome characteristics of the women and their newborns.  
Study Group Exclusions V1  (Total Sample) V2 V3 V4 
Number of Participants (n) 54 278 56 100 68 
Characteristic Mean (±SD) 
Gestational Age (Weeks) 39.4 (±1.3) 39.4 (±1.3) 39.4 (±1.4) 39.3 (±1.3) 39.6 (±1.2) 
Birth Weight (g) 3361.2 (±377.9) 3299 (±368.3) 3270.4 (±355.3) 3293.1 (±364.7) 3281.9 (±378.7) 
Head Circumference (cm) 34.5 (±1.0) 34.6 (±1.0) 34.5 (±1.0) 34.6 (±1.0) 34.6 (±1.2) 
Length (cm) 50.0 (±1.6) 50.0 (±1.6) 50.2 (±1.5) 50.0 (±1.5) 49.9 (±1.7) 
Maternal Hemoglobin ≤7 Days Before Delivery (g/dl) 11.6 (±2.2) 11.6 (±1.8) 11.4 (±1.8) 11.8 (±1.6) 11.6 (±1.8) 
Age of Mother (Years) 27.5 (±6.8) 29.7 (±6.9) 31.2 (±7.3) 28.9 (±6.5) 31.4 (±6.8) 
1 min APGAR Score (0-10) 9.5 (±0.8) 9.6 (±0.8) 9.6 (±0.7) 9.6 (±0.9) 9.6 (±0.7) 
Time from Admission to Birth (Hours) 3.3 (±4.5) 3.2 (±5.2) 3.7 (±5.7) 2.7 (±4.1) 3.5 (±6.6) 
Time from Delivery to V1 Blood Collection (Hours) 13.1 (±5.6) 12.7 (±5.4) 12.3 (±5.7) 13.1 (±5.0) 12.1 (±5.4) 
Time from Delivery to V2 Blood Collection (Hours) - 57.2 (±15.6) 57.6 (±15.6) - - 
Time from Delivery to V3 Blood Collection (Hours) - 105.8 (±17.0) - 105.8 (±17.0) - 
Time from Delivery to V4 Blood Collection (Hours) - 156.7 (±21.0) - - 156.7 (±21.0) 
 Percentage % (n) 
Percentage Male (%) 55.5% (30) 54.3% (151) 46.4% (26) 58.0% (58) 54.4% (37) 
G6PD Deficiency Positive (%) 14.8% (8) 11.5% (32) 8.9% (5) 10.0% (10) 13.2% (9) 
Multiple Births (%) 0.0% (0) 2.2% (6) 1.8% (1) 4.0% (4) 1.5% (1) 
Percentage of Mother on Antenatal Iron/Folic Acid (%) 81.5% (44) 81.7% (227) 83.9% (47) 80.0% (80) 82.3% (56) 
Data are presented as arithmetic mean (± SD) or as a proportion (%). Exclusions represent newborns successfully bled at cord and V1 
timepoints but who were lost to follow up or sick before V2-4 blood draw was completed.  
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Table 2: Comparison of iron status, inflammation and hematological parameters in cord and post-natal samples. 
Sample Type n CDV n V1 n V2 n V3 n V4 V1 vs V2 (P value) V1 vs V3 (P value) V1 vs V4 (P value) Trend (P Value) 
Serum Iron (μmol/L) 275 22.7 (±7.0) 271 7.3 (±4.6) 54 10.1 (±3.2) 93 14.7 (±4.7) 62 16.5 (±3.9) 0.0005 <0.0001 <0.0001 <0.0001 
TSAT (%) 273 50.2 (±16.7) 271 14.4 (±6.1) 54 20.2 (±8.1) 91 32.2 (±13.0) 61 36.7 (±9.2) <0.0001 <0.0001 <0.0001 <0.0001 
Serum Hepcidin (ng/ml) 277 19.4 (±14.4) 270 38.9 (±23.9) 55 32.7 (±18.4) 92 45.9 (±17.7) 62 45.2 (±19.1) ns 0.003 ns <0.0001 
UIBC (μmol/L) 273 23.7 (±10.4) 271 44.1 (±18.0) 54 41.5 (±10.3) 91 32.4 (±10.2) 61 29.5 (±9.6) ns <0.0001 <0.0001 <0.0001 
TIBC (μmol/L) 273 46.3 (±8.1) 271 51.4 (±20.7) 54 51.6 (±9.8) 91 46.9 (±9.6) 61 46.0 (±10.5) ns ns ns 0.03 
Serum Ferritin (ug/L) 275 212.6 (±157.7) 266 393.9 (±312.6) 54 343.7 (±206.0) 93 311.8 (±131.3) 62 354.6 (±181.8) ns ns ns ns 
Hemoglobin (g/dl) 270 15.1 (±2.3) 272 19.1 (±2.9) 49 19.5 (±2.9) 95 18.1 (±2.9) 64 16.9 (±2.9) ns 0.03 <0.0001 <0.0001 
Hematocrit (%) 270 42.2 (±7.0) 272 53.9 (±8.9) 49 55.0 (±9.7) 95 50.5 (±8.8) 64 46.9 (±9.0) ns 0.01 <0.0001 <0.0001 
Transferrin (g/L) 275 2.0 (±0.3) 273 2.0 (±0.3) 56 1.9 (±0.3) 93 1.7 (±0.2) 62 1.7 (±0.2) ns <0.0001 <0.0001 <0.0001 
Soluble Transferrin Receptor (mg/L) 273 6.0 (±2.0) 271 6.9 (±2.2) 54 6.6 (±2.0) 92 6.1 (±2.2) 62 5.1 (±1.3) ns 0.003 <0.0001 <0.0001 
Haptoglobin (g/L) 275 0.02 (±0.1) 273 0.03 (±0.07) 56 0.1 (±0.2) 93 0.08 (±0.2) 62 0.08 (±0.1) <0.0001 0.001 0.01 <0.0001 
Serum AGP (g/L) 275 0.2 (±0.1) 273 0.3 (±0.2) 56 0.4 (±0.2) 93 0.4 (±0.1) 62 0.4 (±0.1) <0.0001 <0.0001 <0.0001 <0.0001 
Serum CRP (mg/L) 275 0.2 (±0.7) 273 2.3 (±4.1) 55 5.6 (±9.3) 93 2.0 (±2.2) 62 0.9 (±1.5) <0.0001 ns 0.01 <0.0001 
Mean Corpuscular Volume (fl) 270 97.8 (±6.3) 272 97.7 (±6.0) 49 97.6 (±5.1) 95 96.0 (±5.9) 64 94.1 (±5.6) ns ns 0.0002 <0.0001 
Mean Corpuscular Hemoglobin (pg) 270 35.1 (±2.4) 272 34.8 (±2.4) 49 34.8 (±2.1) 95 34.5 (±2.2) 64 34.1 (±2.2) ns ns ns ns 
Mean Corpuscular Hemoglobin Concentration (g/dl) 270 35.8 (±1.0) 272 35.6 (±1.1) 49 35.6 (±1.5) 95 35.9 (±0.9) 64 36.2 (±1.1) ns ns <0.0001 0.0002 
White Blood Cell Count (unit/L) 269 13.3 (±5.7) 271 16.4 (±5.8) 48 10.5 (±5.4) 93 8.8 (±3.0) 64 9.2 (±2.5) <0.0001 <0.0001 <0.0001 <0.0001 
Lymphocyte Count (unit/L) 269 4.8 (±3.5) 271 4.2 (±2.9) 48 3.1 (±1.6) 93 3.3 (±1.2) 64 3.5 (±1.0) 0.01 0.01 ns 0.0005 
Lymphocyte Percentage (%) 269 35.2 (±7.9) 271 26.5 (±8.8) 48 31.1 (±9.3) 93 38.7 (±7.6) 64 38.4 (±7.0) 0.006 <0.0001 <0.0001 <0.0001 
MID Cell Count (unit/L) 269 1.04 (±0.6) 271 1.54 (±1.0) 48 1.1 (±0.8) 93 1.2 (±0.8) 64 1.7 (±0.8) 0.03 0.04 ns 0.0005 
MID Cell Percentage (%) 269 8.1 (±2.4) 271 9.8 (±5.6) 48 11.5 (±7.0) 93 14.8 (±7.8) 64 18.9 (±8.1) ns <0.0001 <0.0001 <0.0001 
Granulocyte Count (unit/L) 269 7.5 (±2.7) 271 10.7 (±4.2) 48 6.3 (±4.0) 93 4.2 (±1.9) 64 4.1 (±1.8) <0.0001 <0.0001 <0.0001 <0.0001 
Granulocyte Percentage (%) 269 56.6 (±8.7) 271 63.7 (±8.8) 48 57.4 (±9.3) 93 46.4 (±9.2) 64 42.7 (±9.1) 0.0001 <0.0001 <0.0001 <0.0001 
Red Blood Cell Count (unit/L) 270 4.3 (±0.7) 272 5.5 (±0.9) 49 5.6 (±1.0) 95 5.3 (±0.9) 64 5.0 (±0.9) ns ns 0.0005 <0.0001 
Red Blood Cell Distribution Width (%) 270 15.2 (±1.2) 272 15.4 (±1.4) 49 15.6 (±2.8) 95 15.1 (±0.9) 64 15.1 (±2.2) ns ns ns ns 
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Red Blood Cell Distribution Width - Absolute (fl) 270 80.7 (±8.9) 272 82.0 (±8.6) 49 82.5 (±15.7) 95 77.9 (±8.0) 64 75.3 (±7.0) ns 0.004 <0.0001 <0.0001 
Platelet Count (unit/L) 270 243.8 (±92.8) 272 258.7 (±94.0) 49 261.2 (±90.8) 95 234.8 (±97.0) 64 267.7 (±94.0) ns ns ns ns 
Mean Platelet Volume (fl) 267 8.4 (±0.8) 271 8.5 (±0.8) 48 8.5 (±0.9) 93 8.7 (±0.8) 64 9.3 (±0.7) ns ns <0.0001 <0.0001 
Platelet Distribution Width (%) 267 43.5 (±3.0) 271 43.9 (±3.3) 48 44.5 (±3.5) 93 45.4 (±3.6) 64 46.4 (±2.7) ns 0.05 <0.0001 <0.0001 
Platelet Distribution Width - Absolute (fl) 267 11.8 (±1.3) 271 12.1 (±1.4) 48 12.1 (±1.6) 93 12.5 (±1.5) 64 13.3 (±1.2) ns 0.003 <0.0001 <0.0001 
Platelet Crit (%) 267 0.201 (±0.07) 271 0.215 (±0.07) 48 0.2 (±0.1) 93 0.2 (±0.07) 64 0.2 (±0.08) ns ns ns 0.009 
Plate Large Cell Ratio (%) 267 18.0 (±5.4) 271 19.2 (±5.8) 48 19.4 (±6.3) 93 21.1 (±5.9) 64 24.3 (±5.0) ns ns <0.0001 <0.0001 
Plate Large Cell Count (unit/L) 267 42.1 (±14.6) 271 46.9 (±17.0) 48 48.4 (±17.4) 93 47.6 (±17.8) 64 63.1 (±21.8) ns ns <0.0001 <0.0001 
Data are presented as mean (± SD) and analysed by ordinary least squares analysis of variance (OLS ANOVA). Number of available results 
differs by each parameter, due to limitations in blood sample volume for some participants. Scheffé’s post-hoc tests were conducted between 
V1 vs V2, V3 and V3 groups. P values in bold font are considered significant based on P<0.05. Hepcidin (log), ferritin (log), sTfR (log), AGP 
(Sqrt) and CRP (log) were all transformed to form a normal distribution before ordinary least squares analysis of variance (OLS ANOVA) and 









Table 3: Comparison of iron status, inflammation and hematological parameters in 
cord venous and arterial blood.  
Sample Type n Cord (Arterial) n Cord (Venous) P value 
Serum Iron (μmol/L) 258 22.7 (±6.9) 275 22.7 (±7.0) 0.8 
TSAT (%) 255 47.1 (±15.8) 273 50.2 (±16.7) <0.0001 
Serum Hepcidin (ng/ml)  249 19.7 (±14.4) 277 19.4 (±14.4) 0.34 
UIBC (μmol/L) 255 27.1 (±11.3) 273 23.7 (±10.4) <0.0001 
TIBC (μmol/L) 257 49.8 (±9.1) 273 46.3 (±8.1) <0.0001 
Serum Ferritin (ug/L)  241 277.0 (±234.2) 275 212.6 (±157.7) <0.0001 
Hemoglobin (g/dl) 242 15.2 (±2.6) 270 15.1 (±2.3) 0.53 
Hematocrit (%) 260 43.0 (±7.5) 270 42.2 (±7.0) 0.16 
Transferrin (g/L) 258 2.0 (±0.3) 275 2.0 (±0.3) 0.48 
Soluble Transferrin Receptor (mg/L) (log) 260 6.0 (±1.9) 273 6.0 (±2.0) 0.86 
Haptoglobin (g/L) 260 0.02 (±0.05) 275 0.02 (±0.06) 0.64 
Serum AGP (g/L)  260 0.2 (±0.1) 275 0.2 (±0.1) 0.97 
Serum CRP (mg/L)  242 0.2 (±0.03) 275 0.2 (±0.7) 0.27 
Mean Corpuscular Volume (fl) 241 98.2 (±6.2) 270 97.8 (±6.3) 0.07 
Mean Corpuscular Hemoglobin (pg) 241 35.1 (±2.5) 270 35.1 (±2.4) 0.9 
Mean Corpuscular Hemoglobin Concentration (g/dl) 241 35.8 (±1.1) 270 35.8 (±1.0) 0.09 
White Blood Cell Count (unit/L) 241 14.2 (±6.1) 269 13.3 (±5.7) 0.004 
Lymphocyte Count (unit/L) 241 5.5 (±3.7) 269 4.8 (±3.5) <0.0001 
Lymphocyte Percentage (%) 241 38.0 (±9.1) 269 35.2 (±7.9) <0.0001 
MID Cell Count (unit/L) 241 1.2 (±0.8) 269 1.0 (±0.6) <0.0001 
MID Cell Percentage (%) 241 8.8 (±3.2) 269 8.1 (±2.4) 0.0001 
Granulocyte Count (unit/L) 241 7.5 (±3.0) 269 7.5 (±2.7) 0.53 
Granulocyte Percentage (%) 241 53.2 (±9.4) 269 56.6 (±8.7) <0.0001 
Red Blood Cell Count (unit/L) 242 4.4 (±0.8) 270 4.3 (±0.7) 0.44 
Red Blood Cell Distribution Width (%) 242 15.3 (±1.0) 270 15.2 (±1.2) 0.11 
Red Blood Cell Distribution Width - Absolute (fl) 242 81.5 (±9.2) 270 80.7 (±8.9) 0.008 
Platelet Count (unit/L) 242 193.0 (±86.7) 270 243.8 (±92.8) <0.0001 
Mean Platelet Volume (fl) 237 8.6 (±0.8) 267 8.4 (±0.8) <0.0001 
Platelet Distribution Width (%) 237 44.6 (±3.4) 267 43.5 (±3.0) <0.0001 
Platelet Distribution Width - Absolute (fl) 237 12.3 (±1.4) 267 11.8 (±1.3) <0.0001 
Platelet Crit (%) 237 0.2 (±0.07) 267 0.2 (±0.1) <0.0001 
Plate Large Cell Ratio (%) 237 20.4 (±5.9) 267 18.0 (±5.4) <0.0001 
Plate Large Cell Count (unit/L) 237 42.1 (±14.6) 267 42.1 (±14.6) <0.0001 
Data are presented as mean (± SD) and analysed by one-way analysis of variance. P values 
in bold font are considered significant based on P<0.05. Hepcidin (log), ferritin (log), sTfR 
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(log), AGP (Sqrt) and CRP (log) are all transformed to form a normal distribution before one-































Figure 1: Study recruitment and blood draw design. 
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Figure 6: Weighted Pearson correlation network analysis of iron status and 












Figure 7: Comparison of iron status, inflammation and hematological parameters in 
cord arterial (CDA = BLUE) and venous (CDV = RED) blood. 
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Summary of Chapter 
 
This chapter focuses on describing a flowing narrative of the overall content of this thesis. It 
begins with a description of the essential aspects of study design, the critical learning gained 
from previous pilot studies and the literature review process. A detailed summary of what 
was discovered during the NeoInnate Study and how it addressed critical research gaps 
then follows.  
 
The subsequent section then notes several of the main issues and learning points faced 
during the research study process. At each point in this section, we outline the problem, the 
science behind it and how our research team overcame it.  
 
Finally, this discussion recommends four potential future research areas. This firstly focuses 
on the role the placenta plays in the maternal-fetal iron transfer process. This is followed by 
a review of possible triggers of the neonatal hypoferremic response (e.g. hepcidin-
dependent and hepcidin-independent mechanisms), and what research is required in order 
to understand these mechanisms further. Thirdly, this section describes the current research 
into harnessing hypoferremia to combat other infections and how this area is moving 
forward. This includes the current development of therapies that use iron chaperone proteins 
(e.g. haptoglobin, lactoferrin and lipocalin-2), bacterial iron-uptake mechanisms, and 
hepcidin agonists to treat bacterial infections. Lastly, this chapter outlines how future 
research should focus on the role of macrophages in the neonatal hypoferremic response 




7.1 A Review of the NeoInnate Study 
 
7.1.1 NeoInnate Study: Where Did It Begin? (Chapter 1) 
 
In light of the evidence that suggests hepcidin-induced hypoferremia is protective against 
severe bacterial infections,1 the findings of our team's pilot study were an exciting, 
unexpected finding. This PhD study was formulated after the previous research by Prentice 
et al. (HYPO-G study).2 This study was a non-blinded randomised controlled trial conducted 
on 120 full-term, normal birthweight Gambian neonates. Infants were randomised to receive 
Bacillus Calmette–Guérin (BCG) vaccination on the day of birth or after study completion at 
four days of age. Blood samples for investigation of iron parameters, hepcidin, IL-6 and red 
blood cell parameters were collected at birth (i.e. umbilical cord) and time-points up to 96 
hours of age. This study found that regardless of whether neonates received BCG 
vaccination or not, that during the first 24 hours of life full-term neonates actively reduce the 
serum iron concentration and transferrin saturation of the blood. This was found to occur as 
early as six hours postpartum and lasted for two to three days. This response was in strong 
correlation with hepcidin, suggesting that hepcidin regulates this response as seen in 
previous mechanistic studies.3 This finding was also correlated to levels of IL-6, suggesting 
that inflammatory stimulation was the trigger. Using a micro-adaptation of the ex vivo 
bacterial growth assay previously described in our FeVir study,4 we showed that the lack of 
iron similarly reduced growth rates of E. coli, S. aureus, S. pneumoniae and S. agalactiae 
(common neonatal sepsis causing pathogens) inoculated into venous samples collected at 
6-24 hours of life, in comparison to cord samples. The growth rates were significantly 
associated with TSAT level in the serum.2  
 
Supported by similar but smaller reductions in serum iron concentration and TSAT observed 
in the first week of life in other studies,5–8 this observation suggested that the neonatal 
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hypoferremia may have evolved as a mechanism designed to protect neonates from 
infection during the first critical days of life. This is a result of limiting the pathogenicity and 
virulence of invading bacterial organisms. However, more diverse populations with a range 
of birthweights and gestational ages were required to confirm this. This is especially the 
case in the light of evidence that suggests preterm neonates suffer deficiencies in Toll-like 
receptors (TLRs), a vital component of the inflammation-induced hypoferremic response.9 
We further hypothesised that this might lead to a dampening of this response, or a complete 
failure to reduce systemic iron concentrations. We believed that this might, in part, explain 
why being premature and/or low birthweight may be risk factors for neonatal sepsis.10  
 
7.1.2 A Review of Iron Homeostasis Over the First Month of Life (Chapter 3) 
 
This research studentship started with a systematic search of literature relating to hepcidin, 
serum iron and transferrin saturation levels in full-term and preterm newborns during the first 
month of life (Chapter 3). Retrieved data suggested that hepcidin, serum iron and TSAT 
levels for adults and infants are much lower than those observed in cord blood and venous 
blood during the first month of life. Accumulated data further strengthened our previously 
defined hypothesis that full-term neonates possess the ability to produce a hepcidin-
mediated hypoferremic response post-delivery. Nonetheless, data concerning preterm 
neonates was lacking and subsequently it was unclear as to whether they produce a similar 
response. This dearth of studies is presumably due to their relatively unstable medical 
condition, and the complex ethical issues around bleeding premature neonates. This review 
also highlighted a lack of data from blood samples collected in the first hours of life (6-24 
hours) and over the first week, even in term babies. 
 
Previously, Van der Vorm et al. formulated a series of linear equations to assist in the 
standardisation of each commonly used hepcidin measurement assay.11 In our review, we 
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used these equations to standardise results from previous publications. This allowed the 
calculation of weighted mean averages in cord and venous blood for full-term and preterm 
neonates. We believe the main strength of this review was that it is the first review to 
compare retrospective serum hepcidin concentrations between studies, using standardised 
values. This is the first review of hepcidin, serum iron and TSAT in cord blood and venous 
samples over the first weeks of life, that was stratified by gestational age. The learning 
points from this review for the following observational study were the importance of 
collecting of very early postnatal venous blood (6-24 hours), the use of the DRG hepcidin 
ELISA kit, the importance of detailed labour and delivery data, and standardisation of cord 
blood collection protocols (Chapter 4).  
 
Weaknesses of the review included the allocation of each study group or population in each 
publication to a mean gestational age. This was due to limited access to raw study data. It is 
suspected that this has reduced any natural variation potentially caused by gestational age 
between the reviewed populations. Equally, due to studies rarely stating the average birth 
weight of each population, analysis stratified by birthweight was not possible. Furthermore, 
the retrieval of gestational age was a crucial aspect of the search strategy; however, few 
studies documented the method used to calculate it. Due to the substantial differences in the 
accuracy of different techniques,12 the true mean gestational age of each population may 
vary by differing amounts.  
 
7.1.3 Early Postnatal Hypoferremia in Low Birthweight and Preterm Babies 
(Chapter 5) 
 
Initiation of the NeoInnate Study then began, with the formation of a protocol and data 
analysis plan. The primary objective of the NeoInnate study was to ascertain if there was a 
defect in the ability of preterm and low birthweight newborns to elicit a hypoferremic 
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response immediately after delivery (Chapter 5). This observational study ended with the 
recruitment of 152 babies who were either preterm (PTB) (born ≥32 to <37 weeks 
gestational age) and/or low birth weight (LBW) (<2500g) (PTB/LBW) and 278 term (FTB), 
normal-weight babies (NBW) (FTB/NBW). Blood was sampled from the umbilical cord vein 
and artery, as well as matched venous blood samples taken from all neonates between 6-24 
hours after delivery. In both PTB/LBW and FTB/NBW babies, we observed serum iron 
decreased 3-fold within 12 hrs of delivery compared to umbilical blood, and transferrin 
saturation showed a similar decline with a consequent increase in unsaturated iron-binding 
capacity. C-reactive protein levels increased over 10-fold and hepcidin levels doubled over 
the same period. We can now conclude that there was no difference in any of these 
responses between PTB/LBW and FTB/NBW babies. This result suggests that the innate 
postnatal iron restriction strategy in the first hours of life has evolved as an intrinsic 
mechanism to protect all neonates from common pathogens and/or free-radical damage, 
regardless of gestational age or birthweight. This finding now prompts further research into 
the use of iron restriction as a transient bacteriostatic mechanism to limit bacterial growth 
and virulence in other instances of infection.  
 
One of the limitations of this study includes that we did not recruit mothers with complex 
medical histories (e.g. pre-eclampsia, antepartum haemorrhage or antenatal infection) or 
sick babies (e.g. with birth asphyxia or suspected sepsis). This was deliberate; however, the 
question remains as to whether neonates with suspected sepsis, have sepsis due (in part) to 
them lacking this innate immune response. This question will remain challenging to assess 
as it will be difficult to access the exact point of the initiation of the infection and to what 
degree any change in inflammation or iron restriction is due to the presence of the infection 
itself. Additionally, we did not recruit newborns born <32 completed weeks gestation and/or 
<2000g birth weight, or those delivered via caesarean section, vacuum or forceps. As a 
result, we cannot speculate whether similar hypoferremic responses occur in these 
newborns. However, reciprocally, we can reason that the responses we observed in the 
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NeoInnate Study are a characteristic feature of normal human birth and not due to 
pathological circumstances.  
 
7.1.4 Iron Homeostasis in Full Term, Normal Birthweight Gambian Neonates 
Over The First Week of Life (Chapter 6) 
 
The final objective of the NeoInnate Study was to describe the longitudinal changes in iron 
metabolism and haematological parameters after the initial hypoferremic response at 6-24 
hours post-delivery. This was achieved by the collection of a second venous sample from all 
full-term, normal birth weight newborns later in the first week of life. This resulted in 224 of 
the 278 full-term, normal birthweight neonates (FTB/NBW) providing a cord blood sample, 
and two peripheral venous blood samples at 6-24h and 24-192h of age. This publication 
(Chapter 6) highlights that levels of hepcidin quickly return to previous mean cord-like levels 
at 24-48 hrs, and then subsequently increase to very high levels at 80-136hrs post-delivery. 
Serum iron and TSAT levels also increased during this period. This observation suggests 
that the early postnatal hypoferremia is a fast-acting, yet short-lived, adaptation that is 
followed by a period of hepcidin desensitisation or leaky intracellular iron sequestration. We 
suggest that this is the explanation for increased iron efflux into the serum, even in the 
presence of high serum hepcidin concentrations. This increase in circulating serum iron 
could be heightened by the reduced need for iron for erythropoiesis over the same period. A 
marker of this is the decreasing sTfR level over the first week of life. Weaknesses in 
research directed toward this objective include the lack of data relating to the quality of 
breastfeeding during the first week of life. This would have allowed us to control the analysis 
of V2-4 samples for the effect of enteric iron absorption from breast milk or formula (though 
both are likely to contribute small amounts of iron).13 Similarly, the measurement of maternal 
iron markers before (i.e. midgestation and parturition) and after delivery could have provided 
greater detail into the role of iron endowment between the mother and fetus and also the 
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part that labour-induced inflammation plays in the recorded hypoferremic response. Though 
maternal iron markers have been analysed in relation to cord iron markers,14,15 we believe 
no analysis has been completed concerning the change in serum iron and TSAT we have 
recorded. This analysis could provide further evidence as to what is triggering this 
phenomenon. The measurement of pro-inflammatory cytokines (e.g. IL-6 and IL-22) and 
growth factors (e.g. IGF-1, HGF, EGF and PDGF-BB) in all samples would have provided 
greater insight into the regulation of neonatal iron homeostasis.  
 
7.2 NeoInnate Study: Study Design, Issues Faced and Learning Points 
for the Future  
 
The NeoInnate study was a challenging study to design, due to its time-sensitivity, 
complicated exclusion criteria and complex ethical issues.  
 
The review of the previous literature conducted at the start of the NeoInnate Study provided 
insight into the importance of collecting accurate delivery and labour data. We were 
particularly concerned that the inflammation believed to be responsible for the hypoferremic 
response in the neonate, may be confounded by pro- or anti-inflammatory stimuli received 
during labour and delivery. This included the effect of differing medication prescribed (i.e. 
gentamycin during labour),16 and delivery methods.17 As a consequence of this review, the 
subsequent study collected a detailed assessment of the labour process for each delivery. 
This study design also ensured that all recruited neonates had a cord blood sample 
collected using a standardised protocol, as previous studies have shown differing delays 
between cord-cutting can significantly affect early neonatal iron metabolism.18 Importantly, it 




A fundamental aspect of the study design was the allocation of all neonates to four 
independent groups (e.g. FTB+NBW, FTB+LBW, PTB+NBW, PTB+LBW). This has allowed 
for the analysis of the independent effects of both birthweight and prematurity on neonatal 
hypoferremia. However, we did struggle to recruit full-term, low birthweight neonates during 
the study recruitment period. As birthweight is a predictor of prematurity, I believe this could 
be due to the research clinician, who conducted the New Ballard Score (NBS) of each 
neonate, not being blinded to the birthweight before NBS completion. Thus, there could be a 
degree of misclassification. The study research clinician was however, well trained in NBS 
and was deliberately unaware of specific group recruitment rates. 
 
An important ethical issue facing the design of this study was the earliest time point in which 
a neonate could be bled post-delivery. Our team and hospital staff concluded that six hours 
would be the ideal time. This aspect of study design allowed the mother to recover physically 
and psychologically before providing full consent to the recruitment of the neonate and 
collection of the V1 sample. It also allowed clinical staff to assess if the mother or newborn 
were experiencing any medical complications. This led to the assessment of gestational age 
and anthropometrics at 6-24 hours post-delivery being a less stressful experience for the 
neonate, after being warmed and exposed to early breastfeeding. 
 
Another of the most ethically complex study design aspects was the size of the blood 
volume collected from all recruited neonates, especially those born preterm and low 
birthweight. A sample volume of 3.5 ml of blood was required from each venous bleed of a 
full-term, normal birth weight neonate. This was calculated from the data produced by Howie 
et al.,19 which suggest to the Gambia Government/MRC Joint Ethics Committee to allow a 
single blood draw of 2.4% total blood volume. With regards to maximum cumulative draw 
volume allowed, Howie et al., 2011 referenced multiple institutions that allowed >10ml of 
whole blood from a 3 kg birth weight neonate to be taken for research purposes throughout 
one to two months. These volumes were deemed to provided 'minimal risk' to the neonate. 
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Regarding preterm neonates, venous bleed volumes used in prior studies varied according 
to their weight, with an average of ~2ml per venous bleed. In our study, each blood draw 
tube was marked with a specific volume allowed from each neonate. As another layer of 
protection, all neonates received a complete review of systems by a research clinician or 
senior study nurse before any bleed was conducted. This ensured that the subject's health 
was of the highest priority. Furthermore, the study was designed in order to reduce the 
number of bleeds for each neonate. We were aware that repetitive bleeding of healthy 
neonates, would be unpopular with their families and expose each neonate to repetitive 
episodes of stress. As a result, we allocated each full-term, normal birthweight individual into 
a specific study group, in order to repetitively measure iron and inflammation markers at 
specific ranges of time over the first week of life using a maximum of two bleeds per baby. 
 
Bleeding neonates is notoriously difficult. At the start of the study, the study team faced the 
complex challenge of completing 750 neonatal peripheral bleeds. On bleeding the first study 
participant, we became aware that the long tubing section of the vacutainer set-up was 
resulting in the loss of the pressure required to complete a successful blood draw. An 
extended study meeting successfully overcame this hurdle, where we were able to safely 
adapt the blood draw equipment, while still maintaining its sterility. However, in some cases, 
the blood volume collected was not high enough to conduct the ex vivo bacterial growth 
assay on some serum samples. This was primarily due to the difficulty of bleeding neonates, 
resulting in clotting taking place before the required sample volumes could be reached. 
Efforts were made to miniaturise the assay; however, the reduced assay-well volume 
caused a breakdown in the relationship previously documented between bacterial growth 
and TSAT. Sadly, as a result, one of the study objectives set out in the protocol (e.g. ex vivo 
bacterial growth assay) could not be achieved.  
 
Before the study initiation, our study team was informed that bleeding neonates in the 
community would be an impossible challenge, primarily due to the interference from 
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members of the family on the bleeding procedure. Experienced studies teams had 
suggested that the study design should ask the mother and their newborn to return to the 
maternity ward during this period. However, we were aware of experiences in other 
communities in The Gambia, where many neonates would have been lost to follow up if this 
design was adopted. With no other option available to acquire samples from discharged 
neonates between 24-192 hour post-delivery, we recruited an immensely experienced 
neonatal nurse with good local connections to conduct all community bleeds. We also 
worked as a study team to deliver safe and effective study protocols using the knowledge of 
local practices and cultural structures to drive this protocol. This resulted in 224/278 
community bleeds being completed.  
 
The NeoInnate Study suffered toward the end of the study from a lack of funds. This was 
primarily due to the issues relating to delays in the study initiation and the recruitment rate. 
The lack of funds resulted in our study being unable to examine how hypoferremia relates to 
maternal iron and inflammation makers (before, during and after labour). Similarly, this also 
led to the inability to measure IL-6, IL-22, haptoglobin (by ELISA assay) and hemopexin in 
all blood samples. This analysis would have informed us as to the role that inflammation and 
other chaperone molecules play in the reported hypoferremic response. The use of the 
Cobas 400+ biochemical analyser to detect haptoglobin concentrations in cord blood in this 
study, has also resulted in us not being to detect mother-neonate pairs that have 
experienced intrauterine infections as previously stated in Buhimschi et al.20 If we had been 







7.3 Recommendations For Future Research 
 
7.3.1 Role of the Placenta in Maternal-Fetal Iron Transfer 
 
As detailed in Chapter 3, sufficient iron stores are critical for a healthy pregnancy. In the 
placental villi, syncytiotrophoblasts uptake transferrin-bound iron from the maternal 
circulation via transferrin receptor 1 (TFR1) (Chapter 3 - Figure 1).21–23 TFR1 releases iron 
into an acidified clathrin-coated vesicle, where it is then transported into the cytoplasm of the 
syncytiotrophoblast by DMT-1,23 Zrt/Irt-like protein ZIP824 and ZIP14,25 collectively. 
Ferroportin, ceruloplasmin, hephaestin, and zyklopen all assist with the transportation of iron 
into the fetal circulation, where it binds to fetal transferrin.22,26–28 However, the regulation of 
maternal-placental-fetal iron transport mechanisms remains unclear. A recent publication by 
Sangkhae et al. provides additional details on the effects of iron-deficient, iron-replete and 
iron-overload conditions on the regulation of this process in mice, humans and human 
trophoblasts.29 
 
As seen in previous publications,30–32 Sangkhae et al. detected maternal hepcidin 
suppression during the pregnancy to ensure increased dietary iron intake and a raised 
systemic serum iron concentration.29 The suppression of hepcidin at this time is believed to 
be regulated by several factors including erythropoiesis in the mother or fetus,32 oestrogen,33 
and progesterone receptor membrane component-1.34 Conflicting evidence now exists as to 
whether pregnancy-induced plasma dilution may also play a role.29,35 
 
In instances of iron-overload, both maternal and fetal hepcidin is produced at higher 
quantities in order to restrict further dietary uptake and protect the fetus from oxidative 
damage via placental iron transfer.29,35,36 However, questions remain as to whether fetal iron 
endowment is regulated by fetal or placental hepcidin in iron-replate or iron-deficient 
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conditions. Previous publications have remarked that in a state of maternal iron deficiency, 
the fetus could be regarded as the "perfect parasite" as human fetal iron endowment is 
maintained regardless of maternal iron status.21 However, Sangkhae et al. recently recorded 
conflicting evidence in murine models.29 Instead, iron transfer to the murine fetus under iron-
deficient conditions was restricted. Decreased expression of ferroportin on the fetal side of 
the placenta is understood to be the cause. Interestingly, also observed was increased 
TFR1 expression on the maternal-facing membrane of the placental syncytiotrophoblasts. 
This suggests that during maternal iron deficiency, iron is held in the placenta to ensure that 
placental metabolic homeostasis is maintained. Sufficient iron concentration of the placenta 
is believed to ensure oxidative phosphorylation can continue, ensuring adequate levels of 
ATP are still produced.29 This allows the continuation of placental protein synthesis and 
other critical transfer functions, protecting against placental dysfunction. 
 
Nonetheless, these findings were only observed in the murine and in vivo human trophoblast 
models.29  When similar analyses were conducted on human pregnancies, expression of 
TFR1 protein increased, yet ferroportin expression did not change. Sangkhae et al. have 
proposed that this may be the case due to the scarcity of severely iron deficient human 
mothers in their study setting.29 Further research is now required to fully understand these 
interspecies differences, and what role placental iron regulation has on the hypoferremic 
response discussed here.  
 
7.3.2 Potential Triggers of Early Postnatal Hypoferremia 
 
7.3.2.1 IL-6 and the JAK/STAT3 Pathway 
 
The initiation of hepcidin synthesis via the actions of IL-6/JAK/STAT3 pathway has been 
extensively characterised.37 IL-6 begins by binding to its receptor activating the formation of 
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a hexameric plasma-membrane signalling assembly. This is formed of IL-6, IL-6 receptor, 
and a gp130 subunit.38 Activation of JAK2 then follows, enabling the phosphorylation of its 
tyrosine residues and those of subsequent downstream STAT molecules. The 
phosphorylated STAT molecules then dimerise, translocate to the nucleus, and target the 
transcription promoters of the HAMP gene.39 Transcription of the HAMP gene results in the 
synthesis of new hepcidin proteins, which are later released into the circulation. Hepcidin 
then binds a single ferroportin protein on the plasma membrane of enterocytes, 
macrophages, and hepatocytes. This causes the endocytosis and co-degradation of both 
bound proteins in the lysosome.40 Hence, enteric absorption of dietary iron is reduced, and 
sequestration of iron in macrophages causes a reduction in serum iron concentration.3 
 
Our study has now confirmed that hepcidin-mediated neonatal hypoferremia exists in all 
healthy neonates (Chapter 5). Potential triggers for this mechanism remain unclear, as IL-6 
was not analysed. However, previous research has found that inflammation (signalled by IL-
6 and other cytokines) is involved in the onset and progression of human labour at term in 
the mother,41–48 in the absence of intrauterine infection. Similarly, inflammatory markers are 
also detected in the cord blood of the neonate.49 Previous authors have suggested that the 
instigating stimuli for this could involve the endocrine events of labour,47,48,50 mechanical 
distension of the membranes and cervix (smooth muscle),41,50–53, placental hypoxia and/or 
hypo-perfusion,50,54 fetal hypoxia-acidemia,55 maternal pain56 or exposure to infective 
agents.46,48,50,57 We suggest that due to the impermeability of the placenta to IL-6,49,58 
independent stimuli of the increased inflammatory response are taking place in the mother 
and newborn. This theory is supported by evidence that there are significantly lower levels of 
IL-6 in the newborn than the mother.59 We propose that this increase in IL-6 leads to the 
previously reported large influx of immune cells (predominantly neutrophils) into the cervix, 
decidua, myometrium, chorioamnionic membranes and amniotic fluid.47,60 We speculate that 
a similar process may occur in the neonate, with the activation of circulating neutrophils 
around the body at delivery. Labour is associated with neutrophilia in the early neonatal 
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period.61 Both neonatal neutrophil activation and antigen expression correlate with the length 
of labour.62 Decreased proportions of T cells expressing CD2, CD3 and CD4, as well as 
increased expression of CD16 and CD56 on natural killer cells from vaginally-delivered 
newborns have been reported.63 This is in contrast to those born by elective caesarean 
section. Interestingly, another publication has documented significantly higher cord hepcidin 
levels in neonates born via standard vaginal delivery and second stage caesarean section 
than those born via elective caesarean section.64 This evidence suggests that stimuli on the 
neonate that cause the proposed inflammation-induced hypoferremia may occur during the 
process of labour, rather than delivery. This is reinforced by a study by Weinschenk et al.,62 
that did not observe a difference in the increased neonatal neutrophil activation between 
modes of delivery after the initiation of labour. We propose that the stimuli during labour 
could be mechanical trauma caused by contractions in the latent and active phases of 
labour, or the rupture of membranes leading to the exposure of the neonate to the uterine 
microbiome.65 Both proposed stimuli would increase in severity as the length of labour 
progressed. In this study, we have analysed the time between arrival to the maternity ward 
and time of delivery, in relation to hypoferremic response. However, as many factors are 
responsible for the time of arrival at the hospital before delivery, especially in LMICs with the 
lack of transport infrastructure and financial constraints,66 it is no surprise that no significant 
effect was observed. Future studies measuring the length of labour accurately in relation to 
hypoferremia could clarify this. As to whether this effect is a deliberate action to generate the 
hypoferremic response is unknown. Previous authors have suggested this pro-inflammatory 
response may also assist in organ system transition at birth (e.g. the lungs and cytokine-
induced synthesis of surfactant proteins)67 and/or the activation of the immune system in the 
newborn.68  
 
Since hepcidin and IL-6 are not thought to cross the placenta,58,69 we have proposed that 
this labour-induced inflammatory response leads to the increase in hepcidin expression in 
the newborn and hence to the systemic sequestration of iron during and immediately after 
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labour/delivery has taken place. Further studies are required to confirm this, with a specific 
focus on the differences in iron and inflammation markers in the newborn over the first 48 
hours of life between vaginally, elective caesarean and emergency caesarean section 
deliveries. However, this hypothetical study would be challenging due to the complex 
confounding clinical reasons for elective and emergency caesarean section delivery.  
 
7.3.2.2 Additional Pro-Inflammatory Regulators of Hepcidin Expression 
 
Additional research is also required to understand the role of other pro-inflammatory 
regulators of hepcidin expression have on early postnatal iron homeostasis.  
 
IL-22 is a member of the IL-10–related family of cytokines, predominately expressed by 
lymphocytes.70 The binding of IL-22 to its receptor leads to activation of Jak1 and Tyk2, 
causing the phosphorylation of tyrosine molecules on STAT1, STAT3, STAT5.71 The 
subsequent transcription of the HAMP gene results in the synthesis of hepcidin and the 
reduction of circulating serum iron levels. The distinct familial differences between IL-22 and 
IL-6, lead the IL-22 pathway to work independently of IL-6-mediated hepcidin expression.72 
IL-22 also mediates the production of other antimicrobial proteins and acute-phase reactant 
proteins in the liver. 73 These include the chaperone protein responsible for restricting 
bacterial uptake of human haemoglobin in the blood, haptoglobin. This finding, besides the 
weak activation of IL-22 from exposure to bacterial LPS,74 makes additional research into 
this cytokine pathway necessary. This research would provide further insight as to whether 
contact with microorganisms during the delivery process is the exclusive trigger of neonatal 
hypoferremia.  
 
Similar to IL-22, IL-1 is a pro-inflammatory molecule that can work independently of the IL-
6/JAK/STAT3 signalling pathway to induce hepcidin expression.75 The synthesis of hepcidin 
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in hepatocytes in both wild-type and IL-6 pathway knockout mice supports this observation.75 
Nonetheless, the action of IL-1 is suggested to more commonly be additive to the 
mechanism of IL-6. STAT3 and NF-κB pathway crossover is believed to be the cause.76,77 
This is supported by murine models showing increased hepcidin synthesis in response to 
LPS inoculation, compared to those that received IL-6 treatment.78 IL-1 binds to its receptor, 
IL-1R, causing the phosphorylation of the cellular protein, IKK. Phosphorylation and 
degradation of pathway inhibitor, IkB then follows, resulting in the activation of NF-κB. NF-κB 
promotes the expression of C/EBPδ, which then binds to P-Smad and promotes the 
transcription of the HAMP gene.78 IL-1Ra is a structurally similar molecule to IL-1; however, 
it binds to IL-1 receptor in a competitive nature and does not induce any intracellular 
response79. At birth, levels of IL-1Ra increase for the first days of life.80 This suggests that IL-
1-mediated inflammation and subsequent hepcidin synthesis may be unfavourable to early 
neonatal life, which is in conflict with the conclusions of our study (Chapters 5 and 6). An 
analysis of IL-1 and its relationship with the mechanisms of neonatal hypoferremia is 
required. 
 
Pro-inflammatory regulators of hepcidin expression also include activin b81, leptin,82 
oncostatin M83,84 and leukaemia inhibitory factor (LIF).84 However, the strength of their 
independent hypoferremia-inducing qualities in the setting of bacterial infection in the human 
host remain unknown. 
 
7.3.2.3 Hepcidin-Independent Mechanisms of Hypoferremia 
 
Ferroportin (FPN1) is the only cell-surface transmembrane protein known to export ferrous 
iron out of mammalian cells.85 Subsequently, FPN1 expression levels, play a key role in the 
control of cellular and systemic iron concentrations. Duodenal enterocytes, placental 
syncytiotrophoblasts, hepatocytes and reticuloendothelial macrophages are the predominant 
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cell types that express FPN1.86 As seen in Figure 1.7, erythropoiesis, hypoxia, iron status, 
and inflammation are all reported to alter the expression levels of FPN1.85 This is primarily 
controlled via the action of its master regulator, hepcidin.37 Inhibition of ferroportin begins by 
hepcidin binding, inducing endocytosis and co-degradation of both molecules.87 This results 
in a reduction in iron export and an increase in pooled intracellular iron.  
 
Nonetheless, FPN1 can also be regulated via hepcidin-independent mechanisms leading to 
a reduction in systemic serum iron concentration.88 Whether hepcidin-independent 
mechanisms contribute to the production of early neonatal hypoferremia (via the direct 
suppressive effects of inflammation on FPN1) remains undetermined. 
  
One such potential hepcidin-independent mechanism is the activation of TLR2/6, leading to 
the direct downregulation of FPN1 mRNA synthesis.89,90 This results in intracellular iron 
sequestration and systemic hypoferremia. Previous authors speculate that TLR2 and TLR6 
do not activate hepcidin upregulation, offering redundancy to the mechanism of 
hypoferremia, enabling a faster, broader and more effective immune response.89,90 These 
same studies have shown that bacterial lipopeptides (e.g. Mycoplasma-derived FSL1 and 
bacterial LPS) that target TLR2 and TLR6 promptly reduce ferroportin mRNA production for 
over three hours.89,90 This is supported by TLR2-knockout models exhibiting no effect on 
ferroportin expression in response to FSL1 inoculation.89 Further analyses are now required 
to understand if whole pathogens can trigger a similar response. This information would 
strengthen TLR2/6 as essential mediators of iron redistribution and may offer an alternative, 
more direct drug target compared to hepcidin-mediated pathways.  
  
Tumour necrosis factor-α (TNF-α) is a cytokine produced by many cell types, including the 
primary producers: macrophages, Langerhans cells, and Kupffer cells.91 Following synthesis 
and release, TNF-α binds to either tumour necrosis factor receptor 1 or 2 (TNFR1 and 
TNFR2) resulting in the initiation of mitogen-activated protein kinase (MAP kinase), caspase, 
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and NF-κB pathways (amongst others).92 In 1989, Alvarez-Hernández et al. proposed that 
TNF-α causes systemic hypoferremia within the first six hours of inoculation, while total iron-
binding capacity remains constant.93 Laftah et al. uncovered a similar reduction in serum iron 
recorded in the first 3 hours after intraperitoneal inoculation of TNF-α.94 These findings are 
supported by evidence that TNF-α mediated hypoferremia is initiated within the first eight 
hours after caecal ligation and puncture in wild-type murine models.95 No such response 
was detected in TNF-α deficient model. As no change in serum hepcidin concentration was 
linked to any of these responses,93–95 studies suggest hepcidin-independent mechanisms 
regulate this method of protection, resulting in the downregulation in FPN1 transcription. 
TNF-α mediated hypoferremia may regulate a proportion of the early neonatal hypoferremia 
we have uncovered; however, additional research is needed to understand its role. 
  
7.3.3 Harnessing Iron to Fight Infections  
 
As previous research by our group has shown, limited iron concentrations reduce bacterial 
growth rates of sepsis-causing pathogens in human serum (Annex 1.16).4 The NeoInnate 
Study discussed here has also shown that iron-sequestration is a potentially fundamental 
aspect of the early life innate immune response. In light of the innate and adaptive 
immunological differences between preterm, full-term and low birthweight newborns,96 the 
observation that neonatal hypoferremia is maintained in the population, regardless of 
gestational age or weight, suggests that it offers a significant benefit to the newborn. As a 
result, it is possible to consider that the limitation of iron sources to invading organisms in a 
multitude of other infection types could offer a partial (in combination with antibiotics) or 
complete (with the use of the host's immune system) treatment option. We hypothesise that 
limiting the growth and replication rates of invading organisms by providing a transient 
bacteriostatic mechanism of protection, would allow the host's neutrophils to engulf and 
destroy bacterial cells. We also propose that reduced replication rates of the bacterial 
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pathogen may allow for a reduction in the recommended dose, frequency and/or duration of 
current antibiotic treatments. We wonder whether combining iron-sequestration plus 
antibiotics may allow for toxic drug regimens and classes to be made available to individuals 
with a decreased maximum tolerable dose. This is particularly the case with neonates, as 
they possess unique physiological processes compared to adults leading to differences in 
drug absorption, distribution, metabolism, and elimination.97 
 
An added benefit of this proposed treatment method would be that it is defined as 
combination therapy. Evidence suggests that antibiotic combination therapies already offer 
an increased benefit against blood infections, including those caused by carbapenem-
resistant K. pneumonia (i.e. a common neonatal pathogen).98 We speculate that similar 
observations may be seen by inducing transient hypoferremia, without causing long term 
adverse effects to iron homeostasis (Chapter 6). This proposed treatment strategy may 
allow for the use of older disused drugs to be redeployed, as observed with other drug 
combination therapies.99 Furthermore, the use of antibiotic combination therapy has been 
found to reduce the spread of antimicrobial resistance.100 This observation, along with most 
microbial pathogens requiring iron for growth and virulence, and bacterial iron acquisition 
mechanisms being genetically coded by pathogenic housekeeping genes, suggests that 
hypoferremia-antibiotic therapies may offer a reduction in the creation of new antimicrobial 
resistance mechanisms. Evidence of the effect that iron chelation therapy could offer in 
combination with an antibiotic can already be seen in the study conducted by Coraca-Huber 
et al.101 This study showed that this form of treatment significantly reduced the formation of 
staphylococcal biofilms during infections. It is worth noting that hepcidin has also been 
previously described to have direct bactericidal effects on bacterial pathogens.102  
 
The sequestration of iron and its moieties by native chaperone molecules in order to 
produce a protective response against invading organisms could also offer a new and novel 
treatment option. A study that supports this is that of Remy et al.,103 the main finding of 
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which is the positive effect haptoglobin treatment has on reducing canine pneumonia and 
sepsis in animal models. Haptoglobin works by binding to cell-free haemoglobin in the blood 
and other body fluids, reducing its availability as an iron source to many bacterial 
pathogens.104 Cell-free haemoglobin is regularly elevated during sepsis, with the level of 
increase correlating with a higher rate of mortality.105 Remy et al. have shown that in a 
canine S. aureus pneumonia model with septic shock, that human haptoglobin concentrate 
infusions lead to the binding with canine cell-free haemoglobin. This results in its clearance 
and lowering of the overall level of iron within the circulation. The resulting effect is an 
increase in survival in the canine model. The theory behind this is an increase in the 
internalisation of haptoglobin-haemoglobin complexes, thus limiting access to iron for 
extracellular organisms. This suggests that haptoglobin therapy can enhance innate host 
immunity, supporting the notion it offers a novel approach to treat systemic bacterial 
infections. Further clinical trials in humans are required to confirm this. This use of 
haptoglobin is particularly relevant to neonates due to enhanced erythrocyte turnover in 
early postnatal life leading to the release of haemoglobin, along with the suggestion that 
haptoglobin synthesis is increased in response to intrauterine infection.20 This supports the 
hypothesis it may be an effective method of innate protection.  
 
Another treatment option in the host-pathogen battle for iron is the use of lipocalin-2. 
Lipocalin-2, also known as neutrophil gelatinase-associated lipocalin (NGAL), is released by 
several cell types (e.g. hepatocytes, pneumocytes, renal epithelial cells, and vascular 
smooth muscle cells) as a result of inflammation, ischemia and infection.106 Recent research 
has shown that lipocalin-2 is produced in response to the infection of macrophages by 
intracellular bacterial pathogens, such as Brucella abortus.107 Lipocalin-2 it thought to 
prevent iron uptake by B. abortus by two mechanisms: 1) by stripping iron from iron-laden 
siderophores and 2) intracellular levels of lipocalin-2 in macrophages inhibit further iron 
uptake by macrophages during infection. This results in the starvation of the pathogen of an 
iron source, which is critical for growth, virulence and replication. This suggests that 
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synthetically increasing the concentration of lipocalin-2 in the host's extracellular 
environment could also protect individuals against extracellular pathogens which commonly 
cause sepsis.108  
 
Lactoferrin is a glycoprotein belonging to the innate immune system, found in saliva, blood, 
tears and human milk. Lactoferrin's central role is to bind to iron, with additional 
immunostimulatory, antimicrobial and anti-inflammatory roles.109 Due to the structural 
similarities between bovine and human lactoferrin, the biological function is similar.110 A 
Cochrane review of six studies detailing its use in preterm neonates has shown that oral 
supplementation of lactoferrin with or without probiotics reduced the risk of late-onset 
necrotizing enterocolitis, bacterial and fungal sepsis.111 Equally, the use of recombinant 
lactoferrin (i.e. Talactoferrin) offers some promise as it does not require pasteurisation, 
increasing its biological activity.112 Interestingly, concentrations of lactoferrin are high in 
colostrum,113 again suggesting that iron-restriction is an essential aspect of neonatal innate 
immune defence in the gut.114 How this might be linked to circulating levels of neonatal iron 
remains unclear. 
 
Lastly, research is also progressing toward harnessing the use of the bacterium's iron 
uptake machinery in order to combat the infections it causes. This comes in the form of the 
manipulation of the action of bacterial siderophores and the bacterial influx transport 
channels. Small-molecule siderophores are produced and released by nearly all bacterial 
species.115 As seen in Figure 1.6 and Table 1.2, the redundancy of these iron-uptake 
systems allows bacteria to bind and consume different forms of iron. This function of multiple 
ligand targets by a plethora of siderophore types is predominately due to their differing 
chemical structures of the iron-chelating chemical groups (i.e. hydroxamate, α-hydroxyl-
carboxylate and catechol).115 The ability to synthesise these molecules is often transferred 
between bacterial isolates by mobile genetic elements.116 Recently, developments have 
been made to exploit these iron-siderophore uptake systems in common bacterial pathogens 
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by using siderophores conjugated to antibiotics. This new form of antibiotics has been 
focused on gram-negative bacteria due to the threat they pose with regards to antimicrobial 
resistance and their vastly characterised bacterial iron uptake mechanisms.117 One drug 
discovery candidate that is showing early promise is cefiderocol. The new expedited 
development program of cefiderocol has led to a recent international, double-blind, 
randomised phase III clinical trial of the efficacy and safety of cefiderocol in patients with 
nosocomial pneumonia.118 These results highlight that cefiderocol met the non-inferiority 
comparison to high dose meropenem in all-cause mortality at 14 days after initiation of 
treatment. Cefiderocol, a siderophore-cephalosporin drug, which uses the bacterium's active 
transport machinery in a "Trojan horse" style to gain entry past the cell wall. As previously 
stated, cefiderocol is now of particular use against carbapenem-resistant gram-negative 
pathogens, including those expressing New Delhi metallo-β-lactamase-mediated 
carbapenem resistance, as seen in cases of neonatal sepsis (Section 1.9.7). Additionally, in 
vitro activity against isolates from the global surveillance studies, SIDERO-WT and SIDERO-
CR have shown that cefiderocol is highly effective against current strains of P. aeruginosa, 
A. baumannii, B. cepacia, B. pseudomallei and S. maltophilia.119,120 Several of these have 
recently been noted in cases of invasive bacterial infection in neonates in sub-Saharan 
Africa.121 
 
7.3.4 Hepcidin Agonists as Hypoferremic Therapies  
 
Here, we speculate that the use of hepcidin agonists or inducers may be the hypoferremic 
therapy that is required to produce this iron-restricted environment in the host. There are 
several therapeutic inducers of hepcidin expression; these include BMP6, TMPRSS6-
silencing oligonucleotides and a number of small molecules.122 One of the inducers that has 
progressed in its development is IONIS-TMPRSS6-LRX (Ionis Pharmaceuticals, Inc.).123 
This molecule is in phase 2 clinical trials and induces hepcidin expression by silencing 
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Tmprss6 mRNA by using lipid nanoparticles linked to small interfering RNAs (siRNAs) 
(ClinicalTrials.gov Identifier: NCT04059406).  
 
A hepcidin agonist of note is minihepcidin PR73, which works by inhibiting the function of the 
transmembrane protein, ferroportin. PR73 has been shown to have possible protective 
effects in animal models against systemic bacterial infection. Researchers have uncovered 
that animal models deficient in hepcidin, when given PR73, are protected against 
siderophilic bacteria such as Vibrio vulnificus1 and Yersinia enterocolitica.124 Additionally, 
PR73 is observed to be protective against non-siderophilic bacteria such as Klebsiella 
pneumoniae or Escherichia coli.125,126 This is due to the PR73 mechanism of action leading 
to a systemic hypoferremic state in the model, repressing bacterial growth, and 
subsequently reducing the likelihood of mortality. These findings are especially remarkable 
as a similar deficiency of hepcidin, seen in hereditary hemochromatosis, leads to increased 
mortality when infected with siderophilic bacteria.127,128 This suggests that these 
observations may be relatable to humans. Currently, all of the research relating to the use of 
PR73 is in the preclinical phase.122  
 
Two hepcidin agonists that have reached clinical trials are LJPC-401 (La Jolla 
Pharmaceutical Company) and PTG-300 (Protagonist Therapeutics Inc.). PTG-300 is now in 
phase II and has previously been shown to reduce serum iron concentration in cynomolgus 
monkeys.129 During phase I trials, the drug was shown to be tolerated by study participants 
and reduced their serum iron concentration in a dose-dependent manner. Hypoferremic 
responses were maintained for almost 144 hours.130 The LJPC-401 phase 1 trial reports 
similar findings with reduced serum iron concentration of the blood in a dose-dependent 





Though the clinical trials referenced suggest that induced hepcidin levels produce a fast-
acting and short-lived response, it is still unclear what effect hormonal augmentation would 
have in the sick neonate in the immediate period after treatment, or the long-term effects 
(i.e. erythropoiesis, microbiome and iron deficiency). Further research is required in humans 
to assess how we might produce a balanced therapy, focused on 1) maintaining iron-
sequestration for a required time allowing for iron starvation in invading organisms, and 2) to 
not produce significant adverse side effects to human iron homeostasis. Realistically it will 




Assessing our data on iron and inflammation markers in full-term, normal birthweight 
neonates over the first week of life (Chapter 6) leads us to question the validity of the 
proposed methods of treatment for severe bacterial infections in newborns seen in Sections 
7.3.3 and 7.3.4. The hepcidin-induced hypoferremia observed in the NeoInnate Study was a 
robust and fast-acting response to early postpartum life. Nevertheless, it was not maintained 
for longer than 72 hours of life in most individuals. This is even the case despite hepcidin 
levels remaining higher than adult levels in the majority of the full term, normal birthweight 
study participants over the first week of life. From our data, we suggest that hepcidin-
resistance may potentially halt the continuation of this protective mechanism after 48 hours 
post-delivery. This is observed in Chapter 6 (Figures 3 and 4) were hepcidin levels are 
maintained at high levels at 48 hours onwards, with serum iron and TSAT levels increasing 
over the same period. We hypothesise that this is due to the effect of high dose excess 
hepcidin, causing occlusion rather than degradation of ferroportin on the membrane of 
neonatal macrophages. Previous research has shown that excess hepcidin can 
preferentially cause occlusion, leading to the intermittent binding and releasing of hepcidin to 
the central cavity of individual ferroportin molecules.132 We propose that this may allow for 
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the steady and slow increase of serum iron concentration over the following days. This 
finding is noteworthy, as dietary iron absorption during this period is very low.133 Therefore, 
any increase in serum iron is unlikely to be caused due to enterocyte iron efflux.  
 
A previous study in suckling 15-day old mouse models has found a potentially related 
discovery in the context of early life hepcidin resistance.134 Frazer et al. aimed to elicit if, as 
previous studies had suggested, iron absorption in suckling mammals was resilient to stimuli 
that ordinarily decreased absorption in adults. Interestingly, this study uncovered that 
enterocyte ferroportin was hyporesponsive to the effect of circulating serum hepcidin during 
the suckling period. Immunofluorescence assays suggested that this finding was not due to 
changes in ferroportin localisation, making it inaccessible to the actions of hepcidin, as 
previously reported by Theurl et al. concerning hepcidin resistance in the retinal pigment 
epithelium.135 Similarly, this could be the possible cause of hepcidin-resistance in our study, 
due to impermeable physical barriers between molecules of ferroportin and hepcidin in a 
subset of cell types responsible for iron release at the latter part of the first week of life. On 
balance, this is unlikely to be the case as we believe circulating and splenic macrophages 
are the target cells for iron sequestration during neonatal hypoferremia.  
 
Furthermore, Frazer et al. found that decreases in serum iron levels occurred after hepcidin 
stimulation, suggesting that hepcidin activity was present in some cell types.134 However, 
this was not the case concerning enterocytes. After further laboratory analysis, ferroportin in 
these murine enterocytes was shown to be smaller than standard adult ferroportin 
molecules. The authors suggested that this may be due to early life murine ferroportin being 
spliced or glycosylated differently. This evidence suggests that in murine models, age-
specific modification of ferroportin is found in the transmembrane of enterocytes. Further 
research is required to assess if that is the case with respect to human neonatal 




Similar to our reports, Frazer et al. note that hepcidin-resistance could be the result of high 
hepcidin excess favouring the occlusion of ferroportin rather than its degradation. As seen in 
Aschemeyer et al. hepcidin is thought to bind to the central metal-binding cavity, leading to 
the hinderance of the conformational changes required for iron efflux.132 Additionally, we 
submit that with the hepcidin levels in excess, intermittent binding and releasing of hepcidin 
to the central cavity of individual ferroportin molecules may allow for slow rates of iron efflux 
into the circulation (Chapter 6). This leads us to consider that there could be scope for 
research into the optimum dose of minihepcidin required to swing the balance back into the 
favour of degradation rather than occlusion, should our hypothesis be found to be correct. 
Equally, it would also be interesting to access the endocytic machinery of neonatal 
macrophages to uncover if deficiencies in degradation mechanisms may be the cause of 
these proposed reasons for hepcidin-resistance.136,137 
 
Why hepcidin-resistance occurs in young mice and humans remains unclear. However, it 
could be that both the hyporesponsiveness of murine enterocytes in 15-day mice pups and 
the hepcidin-resistance uncovered in our study in human neonates is a semi-protective 
mechanism against the iron deficiency in early life, which is particularly common.138 It may 
be possible that human neonates are trying to strike a balance between inducing protective 
hypoferremia at the point it is most required to protect against infection (i.e. 24 hours of life) 
and ensuring serum iron is still available to the tissues responsible for erythropoiesis and 
growth.  
 
Further research is required to determine whether neonatal ferroportin is differentially spliced 
or glycosylated and if so, what cell types this occurs in. It is also crucial that we establish 
whether, like adult ferroportin, the expression of the hypothetical variant form of ferroportin 




Until these questions are answered, it would not be worthwhile supporting the use of 




The research of this thesis has contributed three key components to our present 
understanding of neonatal iron homeostasis. Firstly, it has evaluated our current knowledge 
of iron and inflammation markers (hepcidin, serum iron and TSAT) in the neonatal period in 
respect to gestational age. This was only possible because of the newly developed methods 
in the standardisation of hepcidin values across multiple retrospective studies in order to 
produce comparisons and averages. Secondly, it has unequivocally refuted our previous 
hypothesis that immature or growth-restricted neonates might have a lesser ability to trigger 
a hypoferremic defence and that this might explain their greater susceptibility to 
septicaemias. Consequently, we have shown that the premature and low birthweight 
neonates all exhibited a profound hypoferremia during the first 24 hours of life, with no 
detectable differences from the full-term, normal birthweight controls. The remarkable 
similarity in the hypoferremic response across all the study groups further accentuates the 
efficiency of the process and supports the likelihood that it occurs by the process of 
evolution. Thirdly, our results suggest that after a fast-acting, short-lived early postnatal 
hypoferremic response at birth, there is a period of hepcidin-resistance, resulting in slow and 
consistent iron efflux into the circulation over the next week of life. Further research is 
required to understand why neonatal iron homeostasis is unresponsive to high serum 
hepcidin concentrations after the hypoferremic period. While contemplating the use of iron-
sequestration as a method of combatting antimicrobial resistant infections seems untimely, 
in light of our results and the threat we all face, the importance of scrutinising hypoferremia 
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Oral iron acutely elevates bacterial 
growth in human serum
James H. Crossͷ, Richard S. Bradburyͷ,͸, Anthony J. Fulfordͷ,͹, Amadou T. Jallowͷ, 







are unclear. We here investigated the ex vivo 
ͺ͸Ȁ 










Iron de!ciency (ID) remains the most pervasive nutritional de!ciency worldwide. "e prevalence of 
ID in mothers and young children frequently exceeds 50% in low-income countries. Insu#cient iron 
impairs growth and cognitive development in childhood1,2.
Low cost iron supplements are e$ective for the treatment of ID and in countries with ID rates of > 40%, 
the World Health Organization recommends universal iron supplementation of pregnant women and 
young children3–5. To overcome perceived limitations in the ability to absorb iron, supplements usually 
employ highly soluble forms of iron (ferrous sulfate or fumarate) given in rather large non-physiological 
bolus doses. "e wisdom of these policies has long been questioned6,7 and has come under serious 
scrutiny starting in 2006 with the premature termination of a large trial in Pemba, Tanzania a%er sig-
ni!cant increases in serious adverse outcomes (hospitalizations and deaths) in young children receiving 
iron-folate supplements were seen8. "e emphasis was originally focused on malaria as the causative 
agent for the increases in morbidity and mortality during iron supplementation9 but subsequent trials 
have described excesses of other infections in groups randomized to iron or multiple micronutrients 
containing iron10–15. "ese !ndings have paralyzed iron supplementation policies.
"e underlying mechanisms and the types of organisms responsible for these clinical and epide-
miological observations remain unclear. Recent !eld studies suggest that oral iron supplementation in 
children increases susceptibility to bacterial infections, particularly diarrhea13,16, alters the gut microbi-
ota16,17, and increases the virulence of many common bacterial enteropathogens18–20.
ͷMRC Keneba, MRC Unit, The Gambia, Atlantic Blvd, Serrekunda, Gambia. ͸School of Medical and Applied 
Sciences, Central Queensland University, North Rockhampton, Queensland, Australia. ͹MRC International Nutrition 












Numerous animal studies over many decades have shown that administration of iron in diverse forms 
accelerates the growth of peritoneally-injected pathogens, causing a septicemia with rapidly fatal out-
comes21,22. We here examine the possibility in humans that a simple oral dose of supplemental iron could 
promote bacterial growth in serum. We used a series of ex vivo bacterial growth assays with sentinel 
organisms that were selected on the basis of their varying modes of pathogenesis and abilities to scavenge 
iron from the host.
Results
Ǥ To determine the e$ects of oral 
iron supplementation on bacterial growth in human serum, we enrolled 48 normal healthy non-ane-
mic male subjects [mean ± SD: Hemoglobin (Hgb) = 14.5 ± 1.13 g/dL; Mean Corpuscular Volume 
(MCV) = 83.8 ± 5.5 fL; Ferritin = 62.8 ± 53.2 ng/mL]. Volunteers donated serum immediately before, and 
then four hours a%er, oral ingestion of 400 mg ferrous sulfate (containing the equivalent of 130 mg of 
elemental iron). Transferrin saturation (TSAT) increased from 42.1% (± 12.5%, SD) to 75.7% (± 18.1%, 
SD) and total serum iron increased from 30.3 &mol/L (± 10.2&mol/L, SD) to 53.0&mol/L (± 15.8&mol/L, 
SD) four hours a%er iron supplementation.
ơex vivo bacterial growth in serum. We next measured 
the growth of the !ve species of sentinel bacteria in the baseline and post-dose sera. To account for the 
between-subject variance in the starting transferrin saturation levels, we used mixed statistical models to 
allow two nested higher levels of variation: patient and bleed (pre- and post-iron supplementation). "is 
enabled us to independently analyze the e$ects of TSAT and iron supplementation.
S. aureus, an organism with a strong preference for heme-derived iron23, behaved di$erently from the 
other four bacteria (Fig.'1A). Iron supplementation had no impact on the general pattern of the growth 
curve (p = 0.3). Both the time to reach peak doubling time (p = 0.21), and the doubling time during the 
exponential growth phase (p = 0.78) were also unchanged by iron supplementation (Table' 1). Growth 
did not correlate with TSAT (p = 0.08) (Table'2).
S. epidermidis (Fig.'1B) demonstrated an initial delay in growth in comparison with the other species. 
Iron supplementation in(uenced the overall pattern of the growth curve (p < 0.0001). Speci!cally, iron 
supplementation reduced the lag phase, the time to reach peak doubling time (p = 0.001), and increased 
the doubling time during the exponential growth phase (p < 0.001) (Table' 1). "e very strong e$ect 
of iron on the overall increase in bacterial growth (X2 = 55 (approximately), p < 0.0001) was equally 
explained using pre/post supplementation as a dichotomized variable or by TSAT (Table'2).
S. Typhimurium (Fig.' 2A) and E. coli (Fig.' 2B) both showed highly signi!cant di$erences in their 
growth curves a%er iron supplementation (p < 0.0001). "e doubling times post-iron supplementation 
were signi!cantly shorter than pre-iron supplementation (p < 0.0001), but time to reach peak doubling 
time was una$ected by treatment (Table' 1). Transferrin saturation had a very strong e$ect on overall 
Figure 1. Growth of sentinel gram-positive bacteria in human serum before and a!er oral iron 
supplementation. S. aureus (A) and S. epidermidis (B) were grown in serum from subjects before (blue) 
and a%er (red) oral iron supplementation with 400 mg ferrous sulfate (containing the equivalent of 130 mg 
of elemental iron). "e thicker central lines represent the !tted curves for an average individual and the 
thinner lines the 95% con!dence intervals for these estimates. "e points show individual values of OD620. 
Curves were derived from mixed e$ects models !tting degree-four orthogonal polynomials in time to 
log(OD620), where OD620 is the mean optical density of the three replicates at time (t).
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growth rates of both S. Typhimurium (X2 = 348, p < 0.0001) and E. coli (X2 = 300, p < 0.0001), com-
parable to, indeed a little larger than, that of iron supplementation in both S. Typhimurium (X2 = 213, 
p < 0.0001) and E. coli (X2 = 221, p < 0.0001). For E. coli, iron supplementation (X2 = 35, p < 0.0001) and 
TSAT (X2 = 69, p < 0.0001) each had signi!cant e$ects on bacterial growth a%er controlling for the other. 
"e same held true for S. Typhimurium growth where both iron supplementation (X2 = 22, p = 0.0004) 
and TSAT (X2 = 105, p < 0.0001) each had signi!cant e$ects on bacterial growth a%er controlling for 
the other (Table'2). "is is likely to be because, in addition to capturing the e$ect of supplementation, 
transferrin saturation also explains di$erences between individuals.
Analysis of Growth S. aureus S. epidermidis E. coli S. Typhimurium Y. enterocolitica
Growth Curve
X2 (5 df) 6.05 65.70 225.00 232.00 117.70
p-value 0.30 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Time to Reach Peak 
Doubling Time (hours)
Mean pre (CI95%) 3.34 (3.21, 3.47) 13.7 (11.8, 15.7) 1.86 (0.50, 3.21) Not Applicable - No MAX
Not Applicable - 
No MAX
Mean post (CI95%) 3.25 (3.12, 3.38) 10.70 (10.0, 11.4) 2.56 (2.32, 2.79)
z ! 1.26 ! 3.24 1.03
p-value 0.21 0.001 0.3
Doubling Time During 
Exponential Phase 
(hours)
Mean pre (CI95%) 1.74 (1.67, 1.81) 4.82 (4.2, 5.5) 2.14 (1.99, 2.29) 2.03 (1.81, 2.26) 4.96 (3.0, 7.0)
Mean post (CI95%) 1.75 (1.68, 1.82) 3.36 (3.0, 3.7) 1.50 (1.44, 1.56) 1.60 (1.37, 1.62) 4.37 (2.8, 6.0)
z 0.28 ! 4.56 ! 8.04 ! 4.34 ! 1.73
p-value 0.78 < 0.001 < 0.0001 < 0.001 0.62
Table 1.  Statistical analysis of ex vivo bacterial growth assays. For each species of bacterium we 
compared its growth pre- and post-iron supplementation by examining di$erences in (1) Growth Curve, i.e. 
general pattern curve of the overall growth trajectories; (2) Time to Reach Peak Doubling Time, i.e. the time 
at which the rate of increase in log(OD620) was at a maximum; and (3) Doubling Time During Exponential 
Growth Phase.
Hypothesis Testing S. aureus S. epidermidis E. coli S. Typhimurium Y. enterocolitica
(1) Iron supp. 
a$ects growth
X2 (5 df) 5.92 55.70 221.00 213.00 108.17
p-value 0.31 <0.0001 <0.0001 <0.0001 <0.0001




X2 (5 df) 8.85 7.53 35.10 22.40 32.71
p-value 0.12 0.18 <0.0001 0.0004 <0.0001
(3) TSAT a$ects 
growth
X2 (5 df) 9.79 55.50 300.00 348.00 120.41






X2 (5 df) 12.70 6.22 69.50 105.00 36.89
p-value 0.03 0.29 <0.0001 <0.0001 <0.0001
Table 2.  Statistical testing of the independent e"ects of iron supplementation and transferrin 
saturation (TSAT). "ree models (mathematical equations) were !tted for each bacterial species: 
(a) iron supplementation " (t1 t2 t3 t4), i.e. iron supplementation, the time polynomials and their 
interactions; (b) TSAT " (t1 t2 t3 t4), i.e. TSAT, the time polynomials and their interactions; (c) (iron 
supplementation + TSAT) " (t1 t2 t3 t4), i.e. iron supplementation, TSAT and both their interactions 
with the time polynomials. We employed the likelihood ratio test to compare models for which the 
growth patterns were and were not dependent on TSAT or iron supplementation. "e e$ects of iron 
supplementation and TSAT were derived from models (a) and (b) respectively and refer to the joint 
e$ects of the variable and the terms for its interaction with the time polynomials. "e independent 
(conditional) e$ects of iron supplementation a%er controlling for TSAT, and TSAT a%er controlling for 
iron supplementation, are both derived from model (c) and again refer to the joint e$ects of the variable 
and the terms for its interaction with the time polynomials. For each bacterial species, each of the 
following four hypotheses were tested: (1) iron supplementation has an impact on bacterial growth; (2) iron 
supplementation has an impact on bacterial growth independently of TSAT; (3) TSAT has an impact on 
bacterial growth; and (4) TSAT has an impact on bacterial growth independently of iron supplementation. 
Signi!cance was determined using a chi-squared test. Chi-squared and p-values are reported.
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For Y. enterocolitica (Fig.' 2C), the maximum growth rate was di#cult to locate. In fact, although 
the growth curves clearly di$er signi!cantly (p < 0.0001), the doubling times at one hour did not di$er 
signi!cantly. As was the case for S. Typhimurium and E. coli, TSAT had an impact on growth (X2 = 120, 
p < 0.0001) as did iron supplementation (X2 = 108, p < 0.0001). Additionally, iron supplementation 
(X2 = 33, p < 0.0001) and TSAT (X2 = 37, p < 0.0001) each had signi!cant e$ects on bacterial growth 
a%er controlling for the other (Table'2).
Discussion
"e biologically useful redox characteristics of the Fe(II) to Fe(III) transition place iron apart from other 
nutrients. Additionally, it lies at the epicenter of the host-pathogen battle for resource control. Host 
defense mechanisms to withhold iron from invading pathogens are some of the most evolutionarily 
conserved innate strategies against infection24, but most bacterial species have evolved counter-acting 
strategies for pirating host iron including: (1) receptors that bind transferrin, lactoferrin or hemoglobin; 
and (2) low molecular weight siderophores that acquire iron from host proteins or from low molecular 
weight iron compounds25.
"e potential health threat posed by exogenous iron, repeatedly demonstrated in animal models25, 
has tended to be overlooked in clinical settings. "e recent iron trials with adverse outcomes in children 
in developing countries8,10–15 have prompted new mechanistic studies providing experimental veri!ca-
tion that oral iron adversely modi!es the gut microbiome17,26 and increases the virulence of pathogenic 
enteric bacteria18,20. In this study we focused on the issue of systemic, as opposed to enteric, bacterial 
infections building upon prior knowledge that iron can precipitate septicemias (for instance, based on 
the disastrous outcomes of intramuscular iron-dextran administration to Polynesian neonates27).
"e ex vivo assays we describe here show that customary oral supplementation with highly-soluble 
iron as ferrous sulfate can profoundly a$ect the growth dynamics of four of the !ve sentinel species we 
studied. "is could potentially undermine a key component of innate immunity allowing such organisms 
to achieve overwhelming numbers by the time adaptive immune defense mechanisms are up-regulated. 
Note that the very strong correlations between TSAT and growth rates emphasizes the importance of this 
variable even in the presence of likely inter-individual di$erences in other iron-related (e.g. lipocalin-2, 
haptoglobin) and other (e.g. defensins) non-cellular defense mechanisms within the sera.
Recent molecular insights into human iron metabolism have challenged the basic pillars on which 
public health strategies involving highly soluble iron supplements have been developed. "e prior belief 
that humans are constitutionally ine#cient at absorbing iron, and hence require large non-physiological 
doses taken apart from food, is now overturned by the knowledge that hepcidin actively down-regulates 
iron acquisition especially in the presence of an infectious threat24. "e dual regulation of hepcidin 
by iron and infection (in(ammation) underscores the threat posed by exogenous iron. An increase of 
hepcidin caused by an infection might have the evolutionary function of decreasing further iron uptake 
from the intestine to reduce circulating iron fuel for microorganisms. "is suggests that we should not 
interfere via high dose iron supplements.
Figure 2. Growth of sentinel gram-negative bacteria in human serum before and a!er oral iron 
supplementation. S. Typhimurium (A), E. coli (B) and Y. entercolitica (C) were grown in serum from 
subjects before (blue) and a%er (red) oral iron supplementation with 400 mg ferrous sulfate (containing the 
equivalent of 130 mg of elemental iron). "e thicker central lines represent the !tted curves for an average 
individual and the thinner lines the 95% con!dence intervals for these estimates. "e points show individual 
values of OD620. Curves were derived from mixed e$ects models !tting degree-four orthogonal polynomials 




Transferrin saturation is homeostatically controlled with a normal range between 15–50% in males. 
Our data show that increasing TSAT from a mean of 42% to 76% profoundly stimulated bacterial growth 
with a continuous association across all levels of TSAT. "e role of TSAT in mediating host susceptibility 
to infection has been known for almost half a century28. However, neither the strength of this association, 
nor the ability of acute increases in TSAT following iron doses to so rapidly favor bacterial growth, have 
been previously appreciated. "e dose level selected for the adults in this study was based on that most 
frequently used for young children with iron de!ciency (2 mg/kg/day), however our subjects were iron 
replete. In iron de!cient children, hepcidin would be down-regulated to allow maximal iron absorption29 
and hence TSAT would be expected to rise even further. Although a higher percentage of increase can 
be expected, the TSAT baseline will be lower and may still end up lower than in iron replete men. In the 
event of accidental ingress of pathogens through a cut, abrasion or leaky gut, these high levels of TSAT 
could precipitate a fulminant bacteremia before other cognate immune defenses have time to respond.
Iron absorbed from a natural food matrix, or even when ferrous sulfate is given with food30, is released 
much more slowly and causes minor deviations in TSAT and in non-transferrin bound iron (NTBI)30 
which, according to the data presented here, would be much less likely to promote bacterial growth. In 
regions of the world where iron-rich foods are scarce, or too costly, supplementation with slow release 
nano-molecular formulations that mimic a food matrix31 may provide a safer option and might addition-
ally reduce the adverse e$ects of unabsorbed iron on the gut microbiota. Field trials of such compounds 
are warranted. Additional safe approaches to supplement iron include the use of oral bovine lactoferrin32.
Materials and Methods
Subjects. Forty-eight male Gambian subjects (averaging 40y; range 21–64y) were recruited. Subjects 
had no history of fever, illness or anti-microbial use during the preceding seven days; were malaria rapid 
test negative and were non-anemic (Hemoglobin > 12 g/dL). All patients donated blood between 9 and 
10 am, on an empty stomach, immediately prior to and four hours a%er taking 400 mg ferrous sulfate 
orally. Food was provided two hours a%er iron supplementation.
Informed consent was obtained from all subjects. "is study was approved by the Gambian 
Government/MRC Joint Ethics Committee (SCC1312v2) and by the University of North Carolina 
Institutional Review Board (protocol #143044). All experiments were performed in accordance with the 
approved guidelines.
Biochemical Parameters. Complete blood counts were obtained using a Medonic M series (Boule 
Diagnostics Int AB, Stockholm, Sweden) hematology analyzer. Serum biochemical parameters including 
serum iron, transferrin, ferritin and transferrin saturation were obtained using a Cobas Integra 400 plus 
(Roche, Basel, Switzerland) biochemistry analyzer.
 
 Ǥ Staphylococcus aureus (strain NCTC8325), Staphylococcus epidermidis 
(FDA strain PCI1200, ATCC12228), Salmonella enterica serovar Typhimurium (strain LT2, ATCC19585) 
and Escherichia coli (strain Crooks, ATCC8739) were grown overnight for 18 hours at 37 °C in 5 mL 
iron free minimal growth media, Iscove’s Modi!ed Dulbecco’s Medium (IMDM, Invitrogen). "is was 
conducted in air with continuous shaking (250 rpm). A high-virulence, siderophore producing Yersinia 
enterocolitica (strain WA-314, ATCC51871) was grown in IMDM containing 10 mM ethylene glycol 
tetraacetic acid (EGTA, Sigma) (pH7). All growth assays were run in triplicate in IMDM containing 
50% heat-inactivated human serum. Bacterial growth was monitored by measuring the optical density 
at 620 nm (OD620) hourly for 12 hours (Staphylococcus aureus, Salmonella enterica serovar Typhimurium, 
and Escherichia coli) and then at 20, 28, 36 hours (Staphylococcus epidermidis and Yersinia enterocolitica) 
using a Multiscan FC ELISA plate reader ("ermo Scienti!c).
Statistical analysis. We analyzed the growth assays with a mixed model using a quartic polynomial 
in Stata12 (StataCorp, College Station, TX). We used the logarithm of the mean of the three replicate 
OD readings at each time point as the response variable and modeled growth trajectories by !tting this 
to orthogonal polynomials (to degree 4) in time using mixed e$ects models with random intercept and 
coe#cients due to patient and, nested within patient, bleed (pre and post). In e$ect, therefore, the growth 
trajectory for the ith blood sample was modeled by an equation of the form:
( ) = (! + " ) + (! + " ) + (! + " ) + (! + " ) + (! + " ) + # ,log[OD t ] t t t ti 0 0i 1 1i 2 2i 2 3 3i 3 4 4i 4 it
where t is time since inoculation, the # s are estimated coe#cients and the $ s and % are the random 
e$ects.
For each species of bacterium, we compared its growth pre- and post-iron supplementation by exam-
ining di$erences in (1) Growth Curve i.e. general pattern of the overall growth trajectories; (2) Time to 
Reach Peak Doubling Time, i.e. the time at which the rate of increase in log[OD] was at a maximum and 
(iii) Doubling Time During Exponential Growth Phase, i.e. when the doubling time was at its greatest, 
or, if the lag phase was not detectable at 1 hour a%er inoculation. We estimated the timing of the maxi-
mum slope by setting the second derivative with respect to time of the deterministic component of the 
model to zero. We calculated the doubling time at time t as log(2)/(slope of log[OD(t)]). We employed 
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the likelihood ratio test to compare models for which the growth patterns were and were not dependent 
on the transferrin saturation or iron supplementation. We used the delta method to obtain the 95% con-
!dence intervals for the time at which maximum slope occurred and the doubling time.
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